Molecular characteristics of the scrapie agent. by Lewis, P.A.
R EFERENCE O NLY
UNIVERSITY OF LONDON THESIS
Degree  Year  Name of Author
?U )  Zoos  iFUiS  ,  ?ATR|C<  A.
CO PYR IG HT
This is a thesis accepted for a  Higher Degree of the  University of London.  It is an 
unpublished typescript and the copyright is held by the author.  All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
C O PYR IG HT DECLARATIO N
I  recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from it or information derived from it may be published without the 
prior written consent of the author.
LOANS
Theses may not be lent to individuals, but the Senate House Library may lend a copy 
to  approved  libraries  within  the  United  Kingdom,  for  consultation  solely  on  the 
premises  of  those  libraries.  Application  should  be  made  to:  Inter-Library  Loans, 
Senate House Library, Senate House, Malet Street, London WC1E 7HU.
R EPRO DUCTIO N
University  of  London  theses  may  not  be  reproduced  without  explicit  written 
permission  from  the  Senate  House  Library.  Enquiries  should  be  addressed  to the 
Theses Section  of the Library.  Regulations concerning  reproduction vary according 
to the date of acceptance of the thesis and are listed below as guidelines.
A.  Before  1962.  Permission granted  only upon the prior written consent of the 
author.  (The Senate House Library will provide addresses where possible).
B.  1962- 1974.  In many cases the author has agreed to permit copying upon 
completion of a Copyright Declaration.
C.  1975 - 1988.  Most theses may be copied upon completion of a Copyright
Declaration.
D.  1989 onwards.  Most theses may be copied.
This thesis comes within category D.
PI  This copy has been deposited in the Library of  __________V  ^ _________
□
This copy has  been deposited  in the Senate  House  Library,  Senate  House, 
Malet Street, London WC1E 7HU.M olecular C haracteristics
O f The S crapie A gent
Patrick A. Lewis 
MRC Prion Unit 
Institute O f Neurology 
University College LondonUMI  Number:  U592283
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did  not send a complete manuscript 
and there are missing  pages, these will be noted.  Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI  U592283
Published  by ProQuest LLC 2013.  Copyright in the Dissertation  held  by the Author.
Microform  Edition © ProQuest LLC.
All rights reserved.  This work is protected against 
unauthorized copying  under Title  17, United States Code.
ProQuest LLC 
789  East Eisenhower Parkway 
P.O.  Box  1346 
Ann Arbor,  Ml  48106-1346M olecular Characteristics 
of the Scrapie A gent
A thesis presented in partial fulfilment of 
the requirements for the degree of Doctor 
of Philosophy to the University of London
by
Patrick Alfryn Lewis BSc 
Institute of Neurology, University College London
Supervisors:  Dr Graham S. Jackson
Professor Anthony R. ClarkeAcknow ledgem ents
The research contained within this thesis would not have been possible without the 
help and guidance of many people.  The author wishes to thank his supervisors, Dr 
Jackson and Professor Clarke, for support and scholarly tutelage throughout the three 
and a half years of his postgraduate study.  Special thanks are due to Professor John 
Collinge,  director  of the  Medical  Research  Council  Prion  Unit,  for  providing  the 
environment and securing the funding for prion research to flourish.  Many thanks are 
also due to the members of the Prion Unit protein research group; Sam Jones, Mark 
Batchelor, Daljit Bhelt, Dr Howard Tattum and Dr Clare Trevitt; all of whom were 
generous  in  handing  out  advice  with  regards  to  techniques  and  experimental 
approaches.  Their  support  and  encouragement  are  gratefully  acknowledged. 
Although many individuals in the Prion Unit have provided help and advice over the 
past forty months, the author would like to single out Dr Francesca Properzi for her 
help with the scrapie cell assay, Jackie Linehan and Professor Sebastian Brandner for 
histological examinations, Ray Young for assistance with figures and the technicians 
at the Prion Unit animal facility for help with the bioassay of C-terminally truncated 
PrPSc.
Without the tolerance and patience of the authors family;  Rhys Thomas  Lewis,  Dr 
Peter Rhys Lewis, Shelagh Lewis, David Alistair, Fiona Elizabeth and Roger Oliver 
Lewis; the author would long ago have had a nervous breakdown and probably joined 
the Foreign Legion.  The author is also indebted to (in no particular order): Captain 
Benjamin J.  Stell KORBR (Retd.), Captain Benjamin Watts RDG, Captain Douglas 
Bartholemew  BW,  Lieutenant  Samuel  D.  R.  Steevenson  D&D,  Benjamin  Quirk, 
Seamus O’Cleary, Dr Anna J. H. Malone and Matthew Kerruish-Jones, barrister-at- 
law.  All  of the  above  have provided  valuable  insight,  solid  support,  enlightening 
perspective and interesting times for the last three years.
“It is one thing to show a man that he is in error, and another to 
put him in possession of the truth” (1)
This work is dedicated to the memory of Catherine Redmond
3Abbreviations
TSE  -  Transmissible  Spongiform  Encephalopothy,  TME  -   Transmissible  Mink 
Encephalopathy,  CWD  -   Chronic  Wasting  Disease,  BSE  -   Bovine  Spongiform 
Encephalopathy,  CJD - Creutzfeldt Jakob  Disease,  FFI -  Fatal  Familial  Insomnia, 
GSS - Gerstmann Straussler Scheinker Syndrome, PrP -  prion protein, PrPc -  cellular 
prion protein, PrPSc -  scrapie prion protein, PrPR E S - protease resistant prion protein, 
RML - rocky mountain line, DNA - Deoxyribose Nucleic Acid, GuHCl - Guanidine 
Hydrochloride, NMR - Nuclear Magnetic Resonance, CD -  circular dichroism, UV - 
ultra  violet,  SOD -   super  oxide  dismutase,  PK  -  Proteinase  K,  PMCA  -  protein 
misfolding  cyclical  amplification,  GPI  -  glycosylphosphatidylinositol,  PIPLC  - 
phosphodiesterase phosphoinositide phospholipase C,  CNS - central nervous system.
4Abstract
The prion diseases of humans and animals, including Creutzfeld-Jakob disease (CJD) 
and  Kuru  of humans,  scrapie  of  sheep  and  Bovine  Spongiform  Encephalopothy 
(BSE), are a family of closely linked neurodegenerative disorders that have proved to 
be both heritable and transmittable.  The aetiology of these disorders has been shown 
to  be  intrinsically  linked  to  a  novel  infectious  particle  made  up  either  solely  or 
overwhelmingly  of protein,  the  major  component  of which  is  the  prion  precursor 
protein  (PrP).  PrP  is  a  253  amino  acid  protein  modified  during  synthesis  by  the 
addition of a glycophosphatidinol (GPI) anchor and either one or two N-linked sugar 
chains.  PrP normally exists within the cell in a predominantly a-helical conformation 
(PrPc), but can adopt an alternative, predominantly p-sheet structure closely linked to 
the  disease  state.  In  this  thesis,  investigations  into  two  of  the  molecular 
characteristics of the scrapie agent are described:  the impact of the GPI anchor on 
infectivity and the biochemical effect of the codon 129 M/V polymorphism.
The M/V polymorphism plays a major role in the disease process -  with the 
codon 129 status of an individual modifying both susceptibility to disease and disease 
course.  No alterations were observed in the stability, structure, protease resistance or 
copper binding properties of the  a-helical  form of PrP  due  to  this  polymorphism. 
Both forms had a similar propensity to form the P-rich isoform of PrP and, once in the 
P-rich conformation, no differences in structure, protease resistance or stability were 
observed between the two polymorphic variants.  The codon  129 polymorphism was 
found, however, to have a dramatic impact on the ability of the prion protein to form 
ordered aggregates.
To investigate the contribution of the GPI anchor to the infectivity of PrPSc, a 
novel  proteolytic  treatment  was  used  to  remove  the  C-terminal  and  GPI  from  the 
prion  protein.  The  infectious  properties  of PrP80  lacking  the  GPI  were  examined 
using in vitro, cell based and in vivo models of prion replication.  No alteration in the 
ability of C-terminally truncated PrP80 to propagate was observed.
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1.0 Introduction
The prion diseases of humans and animals, including Creutzfeld-Jakob disease (CJD) and 
kuru  of  humans,  scrapie  of  sheep  and  Bovine  Spongiform  Encephalopothy  (BSE) 
affecting  cows,  are  a  family  of closely  related  neurodegenerative  disorders  that  have 
proved to be both heritable and transmissible.  The aetiology of these disorders has been 
shown to be intrinsically  linked to a novel  infectious particle made up either solely  or 
overwhelmingly of protein, dubbed the prion.  The concept of infectious proteins causing 
disease whilst acting independently of nucleic acids is a revolutionary one, and remains a 
subject of some debate and much research.
1.1 The Transmissible Spongiform Encephalopothies
The first documented description of what are now known as prion disorders (also known 
as  Transmissible  Spongiform  Encephalopothies  or  TSEs)  dates  back  to  1755,  when  a 
parliamentary enquiry was held into the incidence of a disease that led sheep to scrape 
themselves  and  eventually  killed  them  (2).  In  1772,  a  veterinarian  called  Comber 
described  a  disease  of sheep  that  was  characterised by  a  loss  of co-ordination  and  an 
uncontrollable  urge  to  itch,  with  the  disease  leading  to  collapse  and  death  (3).  This 
disease was originally described as cuddy trot or yeukie pine, but later became known as 
scrapie, due to the response of the sheep upon the urge to itch.  Since the  18th century, 
TSEs have been described in many mammalian species and have exhibited the ability to
12spread between species.  They are all thought to share a common pathogenesis linked to 
accumulation  of  the  Prion  protein  (PrP)  and  all  exhibit  related  neuropathological 
alterations  -   most  markedly  spongiform  degeneration.  There  are  also  shared 
symptomatic  characteristics,  with  specific  combinations  of behavioural  and  movement 
disorders being  indicative of TSE  disease,  although there  is  marked  variation between 
TSEs  in  different  species,  between  different  TSEs  within  a  species  and  even  within  a 
given TSE (4).
1.1.1  TSEs in Animals
Scrapie
Scrapie is a progressive degenerative disease of the nervous system affecting sheep.  The 
initial presentation is often behavioural,  such as apprehension,  hypersensitivity or even 
dementia.  This is followed by pruritus, resulting in the affected sheep scraping its body 
against objects (hence “scrapie”).  The result of this is a loss of wool and damage to the 
skin  that,  combined with  fatigue  and  weight  loss  associated  with  the  disease  process, 
yields a characteristic emaciated appearance.  As the disease progresses, the sheep suffer 
from gait disorders, typically ataxia of the rear limbs and a high stepping movement of 
the  forelimbs,  often  accompanied  by  tremor.  These  symptoms  progressively  worsen, 
eventually leading to collapse and incapacitation.  Death invariably occurs 6 weeks to 6 
months after the onset of symptoms, with rare cases surviving up to a year (5;6).
The neuropathological hallmarks of scrapie, upon which categorical diagnosis is 
heavily reliant, include global neuronal loss and cytoplasmic vacuolation; the spongiform
13degeneration that characterizes the TSEs (7).  The epidemiology of scrapie is complex 
and, after well over a century of intense scrutiny, still not fully understood.  Throughout 
the  18th and 19th centuries the disease was thought to be hereditary in nature.  Although 
this is now known not to be the case, there is a strong genetic element in the occurrence 
rate of scrapie: this is exemplified by the fact that the disease is not seen at all in some 
breeds and sheep can be selected for resistance to the disease (8;9).  The first attempts to 
transmit scrapie experimentally were made by Besnoit and co-workers in the last years of 
the 19th century (10).  Although unsuccessful, the transmission of scrapie was achieved in 
1936 by Cuille et al, who also showed that infectivity could be removed from inocula by 
filtration  (11).  Scrapie  has  since  been  transmitted  to  several  experimental  animals, 
including mice (12).
Chronic Wasting Disease
First  described  in  the  1960s,  Chronic  Wasting  Disease  (CWD)  is  a  spongiform 
encephalopathy  affecting  elk,  mule  deer  and  white  tail  deer  in  the  US  and  Canadian 
Rockies.  CWD  was  originally  identified  in  farmed mule  deer and was  thought  to  be 
caused by the increased stress of living in captive conditions as compared to the wild.  It 
was, however,  eventually shown to be a TSE and has subsequently been found in wild 
populations of deer and elk in the Rockies (13-15).
The  cardinal  symptom,  as  the  epithet  wasting  would  suggest,  is  progressive 
weight loss.  The disease also shares many other symptoms with scrapie, including ataxia 
and behavioural alterations.  The age of onset is normally between 3 and 5 years, with the 
disease course usually between several weeks and four months with an invariably  fatal 
outcome.  Following  the  advent  of  Bovine  Spongiform  Encephalopathy  in  the  UK,
14medical  and  veterinary  authorities  in  America  are  increasingly  concerned  as  to  the 
possibility transmission of CWD to either cattle or humans (16).
Transmissible Mink Encephalopathy
Although first described in  1965, Transmissible Mink Encephalopathy (TME) is thought 
to  have  first  occurred  amongst  farmed  mink  in  Minnesota  and  Wisconsin  during  the 
1940s and has since been observed in farmed mink from both America and Europe.  The 
origin of TME is unknown, although the disease appears to be spread via contaminated 
food sources and there  is the possibility that scrapie contamination may have a role  in 
TME outbreaks.  As with the other TSEs, the disease is uniformly fatal and shares the 
classic  hallmarks  of spongiform  degeneration  in  the  brain  and  transmissibility.  The 
clinical progression is very similar to that of scrapie (17).
Bovine Spongiform Encephalopathy
Bovine Spongiform Encephalopathy, often described as “mad cow disease”, is one of the 
most recent TSEs to emerge.  The first case of BSE was described in the UK during 1985 
although,  in common with several other TSEs in animals, it is thought the disease had 
been present in the bovine population for several years before this (18-20).  The origin of 
BSE remains elusive, with the likely cause being either passage of scrapie-infected tissue 
into bovine food or an initial, sporadic case of BSE entering the bovine food chain (21). 
The impact of this initial infection was magnified by the reprocessing of bovine carcases 
into cattle feed which resulted in a full-blown epidemic of the disease.  This was brought 
under  control  only  by  radical  alteration  of  cattle  husbandry  practice,  including  an 
overhaul of what could be used in cattle food, and the culling of affected and at risk herds 
on a huge scale.  Over one hundred and seventy thousand cows were diagnosed with BSE
15during the epidemic, and it is estimated that over a million were actually affected by the 
disease (although not all of those infected lived long enough to present symptoms) (22). 
Since it was initially described in the UK, BSE has been identified in cattle throughout 
Europe, in Japan, Canada and the USA (23-25).
In terms of human health concerns, the transmission of BSE to a number of other 
species, including cats, exotic ungulates and humans (see section 1.1.2, variant CJD) (26- 
29),  has  raised  the  possibility  of an  epidemic  of transmitted  prion  disease  within  the 
human population of the UK, although estimates of how many may be affected vary from 
hundreds to tens of thousands (30;31).
1.1.2  Human TSEs
The  human TSEs  share  many  characteristics  with  their animal  counterparts,  including 
similar disease progression and pathological characteristics.  The greater depths to which 
they have been studied, and the more complex neurological nature of those afflicted, have 
yielded a range of closely related, yet differentiated, disorders.
Creutzfeldt-Jakob disease
The most common of the human TSEs, Creutzfeldt-Jakob disease (CJD), takes it name 
from  the  two  doctors  who  first  described  the  disorder.  Hans  Gerhard  Creutzfeldt 
documented a  single case  in  1920:  a 22  year old  who died after a six-year period of 
neurological degeneration (32).  In  1921  Alfons Jakob described five cases with similar 
presentation and neuropathology to Creutzfeldts case (33;34).  Ironically, recent analysis 
of the case histories and tissue has shown that only two of these initial cases would now
16be defined as CJD (35).  The disease, as recognised today, is characterised by rapid onset 
neurological  degeneration.  This  initially  presents  as  dementia,  followed  by  the 
development of movement disorders  such as tremor,  spasticity and rigidity.  A  feature 
common to almost all cases of CJD is myoclonus, and most cases also display abnormal 
EEG  recordings.  Once  symptoms  are  detected,  the  disease  course  is  extremely 
aggressive,  especially  when  compared  to  other  neurodegenerative  diseases  such  as 
Alzheimer’s and Parkinson’s.  The average disease duration is 7.6 months, and the vast 
majority of patients die within  12 months (between 85% and 90%).  By the end stage of 
the  disease,  patients  sink  into  akinetic  mutism,  with  death  usually  occurring  due  to 
systemic  or  pulmonary  infection.  In  terms  of  neuropathology,  CJD  cases  display 
extensive spongiform degeneration and neuronal loss, coupled with gliosis and deposits 
of the  prion protein within the  brain.  In a  small proportion  of cases,  the  presence  of 
amyloid plaques can also be demonstrated (36;37).
CJD presents a complex epidemiological picture.  It has been described in three 
forms, each defined by their mode of emergence.  The most common of these is sporadic 
CJD (sCJD), which constitutes approximately 85% of reported cases.  This occurs at a 
remarkably uniform global rate of one case per million capita per annum.  The disease 
appears to arise spontaneously, with a mean age of onset of 60 years and a mean duration 
of 8 months (37).  With the exception of two polymorphisms in the prion gene at codons 
129 and 219 where homozygosity is significantly over-represented, studies attempting to 
identify risk factors for sCJD have so far been unsuccessful (38-40).
CJD also occurs as a transmissible disease.  This first came to light following the 
kuru  epidemic  in  Papua  New  Guinea  (vide  infra  kuru),  which  led  Drs  Gajdusek  and
17Gibbs  to  investigate  whether  CJD  had  similar  infectious  properties.  This  was 
demonstrated in 1967 by the passage of CJD to chimpanzees, indicating that inter-person 
spread of CJD was, in principle, a possibility (41;42).  Thankfully, such transmission is 
rare and has, thus far, only been described in a small number of cases involving several 
modes of iatrogenic infection (iCJD).  Transmission has been reported due to use of CJD 
contaminated batches of cadaveric human growth hormone or gonadotrophin, following 
dura mater grafts from diseased donors, due to corneal transplants from CJD patients or 
due to use of contaminated neurosurgical instruments (43-46).
The familial form of CJD (fCJD) is also rare, accounting for  14% of CJD cases. 
The disease phenotype has been found to segregate with mutations in the prion protein 
gene located on chromosome 20 (mutations in which also cause other inherited forms of 
prion disease).  The first of these to be identified were an octapeptide repeat insertion (a 
peptide repeat of GGGWGQPH, four of which form part of the normal sequence of the 
prion  protein)  in  the  N  terminal  section  of the  protein  and  a  lysine  for  glutamate 
substitution at codon 200.  These have since been joined by several other mutations (e.g 
D178N,  E196K, T183A).  Compared to sCJD,  fCJD tends to have an earlier onset and 
longer disease duration, although there is wide variation between the different causative 
mutations (47-49).
The  incidence  and  phenotype  of  all  three  forms  of  CJD  are  altered  by  a 
methionine/valine polymorphism within the prion gene at position  129.  As mentioned, 
heterozygosity  at  this  codon  has  been  shown  to  confer  a  protective  effect  against  the 
incidence of sCJD (with heterozygotes being underrepresented) and has also been shown
18to be protective against acquisition of iCJD  (38;50).  Within  some  fCJD kindreds,  the 
M/V polymorphism influences both age of onset and disease duration (51;52). 
Gerstmann-Strdussler-Scheinker disease
The familial TSE Gerstmann-Straussler-Scheinker (GSS) syndrome was first described in 
the  1930s by the three doctors who gave the disease its name (53;54).  It is differentiated 
from familial forms of CJD by the predominance of ataxia as its main symptom and by 
the large amyloid plaque burden within the brain.  The original family in which GSS was 
described  was  subsequently  found  to  harbour  a  mutation  at  codon  102  of the  prion 
protein,  and this mutation (proline to  leucine)  has been  found to be the most common 
cause of GSS (48;52;55).  There are, however, a number of mutations within the prion 
gene  associated  with  this  disease  worldwide,  and  there  is  a  significant  amount  of 
variation both in disease phenotype and in duration/age onset (Table 1.1).




P102L 50 45 Ataxic
P105L 45 100 Paraspastic
A117V 40 40 Pyramidal/
Extrapyramidal
F198S 55 70 Extrapyramidal
Table  1.1  Gerstmann-Straussler-Schienker  mutations  and  phenotypes.  Four  of  the 
inherited mutations that can cause GSS are shown, illustrating the range in age of onset, 
disease  duration  and  phenotype.  This  underlines  the  heterogeneous  nature  of  the 
syndrome.
19As  with  fCJD,  the  M/V  polymorphism  has  been  shown  to  have  an  impact  on  the 
phenotype of GSS.
Kuru
Kuru, a fatal neurological disorder found amongst the Fore language group in the Eastern 
highlands of Papua New Guinea, was the first human TSE to be defined as such and was 
critical in establishing the common pathogenesis linking human and animal TSEs.  Kuru 
was initially described during the  1950s,  following the first contact between Europeans 
and  the  Stone  Age  culture  of the  Fore  (56).  The  Fore  used  the  word  kuru,  meaning 
shaking or trembling, to describe the disease.  Indeed, tremor is usually both the first and 
most pronounced symptom.  This progressively worsens, combining with ataxia, until the 
patient is incapacitated (Figure 1.1).  Towards the final stages of the disease, dementia is 
common and incontinence is frequently present.  Death occurs, often through starvation, 
after a disease course of between 6 to 9 months (57).  The neuropathological hallmarks 
have  many  similarities  to  those  of CJD,  although  there  is  the  additional  presence  of 
“kuru-like” plaques within the brain (Figure  1.1) (58).  It is thought that kuru emerged 
during the first few years of the 20th century.  By the late 1950s, it had reached epidemic 
proportions, with over 100 deaths from the disease per year  -  the majority of those dying 
being either adult women or children -  making it the leading cause of death among the 
Fore (59).
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Figure  1.1  A kuru patient and kuru plaque. A) A young Fore boy in the final stages of 
kuru, photographed in the late 1960s.  B) “kuru” plaques of deposited PrP in the brain of 
a  patient  who  died  of  kuru.  Hemotoxylin  and  Eosin  stain  on  the  right  reveals 
ultrastructural cellular detail  and immunohistochemical staining with ICSM  35  (D-Gen 
ltd., London) shows PrP deposits as areas of dark stain on the blue tissue backgrond.  The 
spongiform degeneration characteristic of the TSEs is also clearly visible as vacuoles in 
the tissue.
The  mode  of transmission  was  eventually  determined  to  be  via  the  endocannibalism 
practised by the Fore.  At mortuary feasts to commemorate the dead, women and children 
from  the  immediate  family  would  eat  tissue  from  their  dead  relative,  including  brain 
tissue.  It has been suggested that the disease spread from an initial sporadic or familial 
CJD  case  that  was  subsequently  cannibalised.  The  infectious  nature  of  kuru  was 
eventually  confirmed  by  its  transmission  to  various  primates,  all  of which  exhibited 
extended incubation periods of greater than 10 months (41;60).  This mirrors the situation 
in the human population, with incubation periods in excess of 40 years being documented 
(cannibalism having been eradicated during the  1950s, following which the incidence of
21kuru began to decline), and a mean incubation period of around 12 years (61;62).  Recent 
genetic  analysis  has  shown  a  greatly  increased  susceptibility  to  kuru  in  individuals 
homozygous  for methionine at codon  129  in the prion protein,  due to which the M/M 
genotype  is  now  greatly  underrepresented  in  the  Fore  (63-65).  Both  M/V  and  V/V 
carrying individuals have proved to be susceptible to infection, albeit with an increased 
incubation period (63).
Fatal Familial Insomnia
Fatal  Familial  Insomnia  (FFI)  is  a  recently  characterised  human  TSE,  representing  an 
extreme of the phenotypic variance exhibited in these disorders.  First described in 1986, 
FFI is a predominantly autosomal dominant inherited disorder, although there have been 
subsequent  descriptions  of sporadic  cases  (66-68).  Insomnia  is  the  initial  presenting 
symptom,  with  sleep  disturbance  increasing  as  the  disease  progresses.  The  major 
disturbance appears to be loss of deep sleep due to alterations in, and loss of circadian 
rhythmic  control of, body  functions.  This develops concurrently with gait disturbance 
and hallucinations, although these are thought to be linked to  lack of sleep rather than 
with dementia per se.  Eventually the patient enters a vegetative state and death results 
around  a  year  after  onset  of symptoms,  often  from  respiratory  or  systemic  infection 
(although there  is a wide variation in disease duration).  Pathologically,  FFI  is distinct 
from other human TSEs in that its destructive impact is localised mainly in the thalamus, 
manifesting as neuronal loss.  Spongiform degeneration is, on the whole,  limited,  as is 
PrP deposition.  The classification of FFI as a TSE rests on its transmissibility and the 
fact that genetic analysis of the kindreds suffering from this disorder revealed a mutation 
in the prion protein gene that co-segregates with disease (69;70).  Medori and co-workers
22identified this mutation in 1992: an asparagine for aspartic acid substitution at codon 178 
(D178N)  (71).  Several  other  FFI  families  were  later  shown  to  harbour  the  same 
mutation.  Interestingly,  D178N  has  also  been  documented  in  families  suffering  from 
fCJD -  the modifying factor being the M/V codon  129 polymorphism.  Carriers of the 
D178N  mutation  and  methionine  (on  the  same  allele)  developed  FFI,  whilst  those 
carrying  valine  developed  CJD  (72;73).  Of further note  is  the  fact that the  M/V  129 
status on the none mutant allele affected the age of onset and disease duration in both FFI 
and CJD caused by the D178N mutation (74).
Variant CJD
The  most  recent  TSE  to  be  described,  variant  CJD  (vCJD)  emerged  in  the  1990s 
following the advent of the BSE  epidemic  (75).  vCJD  exhibits marked differences  in 
disease profile to those associated with classical CJD or the other human TSEs.  The age 
of onset varies greatly,  with patients as young as  16 and as old as  51  being diagnosed 
(mean age of onset 29 years) (4).  The initial symptoms are behavioural, with disorders of 
movement such as ataxia occurring weeks to months  later.  Dementia and myoclonus, 
usually  the  initial  symptoms  in  classical  CJD,  occur  towards  the  later  stages  of the 
disease  and  electroencephalogram  (EEG)  abnormalities,  very  common  in  CJD,  are 
frequently absent in vCJD.  The disease course is also longer than classic CJD, with a 
mean of 14 months as compared with 7.6 for sCJD (4).  The neuropathology if vCJD is 
also  in  marked  contrast  to  most  other  human  TSEs,  with  spongiform  degeneration 
concentrated  in  the  basal  ganglia  and  thalamus,  allied  with  the  presence  of so  called 
“florid” plaques (figure 1.2).
23Figure  1.2  “Florid”  Variant  CJD  plaques.  Histological  examination  of variant  CJD 
(bottom panel) compared with sporadic CJD (top panel).  Hemotoxylin and Eosin stain 
on the right reveals ultrastructural cellular detail and immunohistochemical staining with 
ICSM 35 (D-Gen ltd., London) shows PrP deposits.  The vCJD sample shows the “florid” 
plaques associated with this form of CJD (indicated by the area of intense dark staining), 
with the sporadic CJD case exhibiting a more diffuse pattern of PrP deposition.
These are similar to those found in kuru and scrapie.  There is, in addition, widespread 
deposition of PrP throughout the cerebellum and cerebrum (76).
To date 154 people have been diagnosed with vCJD in the United Kingdom, with 
several cases identified overseas including France and the United States (figures from the 
CJD surveillance unit www.cid.ed.ac.uk/figures.htm).  The risk factors thus far identified 
are limited to residency in Britain during the height of the BSE epidemic and a genetic 
susceptibility based on methionine homozygosity at codon  129 in the prion protein (all 
patients  so  far diagnosed with  vCJD  have been  M/M)  (77).  Several  lines  of evidence 
now  support  the  causative  link  between  vCJD  and  exposure  to  BSE-infected  bovine
24tissue.  Transmission studies carried out using mice show a close correlation in disease 
clinicopathology  between  BSE  and  vCJD,  and  molecular  studies  of the  prion  protein 
found  deposited  in  both  bovine  and  human  brains  affected  by  these  diseases  have 
revealed similar biochemical characteristics (21;27-29;78;79).
The current state of the vCJD epidemic in the UK and across the world is one of 
uncertainty.  Whilst the number of new cases each year has remained relatively constant 
since the late  1990s, there is a strong possibility that those succumbing to disease are an 
usual and highly susceptible subset of the population, and that a more general epidemic 
lies  in the  future.  Certainly, using the parallel of the kuru epidemic where  incubation 
periods  greater  than  40  years  have  been  observed  in  a  situation  where  there  was  no 
species barrier to infection, this does not bode well.  Recent clinical research in the UK 
has  uncovered  a  number  of  subclinical  carriers,  identified  by  screening  of archived 
appendix tissue samples, and there has been a report of possible transmission via blood 
transfusion to an individual with heterozygosity at codon  129 (80;81).  Epidemiological 
studies have estimated that the 95% confidence limit for vCJD deaths is between 50 and
50,000  future  deaths,  although  due  to  the  large  number  of unknown  factors  any  such 
projections  must be treated with  caution  (22;31).  Given that human exposure  to high 
infectious  titre  material  from  cattle  during  the  BSE  epidemic  was  on  a  massive  scale 
(with anywhere up to 300,000 infected cattle potentially entering the human food chain), 
it is unlikely that vCJD is a disease that will disappear in the near future (4).
251.2  The Curious Nature of the Scrapie Agent
The nature of the causative agent of the TSEs is an issue that has perplexed scientists for 
over  one  hundred  years,  and  the  diseases  defy  placement  into  any  of the  established 
categories of human disease.  As illustrated in the previous section, the TSEs present a 
complex disease pattern:  the combination of inherited, sporadic and infectious forms of 
the same disease is almost without parallel in medical science.  It is the last of these that 
most complicates the categorisation of the TSEs, as there are several other examples of 
slow-developing neurological  disorders  that occur in both  familial  and sporadic  forms 
(for  example  Alzheimer’s  disease  and  Parkinson’s  disease)  (82).  Closer  study  of the 
infectious process reveals curious aspects of the active agent that cloud the issue even 
more.  First,  transmissible  forms  of the  TSEs  exhibit  extended  incubation  periods  as 
compared to the vast majority of described infectious diseases.  In the extreme case of 
kuru, incubation periods in excess of 40 years have been described, followed by a rapid 
clinical course -  which begs the question as to what the infectious agent is doing during 
this lag period, and where it is propagating.  Secondly, several studies dating back to the 
1960s  showed  that  the  scrapie  agent  could  survive  treatment  that  inactivated  other 
infectious agents:  it was resistant to heat treatment and could withstand high  levels of 
formalin (83).  Examination of the infected and infectious tissue, moreover,  reveals no 
evidence  of bacteria  or  virions.  It  was  also  proven  that  transmission  could  occur  by 
inoculation with cell free isolates, indicative of a small active agent.  Later work further 
investigating  the  size  of the  scrapie  agent  using  ultraviolet  and  y  radiation  treatment 
discovered that it was much smaller than bacteria and viruses, suggesting that the scrapie
26agent might replicate without nucleic acid (84-86).  In addition to this, there was also a 
species barrier preventing the passage of infection between certain species but not others 
(for  example  blocking  infection  of mice  with  goat  scrapie,  or  of mice  with  hamster 
scrapie),  and  the  existence  of  varied  “strains”  identified  by  incubation  time  and 
phenotype  (87;88).  This  specificity  was  suggestive  of a  complex  flow  of phenotypic 
information during the infective process that did not derive from an agent-specific nucleic 
acid genome.
1.2.1  Early Theories
Several theories have been put forward to explain these data.  Sigurdsson first proposed a 
viral origin for the disease  in  1954  (89).  After studying  Rida (the  Icelandic name  for 
scrapie), he suggested that the causative agent was a virus, albeit a slow acting one, and 
used  the  term  slow  infection  or  slow  virus.  This  did  not  explain  the  absence  of a 
detectable  virus  particle  and  was  not  congruent  with  the  ensuing  discoveries  of the 
resistance  of the  agent  to  treatments  that  inactivated  all  other  known  viruses.  In  the 
absence of a better explanation, however, the theory was accepted by many as a reflection 
of what was happening.
Several other theories were developed during the  1960s, when the profile of the 
TSEs  was  raised due to the  demonstration that both  kuru and CJD were  transmissible 
(42;60;90) and the link with scrapie was suggested (91).  Writing in  1967, Gibbons and 
Hunter  summarised  the  possible  mechanisms  of  transmission  and  proposed  that  the
27disease could be associated with an aberrant steric rearrangement of the membrane (table 
1.2) (92).
Hypothesis Mechanism
Virus Extremely small virus with unusual resistance 
to UV inactivation
Protein Self replicating protein/nudeoprotein. Consistent 
with inactivation data but difficult to reconcile 
with central dogma of molecular biology (see 
figure 1.3 for possible mechanisms)
Carbohydrate Poly/oligosaccharide acts as inducer or activator 
of a polysaccharase that synthesises further, 
identical oligosaccharides.  Not consistent with 
lack of resistance to urea and phenol
Membrane Properties of membrane lipids consistent with 
resistance data.  Could self replicate in a 
similar fashion to oligosaccharide mechanism
Table  1.2  Theoretical  mechanisms  of  scrapie  replication.  The  four  hypothetical 
mechanisms for scrapie replication proposed by Gibbons and Hunter in 1967, taking into 
account the unusual properties of the scrapie agent (92).
In the same issue of Nature, Griffith, a mathematician, further elaborated the hypothesis 
of a protein only mechanism of transmission and proposed three possible models for this 
to occur (figure 1.3) (93).
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Figure  1.3 Griffiths models of protein only replication.  The three models of protein only 
replication proposed by Griffith in 1967 (93).  A) Addition of monomeric protein a to an 
a dimer leads to production of trimers (i) and tetramers (ii).  Tetramers can then fracture 
to form dimers (iii), which can feed back into the process.  If it is assumed that a exists in 
the  cell  as  a  monomer  and  monomers  cannot  associate  to  form  dimers  (iv)  then  only 
extrinsic  addition of a dimer will result  in  self propagating behaviour.  B)  Protein  S  is 
required for transcription of gene G -  the product of which is protein S.  Introduction of S 
from an extrinsic source results in production of S from gene G, which leads to a positive 
feedback and infectious behaviour (ii).  C) Autoimmune infectious process.  Antigen A 
stimulates  production  of antibody  A'.  Where  A  is  the  same  as  A'  this  would  be  an 
infectious, self propagating process.
These were, of course, theoretical mechanisms and Griffith did not pretend to have the 
hard  scientific  evidence  to  support  them,  although  they  could  explain  an  intriguing 
number of the characteristics of the scrapie agent.  What should be emphasised, however, 
is the fact that, at the time, these proposals were tantamount to heresy.  The assertion that 
a protein was capable of some form of self-replication ran counter to the central dogma of 
molecular biology as proposed by Francis Crick following the elucidation of the structure 





Figure  1.4  The  central  dogma  of  molecular  biology.  Proposed  by  Crick  after  the 
elucidation of the  structure  of DNA  (94).  A)  The  central  dogma  as  it  stood  in  1970 
showing  transfer  of  information  supported  by  scientific  evidence  (solid  lines)  and 
hypothetically possible (dashed lines).  B) The central dogma following the discovery of 
reverse transcriptase (DNA produced from RNA) and prion behaviour (protein to protein 
replication), indicated by red arrows.
Indeed, the implication of a protein being capable of infectious properties, and therefore 
of self-replication,  was that proteins  were  capable  of acting  as  heritable  agents.  This 
possibility had been dismissed by Crick himself as being intrinsically impossible, and has 
proved highly controversial ever since (95).  It is interesting to note, however, that prior 
to the discovery of the structure of DNA and the proof that it acted as the purveyor of 
inheritance within the cell, polypeptides had been looked on as a favourable candidate for 
this role due to the greater number of possible combinations provided by 20 amino acids 
as compared to 4 nucleic acid bases (96).
Proof of the Griffith hypothesis was not, however, forthcoming.  When Carleton 
Gjadusek received the  1978 Nobel Prize in physiology or medicine for his work on the
30transmissibility of CJD and kuru, he acknowledged that the slow virus theory, whilst not 
ideal, was still the most likely basis for the infectious properties of the scrapie/CJD agent 
(57).
1.2.2  The Prion Hypothesis
Several developments led to the slow acceptance that the causative agents of the TSEs 
were  indeed protein based.  The  first of these was the development of a  sensitive and 
rapid animal assay  for  infectivity.  Using  Syrian Golden hamsters  and hamster adapted 
scrapie  homogenate,  Stanley  Prusiner  and  colleagues  working  at  the  University 
California,  San Francisco,  established an accurate  incubation time  assay for infectivity 
(97).  Prior to this, animal assays for infectivity were severely limited by the length of 
time required for a result to be achieved and the number of animals required for a final 
titre of infectivity to be arrived at.  The newly developed assay provided Prusiner and his 
co-workers  with  a  nearly  ideal  tool  for probing  the  nature  of the  scrapie  agent.  In  a 
seminal paper published in 1982, Prusiner set forth the prion (derived from prateinaceous 
infectious  particle)  hypothesis,  essentially  an  extension  of the  theory  propounded  by 
Griffith over a decade earlier (83).  It stated, in necessarily caged terms, that a protein, 
possibly  acting  with  a  small  nucleic  acid  accomplice,  was  capable  of self-replication 
within vulnerable host cells and that this protein was the causative agent of scrapie. Using 
the hamster scrapie assay, Prusiner was able to support his hypothesis with evidence that 
this was indeed the nature of the scrapie agent (table 1.3).
31Properties of the Scrapie Agent
Resistant to treatment with ribonucleases and deoxyribonucleases, 
UV at 254nm (8 times more resitant than most resistant virus),
Zn2* catalysed hydrolysis, psorelen photoadduct formation and 
NaOH chemical modification
Susceptible to protein denaturants and proteolysis
Stable at 90% for 30 minutes
Molecular mass < 50,000 daltons
Hydrophobic protein required for infectivity
Table  1.3 Evidence supporting the prion hypothesis.  Characteristics of the scrapie agent 
listed by Prusiner in his seminal  1982 paper as evidence supporting a protein only basis 
for  the  TSEs  (83).  Stability  at  high  temperature,  low  molecular  mass,  resistance  to 
nucleases,  sodium hydroxide and zinc  hydrolysis  all  weigh heavily against the  scrapie 
agent  being  nucleic  acid  based,  whilst  the  lack  of resistance  to  protein  denaturants, 
proteolysis and the requirement for a hydrophobic protein point towards a protein based 
agent.
Swiftly  following this work,  the UCSF group  isolated a scrapie associated protein rich 
fraction using a sucrose column purification protocol (98).  The major constituent of this 
fraction was a proteinase resistant protein of molecular mass 27-30 KDa, the presence of 
which in isolated fractions correlated with infectivity (98).  The fraction contained almost 
no  nucleic  acid,  and  the  concomitant  infectivity  was  resistant  to  nuclease  treatment. 
Based  upon  the  prion  hypothesis,  it  was  proposed  that  this  protein  was  the  major 
structural constituent of the scrapie agent and was dubbed the prion precursor protein, or 
PrP.
32All  of this  evidence  supported  the  prion  hypothesis,  but  categorical  proof that 
infectious proteins were causing scrapie was still lacking and there was an understandable 
resistance to a theory that ran counter to some of the most basic principles of molecular 
biology  (although  it  should  be  noted  that,  in  1970,  the  discovery  of retroviruses  and 
reverse  transcriptase  had  resulted  in  a  major  modification  of  the  central  dogma  of 
molecular biology by introducing the possibility of RNA acting as a template for DNA) 
(99; 100).  The essential issue was that, with the purification techniques available, it was 
impossible to prove that it was PrP alone that was acting as the infectious agent, and there 
was as yet no detailed molecular mechanism demonstrating how this could occur.
Genetic Evidence
More  evidence  supporting the prion  hypothesis  was  soon uncovered.  A  Zurich-based 
group  led  by  Charles  Weissmann  identified,  in  collaboration  with  Prusiner,  a  cellular 
gene  in  hamsters  that  shared  the  amino  acid  sequence  of the  27-30  protease  resistant 
scrapie  associated protein  (101).  The  protein  was  coded  for  in  a  single  exon  of 254 
amino acids, with predicted characteristics correlating with those found in the infectious 
form:  the two shared similar molecular masses of 27 KDa and an isoelectric  focussing 
point of 9 to 9.4.  Furthermore, it was shown that the cellular form was present in both 
infected and uninfected hamsters, and that antibodies raised against epitopes within the 
protein  reacted with both  the  purified  scrapie  27-30  protein  and  cellular prion  protein 
(102).  The discovery of the  PrP  gene  provided  a potential  substrate  for an  infectious 
protein to act upon, hinting at a molecular basis for the disease.  Interestingly, the cellular 
form of the  protein did not exhibit the protease  resistance  that had been demonstrated 
with  the  infectious  form.  This  raised  the  possibility  that  there  was  a  conformational
33difference between the two at a tertiary or quaternary level resulting in increased protease 
resistance  for the  scrapie  associated  form.  This  also  provided  a  method whereby  the 
infectious  and  cellular  forms  could  be  differentiated.  It  was  impossible,  however,  to 
exclude that alterations in the post-translational modification of the protein (for example 
glycosylation or phosphorylation) were responsible for the different behaviour of the two 
forms.
Further evidence that the cellular PrP gene was central to the process of infection 
was the establishment that the PrP locus was a crucial determinant in the length of scrapie 
incubation  following  inoculation (103; 104).  It was  also  shown that by expressing  the 
hamster prion gene  in mice,  the  species barrier between hamster and  mouse  could be 
breached and the mice became susceptible to hamster scrapie.  This underlined the role of 
the cellular gene, but did not necessarily equate to a protein based infectious agent: these 
data could also be reconciled with a viral model, with cellular PrP acting as a receptor for 
a putative scrapie  virus.  It could also be postulated that the accumulation of protease 
resistant PrP was a product of the viral infective process, perhaps as a response to cell 
stress, and so was merely a marker for disease rather than a fundamental aspect of prion 
aetiology (105).
A year after the discovery  of the  hamster cellular prion protein,  a homologous 
human gene was located on chromosome 20 (106).  The presence of a cellular gene that 
encoded the prion protein  in  scrapie  suggested that this  might provide  a  locus  for the 
familial TSEs, and this indeed proved to be the case.  In 1989, a missense mutation in the 
prion  gene was  found to co-segregate with GSS  in  two pedigrees  (48).  A cytosine to 
thymine substitution was discovered resulting in a proline to leucine change at codon 102
34in the open reading frame of PrP.  Importantly, affected members of the families were 
found to have protease resistant material  in their brains and horizontal transmission of 
GSS  to  animal  models  had  previously  been  demonstrated.  The  implication  of  this 
discovery was that a mutation in the prion gene could alter the structure of the cellular 
prion protein causing it to adopt an infectious, disease causing form -  although this was 
by no means proven.  Subsequent to  the  discovery  of the  P102L  substitution,  further 
mutations  were  found  in  the  familial  forms  of CJD  and  FFI,  lending  weight  to  the 
argument that mutations in PrP were causally linked to prion disease.  A major advance 
was the production of transgenic mice  expressing the mouse homologue  of the  P102L 
mutation  (P101L).  These  mice  developed  spontaneous  neurodegeneration  with 
spongiosis and gliosis, mimicking the progression seen in the human form of the disease. 
Although the transgene was expressed at extremely high levels (eight times higher than 
endogenous levels), and there was an absence both of amyloid plaques within the brain 
and  of infectivity,  this  model  provided  evidence  of the  pathogenicity  of the  mutation 
(107; 108).
A model was thus emerging of a protein with altered conformation (now dubbed 
PrP scrapie or PrPSc) acting as an infectious agent, converting a normal, cellular substrate 
(dubbed  PrPc)  into  a  conformational  replicate  of the  scrapie  form.  How  exactly  this 
occurred  was  still  a  mystery,  and  the  thermodynamic  issues  associated  with  a  single 
protein with unchanged amino acid sequence occupying two different three dimensional 
conformations, especially in vivo, was the cause of much anxiety in the protein chemistry 
field.  This ran contrary to the hypothesis that the tertiary fold of a protein was coded for
35by  its primary  sequence  alone,  a hypothesis  accepted as  fact by protein scientists  in a 
similar fashion to the acceptance of the central dogma of molecular biology.
Animal Models
In  addition  to  the  animal  models  that  had  been  used  to  assay  scrapie  infectivity  for 
several decades, and the P102L GSS mutation model, several novel animal models have 
leant  weight  to  the  Prion  hypothesis.  Approaching  the  problem  of proving  the  prion 
hypothesis  from  the  reverse  angle,  Weissmann  and  colleagues  set  out  to  falsify  the 
theory.  They  produced  a  PrP  knockout  (PrP0/0)  mouse,  which  was  both  viable  and 
showed a remarkable absence of phenotype (which, in itself, had major implications for 
the cellular role of the prion protein -  see section 1.3) and reasoned that, if the conversion 
of PrPc to PrP80 was the central aspect of the infectious process, a knockout mouse not 
expressing PrPc should be resistant to infection -  if mice were still susceptible this would 
disprove  the  hypothesis  (109; 110).  The  mice  were  indeed  resistant,  and  there  was  a 
direct correlation with the amount of PrP present and infectivity: heterozygous knockouts 
(PrP0/+) exhibited a longer incubation period and extended disease course as compared to 
mice  carrying  two  copies  of the  Pm-p  gene  (111).  In  addition  to  this,  PrP0/0  mice 
expressing  a  copy  of  the  Syrian  hamster  PrP  gene  allowed  the  reconstitution  of 
susceptibility.  Yet  again,  these  experiments  did  not provide  conclusive  proof of the 
hypothesis,  but  were  a  major  factor  in  swinging  the  balance  of probability  towards  a 
protein only basis  for the TSEs.  Most recently,  work by Prusiner and his group  have 
successfully transmitted prion disease to a transgenic mouse producing a shortened prion 
protein  construct  (covering  residues  89-230  of the  mouse  prion  protein)  at  a  level  16 
times  greater  than  endogenous  expression.  The  inoculum  was  comprised  entirely  of
36recombinant PrP assembled in vitro into amyloid fibrils in the absence of any nucleic acid 
(112;113).
Molecular Studies
Molecular studies of both  PrPc and PrP80  also yielded  important  information as  to the 
nature of the infective process, and several major advances were made during the early 
1990s.  The cloning of the prion gene opened the possibility of recombinant studies of 
PrPc,  resulting  in  the  determination  of structures  for  hamster,  mouse  and  human  PrP 
using  nuclear  magnetic  resonance  (NMR)  (114-119).  The  recombinant  protein  was 
determined to consist of a structured C terminal domain, with three alpha helices and two 
short  beta  anti-parallel  sheets,  and  an  unstructured  N  terminus.  Cellular  studies 
confirmed that the protein could be modified by the addition of N-linked glycosylation at 
two locations (N181  and N197) and contains an internal disulphide bond between C l79 
and C214 (120; 121).  The protein was  found to be located at the cell surface and was 
anchored  to  the  cell  membrane  via  a  GPI  anchor attached  to  the  serine  at codon  231 
(122).  The scrapie form has proved more difficult to define.  Studies of purified scrapie 
material using Fourier transform infrared spectroscopy and circular dichroism suggested 
that PrP80 contained an increased proportion of beta sheet, leading to the suggestion that 
the infective process resulted in a switch from the predominantly alpha helical PrP  to the 
predominantly  beta  sheet  PrP8c  (123-125).  The  hydrophobic  nature  of PrP8c  is  not, 
however,  conducive  to  structural  studies  and  little  progress  has  been  made  towards 
elucidation of its atomic structure.  The  importance of an atomic  level model  for PrP8c 
cannot  be  underestimated,  as,  if  the  prion  hypothesis  holds  true,  it  is  the  three­
37dimensional  structure  of the  protein  that  contains  the  information  required  for  self­
replication.
Using  recombinant  PrP  expressed  in,  and  purified  from,  prokaryotes  such  as 
Escherischia coli, several experimental systems have been established to convert globular 
a-PrP,  thought  to  be  representative  of the  cellular  form  of PrP,  into  conformations 
resembling the  scrapie  isoform.  These rely  for the most part on adjusting the  solvent 
conditions that the recombinant prion protein is exposed to.  At a neutral pH and in none 
reducing  conditions,  PrP  adopts  the  predominantly  a-helical  structure  that  has  been 
extensively studied using NMR.  By denaturing the PrP and refolding it at lower pH and 
in reducing conditions, recombinant PrP can be forced to adopt a predominantly [3-sheet 
conformation (126; 127).  How this conformation relates to the scrapie isoform is a matter 
of debate,  although this  P-PrP certainly possesses  some of the  characteristics of PrPSc, 
such as an increased predilection for aggregation and increased resistance to digestion by 
proteinase K.  Another system, developed by Baskakov and colleagues, uses the presence 
of  denaturants  to  allow  the  generation  of  amyloid  fibrils  at  pH  6  in  a  nucleation 
dependant reaction (128; 129).
Ex Vivo Analyses
A  number  of cell  models  of prion  infection  and  propagation  have  been  developed. 
Attempts to generate such lines date back to the discovery of the transmissibility of CJD 
and  kuru  in  the  1960s,  although  these  attempts  met  with  limited  success  (130-132). 
During  the  1980s,  however,  a  number  of cell  lines  were  developed  that  could  stably 
propagate  a  limited  range  of  prion  strains  (e.g.  Rat  PC 12  cells,  Murine  N2a 
neuroblastoma cells, GT1 cells) (133; 134).  These cell lines have proved extremely useful
38for studying the cellular pathogenesis of prion diseases, and have been extensively used 
for identification of compounds with an anti-prion activity (135-137).  It should be noted, 
however, that cell models of prion replication do not provide a complete recapitulation of 
the in vivo situation.  A good example of this is the fact that many of the compounds 
identified using cell models have no impact in animal models of disease (138).  Recently, 
work has been carried out by several groups to produce highly susceptible sub-clones of 
the N2a cell line (139; 140).  This has facilitated the development of cell based assays for 
infectivity  that  are  at  least  as  sensitive  as  in  vivo  models,  but  require  far  shorter 
incubation times  (140).  It has been  suggested that the reason that these cell  lines are 
capable of sustaining prion replication is because their cellular environment is such that 
the kinetics of PrP80 propagation are above the threshold for its continued presence but 
does not reach a level that would be toxic to the cells (the dynamic susceptibility model) 
(141).
In addition to cell models of propagation, numerous cell based studies have been 
carried out using cell lines studying the biology of endogenous PrP or transfected with 
prion  protein  constructs  expressed  from  viral  or  episomal  vectors.  These  have  been 
widely used to probe the normal role of PrP and to analyse the behaviour of mutant forms 
of the protein (142-145).
In Vitro Analyses
The importance of in vitro techniques to both the study of TSEs and the prion hypothesis 
was recognised by Prusiner and by other groups, leading to several attempts to establish 
an  in  vitro  conversion of PrPc  to  PrPSc (146).  The  reduced complexity and  increased 
malleability of an in vitro system, as compared to an in vivo model, would, it was hoped,
39lend itself to a dissection of the infectious process and facilitate the definition of what 
was required for the conversion to take place.  Such a system would thus make proving, 
or falsifying, the premise that a purely protein agent was leading to infection and disease 
much easier.  It was certainly possible that in vitro techniques would open the door to the 
ultimate proof of the prion hypothesis: the constitution of protein-based genuine de novo 
infectivity in the absence of animal derived disease material.
In  1994  Caughey  and  co-workers  developed  the  first  in  vitro  model  of PrPSc 
formation.  They utilised a cell free system where PrPSc isolated from infected hamster 
brains  was  mixed  with  PrPc  material  isolated  from  uninfected  cultured  cells  partially 
denatured  in  3M  Guanidine  Hydrochloride  (GuHCl),  with  a  ratio  of 50  volumes  of 
infected material to 1  volume of uninfected material.  Radiolabelling of the PrPc material 
using  S methionine allowed discrimination between the infectious seed and any de novo 
PrPSc, as identified by protease resistance.  They found that under these conditions new 
protease resistant material could be formed (figure 1.5) (147).  Furthermore, the system 
could be used to model  some aspects of in  vivo prion disease,  for instance the  species 
barrier: hamster PrPc could be converted to a protease resistant form by mouse PrPSc; but 
the  reverse,  with  hamster  PrPSc  converting  mouse  PrPc,  could  not occur (148).  This 
mirrored data from animal models of the species barrier.  Mutational studies of the PrPc 
substrate  for  the  reaction,  creating  mouse/hamster  chimeras,  also  allowed  the 
identification of which regions of the prion protein were required for the species barrier 
to operate.  Later work demonstrated that the cell-free conversion system could be used 
to  assay  compounds  with  anti-prion  activity  and,  importantly,  that  certain  structural 
characteristics of distinct prion strains could be propagated in the system (149-151).
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Figure 1.5 Cell free replication of PrPRES.  Conversion of denatured, radiolabelled PrPc in 
vitro to a protease resistant state by incubation with an excess of PrPSc (147).
The  development  of the  cell  free  conversion  system  represented  a  substantial 
advance in the prion research field, and proved that interaction between PrPc and PrPSc 
could  result  in  the  production  of protease  resistant  material.  It  could  not,  however, 
answer several questions.  Why was such a vast excess of infectious material required for 
the conversion?  What were the specific co-factors needed for the conformational change
41to occur?  Was there a small nucleic acid element associated with the infectious agent? 
Also,  due  to  the  fact  that  such  small  amounts  of  new  PK  resistant  material  were 
produced, it was not amenable to use as sensitive diagnostic test.  Most importantly of all, 
work by  Hill  and  colleagues  demonstrated  that the  newly  generated  protease  resistant 
material did not represent new infectious material by using chimeric hamster/mouse PrP 
for the conversion and assaying for infectivity in Syrian Hamsters (152).
Saborio et al described a second in vitro conversion system in 2001.  Approaching 
the  problem  of in  vitro  prion replication using the  seeding  model  of propagation  as  a 
model,  Saborio  and  colleagues  reasoned  that  by  artificially  increasing  the  number  of 
small  seeds,  the  rate  at  which  prion  propagation  occurred  could  be  accelerated.  To 
achieve this, they spiked a PrPSc seed into an excess of substrate (i.e.  PrPc) by diluting 
brain  homogenate  from  hamsters  infected  with  the  prion  strain  263k  into  brain 
homogenate  from  uninfected  hamsters  (both  prepared  using  low  concentrations  of 
detergent).  Small  aliquots  of this  mixture  were  then  subjected  to  multiple  cycles  of 
sonication followed by one-hour incubations at 37°c with shaking.  This resulted in an 
apparent amplification of protease resistant PrP as analysed by western blotting with anti- 
PrP antibodies (figure  1.6) (153).  Indeed, the results of this technique, dubbed protein 
misfolding  by  cyclical  amplification  or  PMCA,  were  quite  spectacular  -  allowing 
detection  of PrPSc  at  1000  fold  dilution.  But,  as  with  other  in  vitro  models  of prion 
replication,  several  questions  still  remain.  First,  the  amplification  that  results  from 
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Figure  1.6  Protein  misfolding  by  cyclical  amplification.  Developed  by  Saborio  and 
colleagues,  protein  misfolding  by  cyclical  amplification  uses  mild  denaturants  and 
repeated sonication steps to accelerate fragmentation of PrPSc and conversion of PrPc to 
the protease resistant state.
Whether this represents an increase in PrPRES, let alone genuine de novo infectious PrPSc, 
is still a matter of debate.  Recent work by Bieschke and colleagues has  suggested that 
PMCA does  not result in any amplification of infectivity (154).  The  PMCA  technique
43was  subsequently  adapted  by  Suppatapone  and  colleagues,  who  relied  purely  on  the 
action  of detergents  to  “amplify”  the  PrP1158.  This  technique  has  since  been  used  to 
analyse both the sub-cellular biochemical environment and the co-factors required for in 
vitro amplification of PrPRES (155-157).
1.2.3  Models of PrP80 Propagation
Two  main  models  have  been  put  forward  to  explain  how  PrP8c  replicates  within  an 
organism and can be transmitted between hosts:  a refolding model and a seeding model. 
The  former  postulates  that  PrP80,  originating  from  either  an  exogenous  source  (i.e. 
infectious)  or  a  spontaneous,  endogenous  misfolding  event  (i.e.  either  sporadic  or 
favoured by an inherited mutation),  recruits and binds PrPc.  The scrapie isoform then 
somehow forces the cellular form to refold into the altered PrP8c conformation, acting as 
a template for the newly recruited PrPc.  The two then dissociate and are free to recruit 
more PrPc, thereby propagating infectivity (158).
The alternative, seeding model of scrapie replication states that equilibrium exists 
between the two alternate  folded conformers of the prion protein.  This  equilibrium  is 
normally skewed in favour of the cellular form of the protein but can be disrupted either 
by mutations that shift the equilibrium in favour of PrP8c or by the presence of stable, 
aggregated seed material.  Such  seeds  act as nodes that can  lock misfolded PrP  in the 
scrapie form, producing oligomers that aggregate to form amyloid fibrils in a nucleation 
dependant polymerisation reaction.  At some point these polymers will fracture to form
44multiple new  seeds  that can go on to propagate  more misfolded  PrP  (figure  1.7) (159- 
161).
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Figure  1.7 Refolding and seeding models of prion replication.  The refolding model (A) 
proposes  that  PrPSc  recruits  PrPc  and  converts  it  to  the  scrapie  isoform  by  an  as  yet 
unidentified  mechanism.  Newly  converted  PrPSc  is  then  free  to  recruit  and  convert 
further PrP  .  The increased concentration of the scrapie form results in aggregation.  The 
seeding  model  (B)  suggests  that  PrPc  and  PrPSc  exist  in  an  equilibrium  that  normally 
favours the cellular form.  Mutations in PrP or the presence of extrinsic aggregated PrPSc 
shifts the equilibrium towards the scrapie form, favouring accumulation and aggregation 
of the scrapie isoform.
1.2.4  A Yeast Paradigm
Some of the most convincing evidence that some proteins may have the ability to act as 
heritable  elements  comes  not  from  the  field  of mammalian  prion  disease,  where  the 
possibility was first recognised, but from the field of yeast genetics.  During the  1970s, 
several enigmatic non-mendelian epigenetic inherited traits were described in fungi.  In 
1994,  Reed  Wickner  suggested  that  prion-like  behaviour  could  explain  this  epigenetic
45behaviour  and  there  is  now  a  substantial  portfolio  of evidence  supporting  this  for  a 
number  of yeast  proteins  (162-164).  The  emerging  science  of yeast  prions  seems  to 
follow  closely  the  nucleaction-dependent  model  of PrPSc  replication  and  it  has  been 
shown  that  the  action  of yeast  prions  to  control  phenotype  is  dependent  upon  the 
aggregation properties of the proteins involved (165; 166).  Indeed, a crucial prion domain 
has been identified in several yeast prions that can be used to generate de novo chimeric 
proteins that exhibit prion like behaviour.  Interestingly, several groups have uncovered 
evidence that chaperones are closely linked to the efficacy of the prion-like conversion 
that occurs in yeast, with yeast lacking a crucial heat shock protein chaperone activity 
(HSP104)  being  unable  to  propagate  the  [PSI+]  prion  (167; 168).  This  reinforces  the 
crucial  role  of  protein  folding  in  the  process  of  prion  propagation,  and  may  have 
important ramifications for mammalian prions, as there is evidence that PrP interacts with 
cellular  chaperones  (169-171).  Recent  publications  by  the  groups  of Weissman  in 
California and  King  in  Florida  have  shown  that  in  vitro  produced amyloid  fibrils  can 
replicate the infective properties of in vivo derived yeast prions, experimental evidence 
central to the tenets of the prion hypothesis (172; 173).  Crucially, both groups reported 
that they were able to generate and propagate strain specific characteristics.
1.2.5  The Prion Hypothesis Today
In the quarter of a century since the origination of the prion hypothesis, much progress 
has  been  made  towards  its  ultimate  proof.  In  terms  of the  principle  of protein  only 
inheritance,  the  yeast  prion  field  has  provided  close  to  conclusive  evidence  that  this
46occurs  in  nature  (172; 173).  The  fact  that  strain  specific  characteristics,  albeit 
characteristics very different to those observed in the TSEs, could be propagated in vitro 
in  the  absence  of nucleic  acid  has  gone  some  way  to  countering  one  of the  major 
arguments  against  the  prion  hypothesis:  that,  even  if  protein  only  replication  was 
possible, it was not possible for one protein to encode the spectrum of TSE phenotypes. 
An emerging possibility is that the three dimensional structure of the ordered aggregates 
produced by prions facilitates the phenotypic diversity observed in both yeast prions and 
prion disease.  This may well be a function of the differing kinetics of formation and 
degradation  which  fibrils  constructed  from  different  prion  strains  display,  coupled  to 
variations  in the tissue specific expression of both degradation specific  machinery and 
protein folding apparatus.  Interestingly, work in the field of protein folding has shown 
that many proteins, under the right conditions, can be forced to adopt an amyloidogenic 
conformation  and  form  fibrils  (174).  What  may  make  the  yeast  prions  and  PrP 
exceptional  is  that  their  rate  of  folding  or  formation  of critical  nuclei  is  such  that 
propagation  of  this  generic  amyloidogenic  conformation  can  occur  between  cells, 
yielding an infectious process (175).  This correlates well with data indicating that PrP 
folds and unfolds at an unusually rapid rate (176).  One  implication of this  is that the 
basic  disease  mechanism  in prion  disorders  and other diseases  of protein  aggregation, 
such as Alzheimer’s disease and Parkinson’s disease, may well be very closely related.
The advances in our understanding of protein-only inheritance in yeast have not 
yet been wholly translated to the field of mammalian prions, and it is important to note 
that the relationship between the mechanisms observed in the yeast prion field and those 
in  infectious  mammalian disease  remains  unclear.  The  recent  work by  Legname  and
47colleagues, inducing prion disease in a transgenic model using amyloid fibrils produced 
in vitro from recombinant PrP, makes progress towards establishing such a link.  Their 
results  suggest,  albeit  with  many  experimental  caveats,  that  in  vitro  production  of 
mammalian  proteins  capable  of prion  behaviour  in  a  similar  way  to  the  experiments 
carried out in yeast is achievable (112).  Extension of this work, and detailed analysis of 
control experiments, is extremely important.
There remain, however, many questions regarding the exact nature of the scrapie 
agent  and  our  knowledge  of the  critical  steps  leading  to  conversion  of PrP  form  the 
cellular to the scrapie isoform is limited.  It is still not clear which of the models of prion 
replication best reflects the disease process, although the evidence from recombinant PrP 
fibril formation and from yeast studies suggests that the seeding model of replication may 
be closest to the in vivo situation.  From a pathological point of view, there is still a great 
deal of argument as to what is actually causing cell death in the prion diseases.  There is 
increasing evidence that amyloid protein deposits that are common to so many protein 
folding  disorders  are  not  the  actual  toxic  species,  and  that  it  is  the  small  oligomeric 
aggregates  that  lead  to  cellular  loss,  increasing  the  need  to  define  the  chemistry  of 
oligimer formation and the structures that these form (177; 178).
1.3  The Molecular Characteristics of the Cellular Prion Protein
Structure
The human cellular prion protein -  all  subsequent numbering refers to human PrP  -  is 
produced from a 253 amino acid single exon open reading frame located on the short arm
48of chromosome 20 (179).  PrP is highly conserved throughout mammals and birds and is 
widely expressed in adult tissues (180; 181).  Following translation, an N terminal signal 
peptide of 22 residues is removed, as is a C terminal peptide which is replaced with a GPI 
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Figure 1.8 Processing of the prion protein.  Following transcription and translation, N and 
C  terminal  peptides  are  removed.  Asparagine  residues  at  positions  181  and  197  are 
glycosylated,  a  GPI  anchor  is  added  to  residue  231  and  a  disulphide  bond  is  formed 
between cysteines at 179 and 214.
The remaining polypeptide consists of an unstructured N terminus from residue 23 to 124 
and  a  structured,  globular  C  terminus  from  residue  125  to  residue  228  with  a  short 
unstructured  tail  attached  to  the  GPI  anchor  (182).  PrP  can  be  glycosylated  at  two 
residues,  asparigine  181  and  197,  and  exists  in  vivo  as  a  mix  of  unglycosylated, 
monoglycosylated and diglycosylated moieties (121).  The unstructured N terminus of the 
human prion protein contains 5 octopeptide repeats (four repeats of GGGWGQPH and a 
pseudo  repeat of GGGWGQGG)  (183).  These  repeats bind  copper with  a  femtomolar 
efficiency,  a  fact  that  indicates  copper  binding  plays  an  important  part  in  the  prion
♦




49proteins  normal,  physiological  role(183-185).  Away  from the  flexible N  terminus, the 
structured C terminal domain of the prion protein contains 3 regions of a-helix (residues 
144-154,  173-194  and  200-228)  and  a  short antiparallel  (3-sheet (residues  128-131  and 
161-164) (116; 119).  Within the structured domain, an internal disulphide bond is formed 














Figure  1.9  Linear  and  three  dimensional  structures  of the  cellular  prion  protein.  The 
structured C-terminus consists of three a-helices and two short stretches of anti-parallel 
p-sheet.  The  unstructured  N-terminus  shows  the  octopeptide  repeat  region.  Adapted 
from Jackson and Collinge (186).
50Cell Biology
The cell biology of PrP has been studied in a great deal of detail since the cellular form of 
the  protein  was  discovered  in  the  1980s.  PrP  is  translated  in  the  rough  endoplasmic 
reticulum,  where  the  signal  peptides  within  it are  cleaved  off,  the  central  cores  of the 
oligosaccharides are attached and the GPI anchor added.  It is then trafficked to the Golgi 
apparatus where both the glycosylation and the GPI are modified (the GPI by the addition 
of Sialic  acid) (187).  Following translation and post translational  modification,  PrP  is 
passed to the cell surface where it is attached to the outer face of the plasma membrane 







PrP synthesised, GPI and 
core oligosaccharides 
added, disulphide bond 
formed and signal peptide 
cleaved
Oligosaccharides 
modified, sialic acid 
added to GPI and 
oligosaccharides
Passes to plasma 
membrane, 
localised to lipid 













Figure  1.10 Trafficking of the prion protein.  Following translation,  PrP  is modified by 
glycosylation,  disulphide  bond  formation  and  addition  of  a  GPI  in  the  endoplasmic 
reticulum.  It then passes to the Golgi where further modifications occur and thence to the 
plasma membrane where it is attached to the extracellular face of the bilayer via the GPI 
anchor.  Adapted from Alberts et al and Caughey (144; 188).
51In common with many other GPI-anchored proteins, PrP is localised to cholesterol rich 
areas  of  the  plasma  membrane  called  lipid  rafts  or  detergent  resistant  membranes, 
although the functional reason for this is not clear (189-191).  PrP is continually recycled 
from the cell surface through the endocytic pathway into the endosomes, an aspect of its 
cell biology that lends credence to the idea of PrP acting as a receptor of some kind (192). 
This recycling occurs through association of PrP with Clathrin coated pits, invaginations 
of the cell membrane that bud off into the cytoplasm to form the endosomes (193). 
Function
Despite 20 years of research, the normal physiological role of the prion protein remains a 
subject  of  debate.  Although  PRNP  is  a  gene  highly  conserved  throughout  higher 
Eukaryotes,  the  development  of several  lines  of viable  PrP  knock  out  mice  (PrP0/0) 
indicate that it is not essential for viability.  Indeed, the majority of PrP knock out mouse 
models display very little in the way of gross phenotypes.  There is some alteration in 
Calcium signalling and gross anatomy  in the hippocampus and some of the knock out 
models exhibit disrupted synaptic function, suggesting that the prion protein may play a 
role in synaptic transmission (194-196).  PrP0/0 mice also suffer from disrupted circadian 
rhythms,  an interesting fact considering that one  of the human prion diseases  (FFI)  is 
characterised by disorders of sleep although no direct link has been established in terms 
of the impact of PrP on circadian rhythms and the FFI phenotype (197-199).
As noted, PrP binds copper with high affinity, and it has been suggested that the 
prion protein acts in some way as a copper transporter within the brain (200;201).  This is 
supported  by  the  report  that  neuronal  copper  levels  being  decreased  in  PrP  knockout 
mice,  although  the  viability  of these  mice  argue  against  PrP  being  a central  player in
52copper transport (202).  It has also been reported that PrP displays an activity similar to 
that of Super Oxide Dismutase (SOD), providing a link between neuronal survival in the 
face of apoptotic stress and PrP -  which would have ramifications for the mechanism of 
PrPSc induced cell death (203-205).  This agrees with work by Kuwahara et al describing 
the protective effect of PrP against neuronal apoptosis, although it is by no means clear 
that  this  is  directly  linked  to  any  putative  SOD  activity  (206).  It  should  be  noted, 
however, that work by several groups have found no SOD activity associated with the 
prion protein (207).
Given the  location of the prion protein on the cell  surface and evidence that  it 
cycles between the  surface and the endosomes,  there has been much  speculation as to 
whether  the  prion  protein  is  involved  in  cell  adhesion  or  cell  signalling.  Interaction 
between PrP and neuronal cell adhesion molecules, and the  fact that overexpression of 
PrP  increases  cell  aggregation  in  a  neuronal  cell  line,  tend  to  support  a  role  in  cell 
adhesion (208;209).  In terms of cell signalling, direct evidence has not been forthcoming 
although  several  proteins  (including  the  laminin  receptor)  have  been  described  as 
interacting with PrP -  it is whether these interactions have a functional basis that remains 
unclear (210-212).  These is also evidence from antibody mediated cross linking studies 
in cell  culture  that PrP  may act as part of a  signal  transduction cascade,  although  the 
physiological relevance of this has yet to be discerned (213).
531.4 The Molecular Characteristics of the Scrapie Agent
Structure
The  structure  of the  scrapie  agent has  been a  major stumbling block to  TSE  research 
since its earliest days.  Whilst major advances have occurred -  notably the isolation of 
PrP in the early 1980s -  our knowledge of the atomic level structure of the scrapie agent 
remains scanty.  PrPSc retains the primary sequence of its cellular counterpart and is not 
differentiated from  it by covalent modification (102).  The acquisition of resistance to 
both proteolysis and proteasomal degradation by PrPSc is  suggestive of an alteration in 
secondary and tertiary structure (98;214-216).  PrPSc also acquires resistance to PIPLC 
cleavage of its GPI anchor, again suggesting that there has a structural re-arrangement 
occurs  that  results  in  steric  inhibition  of the  digesting  enzyme  (217;218).  Structural 
studies  of  purified  PrPSc  using  circular  dichroism  and  infrared  spectroscopy  have 
indicated  that  it  adopts  a  predominantly  (3   sheet  conformation  (the  isolation  of P  rich 
fibrils  from  TSE  infected  patients  and  animals  supports  this)  (20;125;219). 
Unfortunately, atomic resolution structures for either PrPSc or recombinant p-PrP have, to 
date,  proved  unobtainable  for  a  variety  of technical  reasons.  Most  importantly,  the 
intrinsic  insolubility of the protein to be studied makes it difficult to generate accurate 
structures using NMR or X-ray crystallography.  Despite this, models of PrPSc, featuring 
extensive P-sheet or P-helix, have been produced but, whilst fitting the meagre data that 
is available, remain hypothetical (160;220;221).
A  fascinating  aspect  of prion  structural  biology  is  the  existence  of structural 
variations  in  PrPSc  that  correlate  with  the  pathological  variation  found  in  the  prion
54disorders (222).  These structural strains are associated with specific patterns of protease 
resistant fragments of different sizes and glycoform ratios (between di-, mono- and un­
glycosylated  forms  of the  prion  protein)  following  proteinase  K  digestion.  Specific 
strains,  defined  by  phenotype  and  incubation  time,  and  capable  of propagating  both 
phenotype and structural aspects upon transmission, have been described in both animal 
models and human disease (figure 1.11) (223;224).
Strain Type
MW
(kOa)  Type 1   Type 2  Type 3  Type 4
Sporadic  MM  MM. MV, W   MV. W
Iatrogenic  MM  MM  MV, W
Variant  MM
Figure  1.11  Human molecular strain types.  A western blot (upper panel) and schematic 
(bottom panel) of human molecular strain types.  This illustrates alterations in fragment 
size  following  proteinase  K  digestion  and  altered  glycoform  ratios  (as  indicated  by 
different intensities for the di-, mono- and unglycosylated PrP fragments -  upper, middle 
and  lower  bands  respectively).  Type  4,  predominantly  diglycosylated,  is  associated 
exclusively with variant CJD. Adapted from Jackson and Collinge (225).
55One  of the  key  pieces  of evidence  supporting  the  aetiological  link between  BSE  and 
vCJD  is  the  continuity  of strain  type  between  the  two  diseases  -   both  marked  by  a 
predomination of diglycosylated PrP80 (27).  Indeed,  as  noted earlier (section  1.2),  the 
existence of such strains was initially a major weakness of the prion hypothesis.  In terms 
of the  structural  origin of these  strains,  it  has  been proposed  that  they  originate  from 
subtle alterations in the three dimensional structure of PrPSc, exposing different residues 
in the amino acid backbone of the protein to attack by proteases (224;226).  This leads to 
the  production  of  different  sized  fragments,  and  it  could  be  argued  that  such  re­
arrangements  could  also  result  in  the  differential  inclusion  of  discrete  ratios  of 
glycoforms into PrPSc aggregates within the diseased brain.  A recent report by Petkova et 
al  described  differential  cellular  toxicity  associated  with  different  conformations  of 
amyloid  P  peptide  amyloid  fibrils,  adding  weight  to  the  argument  that  the  strain 
phenomenon in prion  diseases  can  be  explained by  the  protein  only hypothesis  (227). 
Using BSE and vCJD as an example, it may be that di-glycosylated PrP is either recruited 
with greater ease by BSE prions or that it is more stable in the BSE prion conformation. 
This  is  congruent with the  seeding model of prion propagation:  the growth of highly 
ordered amyloid being more likely to occur with a homogenous population of available 
subunits.  In the case of BSE transmission to humans, bovine PrPc is predominantly di­
glycosylated, and the BSE agent reflects this bias in its substrate.  Upon transmission to a 
human host, the BSE prion would be more likely to recruit and propagate with the di­
glycosylated subpopulation of human PrPc rather than the structurally dissimilar mono- 
and  un-glycosylated  forms,  and  this  is  then  reproduced  in  the  strain  profile  of vCJD 
PrPSc.
56Cell Biology
Defining the cell biology of PrPSc has proved nearly as difficult as defining its structure. 
Several cellular models of prion propagation exist; including mouse N2a cells, rat PC 12 
cells and hympothalamic GT1  cells (133;134;228;229).  Exposure of these cell lines to 
infectious brain homogenate results  in the  stable propagation  of infectious  PrPSc.  The 
susceptibility of these lines is, however, severely limited to certain strains and the factors 
that make these cell lines susceptible are not well understood.  In addition to models of 
propagation, mutant forms of PrP overexpressed in a variety of cell lines acquire some of 
the characteristics of PrPSc (for example protease and phospholipase resistance) and have 
been used to investigate the cell biology of the scrapie agent (145;218;230).
In terms of what cell types can propagate PrPSc, the in vivo situation is complex. 
Central nervous system (CNS) tissue is both able to propagate prions and, as witnessed 
by  the  neuronal  death  concomitant  with  prion  disease,  susceptible  to  prion  mediated 
toxicity in all prion diseases.  The pattern of tissue distribution outside the CNS varies 
between  the  different  prion  diseases.  In  most  sporadic  disease,  for  example,  it  is 
primarily the CNS that is affected (4).  In vCJD and in experimentally transmitted forms 
of the prion diseases, the lymphoreticular system is intimately involved in the spread of 
infection from the initial site of infection (for example the digestive system) to the CNS, 
although the greatest concentration of infectivity is still located in CNS tissue (231;232). 
Worryingly,  small  quantities  of PrPSc  have  also  been  documented  in  muscle  tissue, 
raising the possibility of transmission  from ingestion of muscle  (233).  The reason  for 
these differences in tissue pathogenesis between prion diseases is unknown.
57Even given the availability of cell models of prion propagation, the actual cellular 
location of the PrPc to PrPSc conversion remains a mystery.  Research by Millson and 
colleagues in the 1960s and 70s applying cell fractionation to cells isolated from infected 
mice  showed  that  the  majority  of scrapie  infectivity  was  associated  with  the  plasma 
membrane  (234;235).  More  recently,  work by  Susan  Lindquist  and  colleagues  at  the 
Whitehead institute showed that, in uninfected cells, PrP could be forced to adopt a self 
perpetuating protease  resistant  form  following  accumulation  in  the  cytosol,  suggesting 
that this could be the genesis site of PrPSc (143).  How relevant this observation is to true 
infectious propagation is not yet clear, although it has been noted that PrPSc accumulates 
in the cytosol of infected N2a cells (236).  There is also evidence that conversion may 
occur in the endosomes and the lysosomal pathway (237).  Indeed, based upon studies of 
the  recombinant  p-PrP,  the  low  pH  of these  cellular  compartments  would  favour  the 
formation of a [3-sheet rich isoform,  and endocytosis would provide an entry route  for 
PrPSc  into the cell.  Evidence from cell  lines expressing disease associated mutant PrP 
indicates  that  such  proteins  are  retained  in  the  endoplasmic  reticulum,  raising  the 
possibility  that  some  element  of conversion  (perhaps  limited  to  the  inherited  prion 
diseases) may be  located in the endoplasmic  reticulum  (238).  It may be that PrPSc  is 
gregarious,  and  is  capable  of recruiting  PrPc  and  converting  it  to  the  scrapie  form  in 
several cellular locations.  The current data are inconclusive.
Toxicity
In terms of the pathogenesis of prion disease, a central question is how prion replication 
and the accumulation of PrP80  leads to cellular toxicity,  neuronal  loss and,  eventually, 
host  death.  Again,  this  has  been  the  subject  of a  great  deal  of research  but  remains
58unresolved (239).  It was originally proposed that PrPSc in its aggregated form was the 
toxic agent, but studies by Brandner and co-workers showed that PrPSc on its own was 
not enough to cause cell death and that the presence of cellular PrP was required for the 
toxic  effect (240).  This has been reinforced by recent work indicating that,  following 
removal of PrP expression in transgenic mice infected with RML, PrPSc persists and yet 
there is a reversal of spongiosis (241).  Both models suggest that it may be an aspect of 
the prion replication process itself that induces toxicity rather than the end product PrPSc. 
Indeed,  in  a  cell  model  of  Huntington’s  disease  (where  protein  aggregation  is  a 
neuropathological  hallmark),  there  is  evidence  that  there  is  a  protective  effect  upon 
formation of aggregated protein deposits within cells (242).  There does, however, appear 
to be intrinsic cytotoxicity of at least a fragment of the prion protein, covering residues 
106 to  126, although the mechanism of this toxicity is unclear and how relevant such a 
small  fragment  has  to  in  vivo  pathogenesis  is  open  to  debate  (243-245).  There  is 
increasing  evidence  that the  mechanism  of prion  toxicity  is  not  limited  to  PrP,  but  is 
common to several disorders of protein aggregation (178).  This work suggests that it is 
the small oligomeric species formed prior to the generation of large protein aggregates 
that  are  the  cause  of cytotoxicity,  and  that  these  oligomers  share  a  certain  level  of 
structural  similarity  in  prion  disease,  Alzheimer’s  disease  and  Huntington’s  disease 
(177; 178).  This leads to the possibility that it is the “sticky”, none-polymerised growing 
ends  of amyloid  fibrils  that  are  causing  the  damage  in  affected  cells,  as  the  absolute 
number of these is higher in a population of oligomers as opposed to mature fibrils given 
the  same concentration of subunits.  The  formation of fibrillar deposits  then begins to 
look like a self defence mechanism by the cell to try to limit the number of growing fibril
59seeds, an idea supported by the studies of huntingtin aggregation in cell culture.  Another 
possible  mechanism  of toxicity  has  been  described  by  Lansbury  and  co-workers  at 
Harvard University.  They presented evidence from microscopy studies that oligomeric 
amyloid can  form pore  like  complexes,  and  it  has  been  suggested  that  amyloid  pores 
could play a role in the cytotoxicity of amyloidogenic protein disorders,  inserting  into 
membranes  within  the  cell  and  altering  the  osmotic  balance,  leading  to  cell  death 
(246;247).
1.5 The Molecular Characteristics of the Prion Protein Codon 129 Polymorphism
The codon  129 polymorphism of the prion protein coding for either a methionine or a 
valine  was  first  described  by  Goldfarb  and  colleagues  in  1989  and  was  originally 
mistaken  for  a  pathogenic  mutation  (248).  It  was  soon  discovered,  however,  that 
variation at codon  129 was not causally linked to disease and was present in the general 
population (249;250).  The allelic distribution in Caucasian populations is approximately 
62.5%  methionine  and  37.5%  valine  (51%  of  Caucasian  populations  are  MV 
heterozygotes,  37%  MM homozygotes  and  12%  are  valine  homozygotes)  (251).  This 
rate varies around the world, and the codon 129 polymorphism is not found in East Asian 
populations where a lysine or glutamine polymorphism at codon 219 is present (E219K) 
and appears to confer the same advantage as a polymorphic codon 129 (39;40;64;252).
It was  soon apparent that the  codon  129  polymorphism  status  in an  individual, 
although not pathogenic, was a major modifier of the aetiology of prion disease.  This 
first  came  to  light  with  the  discovery  that  homozygosity  at  this  codon  predisposed
60carriers to iatrogenic and sporadic CJD (38;50).  Although homozygotes make up 49% of 
Caucasian populations, they represent 84% of sporadic CJD cases and 77% of iatrogenic 
cases (figure 1.12) (38;50;253)*.  Later studies also showed that methionine homozygotes 
were more susceptible to transmission of kuru and, thus far, all clinically affected vCJD 
patients have also been methionine homozygotes (63;77;254).
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Figure  1.12 Population distribution of codon 129 polymorphic variants.  The distribution 
in  the  population  as  a  whole  shows  a  51:49  split  between  heterozygotes  and 
homozygotes.  In  the  disease  state,  this  shifts  dramatically  to  a  ratio  of  23:77 
heterozygotes  to  homozygotes  for  iatrogenic  CJD  and  16:84  for  sporadic  CJD.  The 
underlying mechanism causing this predisposition of homozygotes to disease is unclear.
Furthermore, the codon  129 status plays a significant role in duration, age at onset and 
even phenotype of prion disease caused by inherited mutations, with homozygotes having
*  The E219K polymorphism seems to have the same effect, with heterozygotes protected 




61younger age  at  onset  and  shorter disease  course  than  heterozygotes  in  large  pedigrees 
with  pathogenic  PrP  mutations  (51;255).  In  several  families  carrying  the  D178N 
mutation of PrP, the  129 codon on the affected allele even defined whether the patients 
developed CJD (D178N, V129) or FFI (D178N, M129) (72;73).  A phenotypic alteration 
based  on  codon  129  status  is  also  witnessed  in  some  families  carrying  the  E200K 
mutation, although not as marked as that found with the D178N mutation (256).  In these 
kindreds,  and  in  sporadic  CJD,  the  codon  129  status  of patients  can  also  affect  what 
biochemical  strain  type  is  produced  within  the  affected  tissue,  indicating  a  possible 
structural  alteration  in  PrPSc,  as  revealed  by  proteinase  K  digestion,  based  upon  this 
polymorphism (figure 1.13) (73;257).
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Figure  1.13  Codon  129  molecular strain  type  variation.  A)  Distribution  of codon  129 
genotypes across the different molecular strain types, illustrating the uneven distribution 
of MM and VV homozygotes.  B) Alterations in glycoform ratio in type 3 human PrPS c 
due to codon  129 genotype.  Type 3  PrPSc from heterozygote patients exhibits a greater 
proportion of unglycosylated PrP.  Taken from reference 257.
62What then is the biochemical basis of the codon  129 phenotypic effects?  There 
are several ways in which heterozygosity could potentially act to affect the aetiology of 
prion disease.  As detailed in section  1.4, there is a wealth of evidence supporting the 
need for sequence homology as an important factor in the transmissibility of the scrapie 
agent,  with  the  species  barrier  being  a  prime  example  of this  (258).  Of particular 
relevance  to  the  codon  129  polymorphism  question  is  that  bovine  PrP  encodes  a 
methionine  at  the  homologous  amino  acid  to  codon  129  in  humans,  immediately 
suggesting  a  possible  basis  for  the  occurrence  of vCJD  in  methionine  homozygotes 
(180;259).  Although the methionine to valine polymorphism is a relatively conservative 
one, it could be that this provides enough of difference to cause an intra species, maybe 
even an intra host, barrier to the propagation of PrPS c (figure 1.14) (260).
Methionine  Valine
Amino Add nyaropnootciiy P Sheet Propensity Charge
Met -0.96 0.26 0
Vat -1.30 0.13 0
d y 0.00 0.60 0
A*P 3.81 0.72 -1
Figure  1.14 Methionine and valine atomic structures and properties.  Three dimensional 
structures  of methionine and  valine (upper panel) and molecular characteristics  (lower 
panel)  compared  to  glycine  and  asparagine.  This  illustrates  the  similarities  in  the 
properties of the two amino acids.
63Based  upon  the  seeding  model  of  prion  propagation,  the  immediate  impact  of 
heterozygosity  within  an  individual  host,  assuming  that  there  was  a kinetic  barrier of 
some kind introduced by the polymorphism, would be a halving of the substrate available 
for  conversion  and  propagation  of  the  amyloid  conformation  (261 ;262).  There  is 
increasing evidence that there is a dose effect in the propagation of amyloid in disease, as 
witnessed by the pathogenic effect of gene triplication of Amyloid (3  in downs syndrome 
and a-Synuclein in some cases of inherited Parkinson’s disease (263;264).  Increasing the 
concentration of available substrate would increase the rate of amyloid formation (as in 
Down’s  syndrome  and a-Synuclein triplication)  and,  conversely,  halving  the  available 
concentration of substrate (the case  in M/V heterozygotes)  would decrease  the  rate  of 
amyloid is a matter of simple physical chemistry (265).  Whether there is a direct link 
between amyloid formation and age at onset, disease course and maybe even phenotype 
is, however, still a matter of debate (266).
In addition to a pure dose effect, there is also the possibility that the heterozygote 
status actively  disrupts amyloid formation due to the heterogeneous population of PrP 
that  is  present  within  the  cell.  The  amyloid  deposits  that  are  formed  in  diseases 
associated  with protein misfolding are  remarkably uniform  in  structure within a  given 
individual fibril, although there is marked variation between fibrils (267;268).  If there is 
intrinsic variation in the subunits, introduced for example by a polymorphism, available 
for  a  growing  fibril  to  recruit,  this  may  act  to  terminate  any  polymerisation  that  is 
occurring.
64Biochemical Studies of  the Codon 129 Polymorphism
Because  of the  obvious  importance  of the  129  polymorphism  in  the  aetiology  of the 
human prion disorders, the biochemical properties of the two variants have come under 
significant scientific scrutiny.  Some structural differences were uncovered by Wong and 
colleagues,  who  looked at the  effect of copper upon mouse  recombinant prion protein 
residues  23-231,  with  either  methionine  at  codon  128  (homologous  to  codon  129  in 
huPrP) or an artificial valine 128 construct, although it should be noted that moPrP is not 
naturally  polymorphic  at  this  codon.  They  found  no  differences  in  copper  binding, 
protease resistance or SOD activity between the two forms,  however they did find that 
there  were  structural  alterations  differentiating  the  two  polymorphs  upon  binding  of 
copper (269).  These were revealed by CD spectroscopy and antibody binding using a 
panel of antibodies to different regions of the prion protein.  A major problem with this 
study is that, in addition to the fact that the codon  129 polymorphism does not occur in 
mice, there is a further 12% variation in sequence homology between mouse and human 
prion proteins (180).  Thus, whilst this study sheds light on the effects of the codon  129 
polymorphism and copper on moPrP, its conclusions are not necessarily transferable to 
human  PrP.  This  limitation  is  further  highlighted  by  a  synthetic  mutation  (changing 
phenylalanine  at residue  175  to a tryptophan)  introduced  into  mouse PrP  to act as  an 
optical probe of conformational change by Glockshuber and co-workers (176).  In mouse 
PrP,  this had no observable  impact on  structure or stability of the protein.  When  this 
mutation  was  created  on  a  human  PrP  background,  however,  it  resulted  in  massive 
destabilisation of the polypeptide, preventing it from achieving its native conformation 
(270).  This result is a dramatic example of the drawbacks of modelling human mutations
65on  a  mouse  framework,  drawbacks  which  act  as  a  caveat  to  the  work  of Wong  and 
colleagues with regard to the copper binding properties of the codon 129 variants.
Using a shortened PrP synthetic peptide covering residues  109-136, Petchanikow 
et al studied the biochemical characteristics of the methionine and valine 129 polymorphs 
under a variety of conditions.  They found that the methionine form of the peptide had a 
greater propensity  to  adopt  a  p-sheet  conformation  (as  analysed  by  CD)  and  to  form 
amyloid like fibrils (examined by electron microscopy) (271).  The fact that this study 
was  carried  out  on  a  27  amino  acid  peptide  rather  than  either  full  length  PrP  or  the 
structured C-terminal domain (roughly residue 90 onwards), calls into question whether 
this truly reflects the behaviour of the mature protein, although it is certainly suggestive 
of a biochemical basis for the phenotypic differences observed in prion disease associated 
with the MW polymorphism.  The propensity of the M and V variants of human PrP 91- 
231  to aggregate and form oligomers was  examined by Tahari-Alaoui et al.  They put 
both  forms  of the  protein  into  conditions  that  favoured  the  formation  of oligomeric 
aggregates (128).  Under these conditions, they found that the methionine form formed 
such aggregates more rapidly then the valine form, again suggesting that the aggregation 
properties  of the  M  and  V  variants  may  play  an  important  part  in  the  phenotypic 
differences between the two forms (272).  Fibrillisation studies carried out using a short 
peptide sequence (residues 118-133 of human PrP) by Come and Lansbury also revealed 
differences  in  the  behaviour  of  the  two  polymorphic  variants  (262).  Studying  the 
nucleation  dependent  polymerisation  of  these  short  peptides,  they  showed  that 
methionine forms fibrils faster than valine, and both undergo polymerisation more rapidly
66than a “heterozygous” mixture*.  This led to the production of a nucleation model for the 
formation of amyloid by the two polymorphs (figure 1.15).  As discussed above, there are 
problems associated with extrapolating results gained with short peptides to the situation 
in the full length or the structured C-terminus of the prion protein.
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Figure  1.15 Nucleation model of the codon 129 impact on prion replication.  This model 
proposes that the formation of dimers (M2, V2 and MV) is energetically unfavourable, as 
is  the  formation  of a  nucleating  critical  mass  (Mn,  Vn  and  MVn).  Once  a  nucleus  is 
formed, the growth of amyloid fibrils becomes energetically favoured.  If the dissociation 
constants  for M and V (KnM  and KnV)  are  lower than that for MV  (KnMV),  then the 
formation of aggregates in homozygotes would have a lower energy barrier to overcome 
than in heterozygotes.  Adapted from Come and Lansbury (262).
This study does, again,  suggest that there may be a biochemical difference between the 
two  forms  based  upon  their  aggregation/polymerisation  properties.  Most  recently, 
however, work by Tahiri-Alaoui and James has suggested that the interaction between the
*  Nucleation time (defined as the time point at which fibril concentration reaches 20% of 
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67two  polymorphic  variants  in  the  formation  of  fibrils  is  more  complex.  A  recently 
published  paper  from  them  shows  no  difference  in  amyloid  formation  (measured  by 
thioflavin T binding)  from the native a-helical rich monomeric conformer between the 
two variants.  Referred to in the paper, however, is data in preparation that suggests that 
there is a large impact of the polymorphism on amyloid formation from the partially or 
fully denatured state, although full details are not given.  Their hypothesis is that there are 
several pathways leading to either amyloid or oligomer formation,  with the codon  129 
polymorphism  differentially  impacting  on amyloid  formation  from the  denatured  form 
and oligomer formation, but not on amyloid formation from the PrP in a fully natured 
state (273).
One obvious possibility for a biochemical difference between the two forms is a 
simple alteration in the secondary or tertiary structure.  Although little progress has been 
made in elucidating the structures of either methionine or valine PrPSc, the NMR solution 
structures of M and V polymorphs of a-PrP have been determined (115; 116;274).  No 
significant difference was observed in structure, stability or amide protection, indicating 
that  it  is  unlikely  that  the  phenotypic  differences  between  the  variants  originate  from 
effects upon cellular PrP (figure 1.16).
68Figure 1.16 Atomic resolution structures of Ml 29 and VI29 prion protein variants.  Panel 
(A)  shows  the  three  dimensional  structure  of  valine  129  a-PrP  with  alpha  helices 
highlighted in red,  beta sheet  structures highlighted in turquoise,  the disulphide bridge 
indicated by a dashed yellow line and residue 129 depicted as a yellow sphere.  Panel (B) 
shows structures for V129 a-PrP (gold) and M129 a-PrP (blue).  There is no significant 
difference  between  the  structures  detectable  at  this  level  of resolution.  Taken  from 
Hosszu et al (275).
Liemann and Glockshuber also examined the stability of the two polymorphic variants of 
PrP,  using  recombinant  a-PrP  covering  residues  121-231.  They  found  no  significant 
difference in the stabilities of the two forms as revealed by urea denaturation (276).  In 
summary,  there  are  some  intriguing  (and,  based  upon  the  conservative  nature  of the 
polymorphism, somewhat unexpected) biochemical data suggesting differences between 
the codon  129 polymorphic variants in terms of their aggregation properties, balanced by 
evidence  showing  very  little  alteration  in  the  basic  structure  of a  PrP.  Much  of the 
biochemistry of the M/V polymorphism, however, remains to be investigated.  There is a 
strong possibility, based upon the absence of alterations in the a-conformation, that the 
polymorphism  may  be  exerting  its  impact  via  an  altered  conformational  state.
692.0 Structural Studies of the Codon 129 Polymorphism
Despite over a decade of investigation, the basis for the codon 129 phenotype still eludes 
researchers.  There remain many areas of the biochemistry of the two PrP variants that 
have yet to be investigated in depth;  areas that may shed light on both the phenotypes 
exhibited  by  the  allelic  forms  of the  prion  protein  and,  more  fundamentally,  on  the 
mechanism of prion replication itself.  This chapter will attempt to assess the impact of 
the codon 129 polymorphism upon several aspects of the molecular characteristics of the 
scrapie agent, comparing and contrasting the basic structural properties of the two codon 
129  variants.  The  investigation  of the  biochemistry  and  structure  of the  codon  129 
polymorphism presents several unique problems.  The greatest of these are the problems 
associated with modelling a protein that can adopt two radically different conformations 
with the  same primary sequence and the  intractable  issue of dealing with the  inherent 
insolubility of the scrapie isoform.  In the absence of PrPSc purified to a level that would 
allow  accurate  structural  studies,  most  biophysical  and  structural  studies  have  been 
carried out using recombinant PrP  expressed in bacteria or yeast.  When purified and 
initially folded under neutral pH conditions, recombinant PrP adopts a predominantly a- 
helical conformation -  representative of the normal cellular conformation of PrP.  Several 
systems have been developed to  refold recombinant PrP  into  a predominantly  p-sheet 
conformation (127;277;278).  Whilst these do not exactly replicate the scrapie isoform, 
they  do  recapitulate  several  of  its  properties  (such  as  the  P-sheet  structure,  partial 
proteinase K resistance  and propensity to  form amyloid fibrils).  The major drawback 
with these systems is that, with the possible exception of a protocol producing amyloid
70fibrils from recombinant PrP developed by Baskakov et al, it has not yet been possible to 
demonstrate infectivity generated in vitro.  Since within the protein only hypothesis this 
is the defining characteristic of PrPSc, recombinant forms of p PrP are, at best, incomplete 
models  of the  scrapie  agent.  Despite  this,  the  amenability  of recombinant  PrP  to 
structural analyses makes it the best available model at present and recombinant protein 
was  used  in  this  study.  Using  recombinant  PrP  as  a  model,  the  structure,  stability, 
protease resistance and copper binding properties of M l29 and VI29 PrP were examined 
using a range of techniques in an attempt to uncover a biochemical basis for the codon 
129  phenotype.  Due  to  the problems  associated with  modelling human mutations  or 
polymorphisms on a mouse protein background (see section 1.5), all studies were carried 
out using recombinant human prion protein.  There are several alternatives as regards the 
size of the recombinant prion protein to be used in such studies, with a range of different 
length constructs having been used in previous studies.  As described in section 1.4, the 
prion protein consists of an unstructured N-terminal region and a structured C-terminal 
region, comprising approximately residues  124 to 231.  Most studies have been carried 
out using full-length prion protein, residues 23-231 (residues 1-22 being removed in vivo 
as a signal peptide), or the structured C-terminal region plus a copper binding domain, 
residues 91-231.  In terms of structural properties, several studies have shown that the C- 
terminal ordered domains have broadly similar properties to the frill length protein and 
so,  for the purposes  of this  study,  recombinant human protein covering the  structured 
region of residues 91-231 will be used (276).
712.1 Purification of Recombinant PrP
In  order to  carry  out  these  investigations,  recombinant  human  prion  protein  covering 
residues  91-231  and encoding  either a methionine or a valine  at codon  129 had to be 
produced and purified from bacteria.
2.1.1  Production of a PrP
All  work  with  recombinant  prion  protein  was  carried  out  in  a  class  III  laboratory 
following strict biosafety protocols.  Decontamination of equipment and materials was 
carried out as per institutional guidelines using either Sodium Hypochlorite (at greater 
than 20,000 parts per million available chlorine) or 2M Sodium Hydroxide.
A human prion protein construct coding for residues 91  to 231  was amplified from the 
open reading  frame  of huPrP M l29  and inserted into the  expression vector pTrcHisB 
(Invitrogen).  Residue 90 was converted to a methionine in order to insert a thrombin 
cleavage site into the protein and a His tag was added to the N terminal of the protein. 
Using site directed mutagenesis, a duplicate construct containing valine at codon 129 was 
created.  Both  constructs  were  transformed  into  Escherichia  coli  strain  BL21  (DE3) 
(Novagen) and the bacteria then grown on agar plates containing lOOpg/ml carbenicillin 
to  facilitate  selection  of  transfected  clones.  Following  selection,  constructs  were 
sequenced to confirm the presence of the correct PrP variant.  To grow bacteria sufficient 
for purification of protein, a clone of each construct was inoculated into  lOOmls of LB
72growth  media  containing  lOOpg/ml  carbenicillin  and  grown  overnight  at  37°C  with 
shaking.  lOmls of this overnight growth was then placed into 1   litre flasks of LB media 
(total volume 9 litres), also containing carbenicillin, and grown until the optical density at 
600nm reached 0.6.  Induction of prion protein expression was achieved by the addition 
of IPTG to a final concentration of ImM.  The bacteria were then grown for 16 hours and 
harvested by centrifugation at 9,600 rpm for 10 minutes.
Harvested cells were then resuspended in 50ml extraction buffer (50mM TRIS.C1 
pH  8.0,  200mM  NaCl,  0.1%  Tween-20,  50U/ml  Benzonase,  lOug/ml  Lysozyme)  and 
sonicated with a  15  second burst at 25% power 5 times.  The resulting suspension was 
centrifuged  for  30  minutes  at  9,600  rpm,  the  supernatant  discarded  and  the  process 
repeated.  50ml of solubilisation buffer (6M GuHCl,  50mM TRIS.C1 pH8.0,  0.8% v/v 
beta-mercaptoethanol)  was  then  added  to  the  pellet  and  the  protein  resuspended  by 
sonication for 30 seconds at 25% power 4 times.  The suspension was then centrifuged at 
14,000 rpm for 45 mins and the supernatant removed.  The process was repeated with the 
resulting  pellet  and  the  supernatants  pooled.  The  protein  concentration  was  then 
determined by measurement at A280nm and the solution diluted to ~ 5mg/ml protein.
To  remove  contaminating  endogenous  bacterial  proteins,  the  crude  solubilised 
protein was then purified using metal chelate affinity chromatography.  A nitrilotriacetic 
acid  sepharose  matrix  loaded  with  nickel  ions  was  used  and  the  recombinant  prion 
protein  bound  via  the  His  tag  at  its  N  terminus.  The  column  was  washed  with  6M 
GuHCl, 50mM TrisCl pH 8.0 to remove any non-specifically bound proteins and the PrP 
eluted using  a gradient  of the  wash buffer with  the  addition of 1M  Imidazole,  which 
competes with the histidines for binding to the nickel.  The flow through from the initial
73loading  was  reloaded onto  the  column  and  eluted prion protein  fractions  pooled.  The 
pooled fractions were diluted to ~ 1  mg/ml protein, and lpM copper sulphate added to the 
mix.  The protein was then allowed to oxidise  for  16 hours by vigorous  stirring in the 
presence of atmospheric oxygen.  The resulting oxidised protein was then dialysed four 
times  against 25mM TRIS.C1 pH  8.4,  0.02% Na azide to remove the GuHCl,  with the 
final dialysis against 25mM Tris.Cl pH8.4,  150mM NaCl, 2.5mM CaCl and 0.02% azide 
to facilitate thrombin cleavage.  To remove the poly-histidine tag,  the protein was then 
treated  with  0.1  units  of  Thrombin  per  milligram  of  protein  for  16  hours  at  room 
temperature,  with  the  digest  terminated  by  the  addition  of 4-(2-aminoethyl)-benzene 
sulfonyl fluoride (AEBSF) to a final concentration of 5mM (figure 2.1).
Figure 2.1  Thrombin cleavage of recombinant 
prion protein.  Coomassie blue stained M l29 
91-231  PrP separated by SDS gel electrophoresis 
before and after incubation with thombin.  This 
shows the decrease in relative molecular mass 
following removal of the polyhistidine purification 
tag.
Thrombin  -  +
The pH of the buffer was reduced to  7  by the addition of dilute hydrochloric  acid.  In 
order to remove the cleaved His tag from the protein solution, the protein was then run 
over a nickel column,  to which the  His tag bound tightly but the protein did not.  The 
protein was eluted by a wash with 20mM TrisCl pH 7.5  containing 25mM imidazole, a 
concentration of imidazole high enough to release the PrP but not high enough to disrupt 
the binding of the His tag to the nickel.  The eluted protein was dialysed against  lOmM 




74concentration, analysis of purity by SDS polyacrylamide gel electrophoresis and staining 
with  Coomassie  blue,  and  analysis  of  conformation  by  circular  diochroism 
spectropolarimetry.  The protein was then stored at 4°C in the presence of ImM AEBSF 
and 0.02% sodium azide until required for use.
2.1.2  Conversion of a-PrP to 0-PrP
Conversion to  the  p-PrP  conformation was  carried  out using  a protocol  adapted  from 
Jackson et al (127).  a-PrP comprising residues 91  to 231  containing either M or V at 
codon 129 was concentrated to 2 mg/ml and dialysed against lOmM NaAcetate pH 7 to 
remove AEBSF and sodium azide.  Solid GuHCl was then added to a final concentration 
of 6M, assuming a doubling of the initial volume, to denature the protein and solid DTT 
was added to a final concentration of lOOmM in order to reduce the disulphide bond.  The 
protein was then left at room temperature for 2 hours.  Refolding of denatured, reduced 
PrP was carried out: the protein was dialysed against 50 volumes of lOmM NaAcetate 
pH4.0,  lOOmM DTT for 6 hours and then transferred to 50 volumes of lOmM NaAcetate 
pH4.0, lOmM DTT for 16 hours.  This last step was repeated for a 6 hour dialysis against 
fresh buffer and  final  dialysis  was  carried out against  lOmM NaAcetate pH4.0,  2mM 
DTT, 0.02% w/v NaAzide for  16 hours.  The protein was concentrated to 2mg/ml and 
spun at  150,000g for 4 hours in Beckmann Optima XL-100k preparative ultracentrifuge 
to remove any aggregated protein.  The  supernatant was removed,  assayed for protein 
concentration by measuring absorbance at >,280nm, and analysed for secondary structure 
conformation using circular dichroism spectropolarimetry (see below, section 2.2).2.2  Structural and Stability of the codon 129 polymorphs
There are several techniques that can be used to analyse the structural characteristics and 
properties of recombinant protein.  These vary in the level of detail they reveal and the 
complexity of the technique and preparation required for analysis.  In terms of structural 
detail,  NMR  and  X-ray  crystallography  reveal  the  highest  level  of  atomic  detail. 
Unfortunately, both require carefully prepared material,  free  in solution in the  case  of 
NMR and in the form of crystal lattices in the case of x-ray determination.  NMR has 
been  successfully  applied  to  the  a-helical  form  of recombinant  PrP  (both  M  and  V 
forms), but has not yet yielded results for the P-rich form.  To date, no crystal structure 
has been elucidated for p-PrP,  although several exist for the a-helical  form (279;280). 
Far cruder in terms of the detail they reveal, but simpler to use, are infrared and circular 
dichroism (CD) spectropolarimetry.  Both can be used to examine the global folding of 
proteins,  yielding  information  about  the  proportion  of  alpha  helical  and  beta  sheet 
structure  to  be  found  within  a  given  polypeptide.  These  techniques  also  have  the 
advantage that they can be used to follow folding as conditions change, for example as 
temperature, pH or the concentration of denaturants alters.
Analysis by Circular Dichroism
Analysis  of recombinant PrP  secondary  structure  was  carried out using  a Jasco  J-715 
circular  dichroism  spectropolarimeter  (figure  2.2).  Circular  dichroism  relies  on  the 
interaction of optically active molecules (those with a chiral centre) with left and right 
handed circularly polarised light.
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Figure  2.2  Circular  dichroism  spectropolarimeter  setup.  Linearly  polarised  light  is 
produced  in  a  monochromator.  This  light  is  then  circularised  by  a  photoelectric 
modulator  and  passed  through  the  sample  of interest.  Any  alterations  in  molecular 
ellipticity at different wavelengths due to the sample are recorded by the detector.
Such  light  interacts  differently  with  L  and  D  enantomers  of a  given  chiral  molecule, 
producing  different absorbances  (A l  and  A R)  at  different  wavelengths.  In  addition  to 
allowing determination of chirality in a non-racemic mixture, CD is highly sensitive to 
conformational alterations in complex biomolecules (composed, as most of them are, of 
optically active subunits) (281;282).  From the standpoint of protein chemistry, the fact 
that  a-helical  and  P-sheet  conformations  interact  with  circularly  polarised  light  at 
different wavelengths in different ways provides a useful, if somewhat crude, tool for the 
estimation  of protein  structure  (283;284).  The  distinctive  CD  spectra  in  the  far  UV 
region  for a-helical,  p-sheet and random coil  structures  adopted by polypeptide  chains 
have  been  defined  experimentally  (285).  Predominantly  a-helical  structures  exhibit  2 
negative  minima  at  X  208  and  X  222nm,  with  a  positive  maximum  at  190nm. 
Predominantly p-sheet polypeptides exhibit a single negative minimum at 217nm, with a
77positive maximum at  195nm.  There are a greater variety of spectra recorded for p-sheet 
domains, possibly due to the greater diversity of structures sharing a P-rich conformation 
(for example parallel p-sheets, anti-parallel p-sheets and p-tums).  A disordered, random 
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Figure  2.3  Experimentally  determined  circular dichroism  spectra  for a-helical,  p-sheet 
and  random  coil  protein  structures,  a-helical  polypeptides  exhibit  double  minima  at 
208nm and 222nm, p-sheet polypeptides a single minimum at 217nm and polypeptides in 
random coil conformation a minimum around 200nm.  Data taken from Greenfield and 
Fasman (285).
In addition to global folding information, CD can also be used to examine the stability of 
proteins  upon either heat or  chemical  denaturation.  As  the  minima  observed  between 
222nm and 208nm are indicative of 2° structural organisation, changes in this region can 




78application  of  denaturing  conditions  (for  example  increased  heat  or  increased 
concentrations  of chemical  denaturants  such  as  Guanidine  Hydrochloride),  absorption 
values  in  this  region  will  become  less  negative  as  the  protein  loses  2°  structure  and 
becomes  more  random  coil  like.  By  increasing  the  temperature  or  denaturant 
concentration  stepwise  and  measuring  the  concomitant  alteration  in  CD  signal,  it  is 
possible to follow the unfolding of a protein.  Data from this unfolding process can then 
be used to  calculate the  free  energy  of folding,  AG,  allowing  the  stability  of the  two 
polymorphic  forms  of  PrP  to  be  directly  compared  (286).  To  calculate  AG  for 
physiologically relevant conditions  (id est with water as the  solvent,  AGW ),  the AG  at 
different concentrations of denaturant (AGd) is calculated using formula i:
AGd * -RT In (FIU)
Where F and U describe the concentrations of protein in the folded and unfolded states 
(calculated using CD data).  For proteins that undergo an unfolding transition between 0 
and 1M GuHCl, these data can be extrapolated in a linear fashion using equation ii:
AGd = AGW + m [denaturant]
Where m is the gradient of the data in the linear plot.  By extrapolating to a denaturant 
concentration of zero, the AGW  can be derived.  For proteins that undergo an unfolding 
transition  at  concentrations  of GuHCl  between  1   and  4M,  however,  a  simple  linear 
extrapolation  does  not  result  in  an  accurate  value  for AGW .  In  these  conditions,  the
79solvation energy of the side chains involved in the unfolding process must be taken into 
consideration using formula iii:
AGd = AGW + /?wrAGsm [denaturant] 
(Kden+ [denaturant])
Where  is the number of completely buried residues in the fully folded protein, AGs,m  
is the maximum change in solvation energy at an infinite concentration of denaturant, 
A T den is the dissociation constant for the denaturant concentration required to achieve half 
of AGs,m.  These  values  can be  calculated from the  atomic  resolution  structure  of the 
protein in question.  Using this formula, an accurate estimation of AGW  can be achieved, 
allowing comparison of protein stability in the folded state.
Methods
For collection of CD spectra in the far UV range, protein was diluted to lmg/ml, spun for 
20 mins at  15,000 rpm and placed in a 0.01cm path length cuvette.  Absorption values 
were recorded using a Jasco J-715 CD spectropolarimeter at 20°C from X 250 to X  190 
nm with a lnm pitch and a band width of lOnm.  Scanning speed was set at 200nm/min 
and the final spectra were averages from 40 individual scans.  In parallel to sample CD 
spectra,  scans  were  recorded under the  same  conditions  for buffer alone -  values  for 
which were subtracted from sample readings to remove any background absorption.
For stability analysis, protein was diluted to 0.1 mg/ml, spun for 20 mins at 15,000 
rpm and placed  in  a  1cm path  length,  3 ml cuvette with  a minimum initial  volume  of
801.5ml.  To ascertain the starting folded population,  an initial reading was taken with a 
lOnm bandwidth around X 220nm.  A set volume of denaturant was then added to the 
fully natured protein and mixed well, with the absorption reading allowed to settle to a 
flat line before subsequent additions were made.  Absorption values were recorded for 
each stepwise addition of denaturant.  Taking the initial reading as being representative of 
100%  of molecules  in  the  native  state,  these  were  then  converted  to  a percentage  of 
molecules folded -  taking into account the dilution effect of denaturant addition.  These 
values  were  then  plotted  against  denaturant  concentration  and/or  denaturant  activity 
(calculated using formula zv), again taking into account any dilution effect.
Denaturant activity =
[GuHCl] x 7.5 
[GuHCl] + 7.5
[Urea] x 22 
[Urea] + 22
2.2.1  Alpha PrP Studies
As  an  initial  investigation,  the  structure  of aPrP  residues  91-231  containing valine  or 
methionine at codon  129 were  examined by CD  spectroscopy.  Spectra in the  far UV 
range (X 190-230nm -  containing information about 2° structure) were recorded for both 
variants.  As one would expect based upon previous studies, both methionine and valine 
forms  exhibited  spectra  characteristic  of a predominantly  a-helical conformation,  with 
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Figure 2.4  a-PrP  91-231  M l29  and VI29  circular dichroism spectra.  Far UV circular 
dichroism spectra for M l29 a-PrP (A) and V I29 a-PrP (B).  Spectra were recorded using 
a  Jasco  J-715  spectropolarimeter  at  a  protein  concentration  of  1  mg/ml  and  over  a 
pathlength of 0.01cm.  Final spectra represent an average of 40 individual  scans.  Both 
M l29 a-PrP and VI29 a-PrP display spectra characteristic of a predominantly a-helical 
conformation, with minima at 208nm and 222nm.
When  overlaid,  the  spectra  were  not  significantly  different,  with  slight  differences  in 
intensity across the  spectra reflecting  small differences  in protein concentration  (figure 
2.5).
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Figure  2.5  Overlaid  M129  ( • )   and  V129  (A) a-PrP  circular  dichroism  spectra.  No 
significant difference was observed between the  polymorphs.  Collection details  are as 
for figure 2.4.
82This agrees with previous work,  using both CD  and NMR,  which  found no  significant 
difference between the two forms in the a-helical conformation (275).
Although there is no apparent difference in the overall global fold of the M and V 
a-PrP  variants  as  ascertained  by  CD  and  NMR,  neither  of  the  techniques  reveal 
information  about  the  relative  stabilities  of the  proteins  under  investigation.  Despite 
having very similar folded structures, it may be that the differences in the M and V side 
chains at residue 129 results in different protein stabilities for the two forms.  To examine 
this,  M  and  V  recombinant prion proteins  were  subjected to  equilibrium  unfolding  by 
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Figure  2.6  Denaturation  profiles  for  M l29  and  VI29  a-PrP  Equilibrium  denaturation 
curves of 129M ( • ) and 129V (A), as measured by amide CD absorption at 222nm. The 
lines superimposed upon the data are fits to the function:
aN  = (K(N/u).exp(m.D))/(l+K(N/u).exp(m.D))
The free energy of unfolding in water was calculated to be 6.62 kcal mol'1  for M l29 a- 
PrP and 6.52 kcal mol'1  for VI29 a-PrP.
83The unfolding process was followed using circular dichroism to measure the percentage 
of molecules present  in  solution  in  a  folded  state,  and  is  displayed in  figure  2.6  as  a 
percentage of folded molecules (taking the measurement in the presence of no denaturant 
as  100%) plotted against denaturant concentration.  As the concentration of denaturant 
increase,  both  forms  initially  unfold  slowly  until  a  GuHCl  concentration  of  2M  is 
reached,  when  both  undergo  a  cooperative  unfolding  transition,  characteristic  of  a 
compacted  single  folded  domain.  Importantly,  both  forms  undergo  this  transition  at 
equivalent GuHCl concentrations -  showing that their relative stabilities in the presence 
of guanidine are very similar.  When the AG of unfolding was calculated for M l29 and 
VI29 91-231 a-PrP, there was no significant difference in the values for the two proteins, 
indicating that the stabilities of the two forms are indistinguishable using this technique. 
This  is  in agreement with previous work, using both shortened PrP constructs and the 
structured C-terminus of PrP (275;276).
2.2.2  Beta PrP Studies
The absence of difference between the NMR solution structure of the two polymorphic 
variants in the alpha conformation, combined with biophysical data using several other 
techniques, suggests that, if a structural difference between the two forms exists, it lies 
either in partly folded intermediates or in the P-rich state (274).  This is supported by the 
results  from CD and unfolding  studies described in the previous  section.  If there  is a 
difference between the  structures  of the  codon  129 polymorphic variants  in the  p-rich 
conformation, this poses the question as to how to uncover such a difference.  As noted in
84section 1.4, a great deal of effort has been dedicated by researchers across the globe in an 
attempt to  elucidate the  atomic resolution structure of the  (3-form of PrP.  At present, 
these efforts remain unrewarded.  Low resolution techniques, such as CD spectroscopy, 
have been used to investigate within the limits of their sensitivity the structure of p-PrP. 
Approaches  such as  CD,  and indirect methods  that reveal  aspects  of protein  structure 
such  as  partial  proteolytic  digestion,  offer  the  best  routes  currently  available  towards 
determining if there is a difference in the structures of M and V forms of p-PrP.
As  a  first  step  towards  investigating  the  M  and  V  polymorphs  in  the  beta 
conformation, the conversion from the a to the (3-state was examined.  This was carried 
out using the protocol of Jackson et al (127).  Briefly, equal volumes and concentrations 
of each variant were unfolded in 10M GuHCl in reducing conditions and then refolded by 
dialysis  into  sodium acetate buffer at  low pH.  After confirming that the protein had 
converted  to  a predominantly  p-fold  using  CD  (see  below),  the  percentage  yield  was 
calculated by  comparing  the  amount  of p-folded protein  left  in  solution  to  the  initial 
amount  of protein.  By  comparing  the  percentage  yields  from  multiple  conversion 
experiments, the relative propensities of the two forms to undergo the conversion to the P 
conformation could be compared (figure 2.7).
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Figure 2.7 Yield for conversion of a-PrP 
M129 and V129 variants to P~PrP form. 
The  yield of folded soluble, monomeric 
protein in a beta-sheet conformation is 
shown for for Ml29 (blue) and VI29 
(red) polymorphs of human PrP91-231. 
Black bars indicate the standard deviation 
from an average of 5 independent 
experiments.
Although  there  was  a  certain  degree  of variation  in the  yields  of the  p-conversion (as 
indicated by standard deviations of ±9.6% for methionine and ±12.4% for valine), there 
was no obvious or significant difference between M l29 and VI29 PrP (p > 0.1, paired T- 
test).  From this it can be concluded that, in this refolding system at least, both M and V 
forms of PrP have an equal propensity to form the p-isoform.
Once in the P-rich state, the structures of the two variants were compared using 
CD spectroscopy in an attempt to uncover any gross differences in structure between M 
and V PrP.  Using the same protocol applied to PrP in the a-helical conformation, far UV 
(between  190nm and 230nm) circular dichroism spectra for p-PrP M l29 and P-PrP VI29 
at  the  same  concentration  (1 mg/ml)  were  recorded.  Both  forms  exhibited  spectra 
characteristic  of a  predominantly  p-sheet  fold  with  a  single  minimum  at  X  216nm,  as 
compared to the double minima (208 and 222) recorded for a-PrP (figure 2.8).
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Figure 2.8 p-PrP M l29 and VI29 circular dichroism spectra.  Far UV circular dichroism 
spectra for M l29 P-PrP (A) and VI29 (3-PrP (B).  Spectra were recorded as for figure 2.4. 
Both  M l29  p-PrP  and VI29  P-PrP display  spectra characteristic of a predominantly p- 
sheet conformation, with a single minimum at 212nm.
These  spectra  were  overlaid  and  there  was  no  observable  difference  between  the  two 
forms (figure 2.9).
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Figure 2.9 Overlaid M l29 ( • )  and VI29 (A) P-PrP circular dichroism spectra.  No 
significant difference was observed between the polymorphs.  Collection details are as 
for figure 2.4.
87It should be noted, of course, that the resolution of this technique is limited and there may 
well be differences in structure that are beyond the detection limits of CD (see section 2.5 
for further discussion of this).  However, it can be stated that, in terms of global fold, M 
and V forms of (3-PrP occupy broadly similar conformations.  As with the a-helical state, 
this technique does not reveal any information about how stable the two forms are in the 
P-rich  conformation,  and  both  M  and  V  PrP  were  subjected  to  equilibrium  unfolding 
using urea as a denaturant.  Previous experiments have demonstrated that P-PrP is prone 
to  aggregation  at  high  ionic  strength  and  therefore  urea  was  used as  an  alternative  to 
GuHCl  in order to avoid any precipitation of P-PrP  (126).  In contrast to the  a-helical 
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Figure 2.10 Denaturation profiles for M129 and V129  p-PrP.  Equilibrium denaturation 
curves  of human  p-PrP  129M  (blue)  and  129MV  (red),  as  measured  by  amide  CD 
absorption at 222nm. The lines superimposed upon the data are fits to the function: 
a N  = (K(N/u).exp(m.D))/(l+K(N/u).exp(m.D))
The free energy of unfolding in water was calculated to be 2.36 kcal mol'1  for M129 P- 
PrP and 2.73 kcal mol'1  for V129 P-PrPBoth  M l29  and  VI29  PrP  exhibited  a  gradual  decrease  in  secondary  structure 
proportional to the concentration of denaturant,  with no  significant difference between 
the two forms.  The lack of a cooperative unfolding transition is in keeping with the idea 
that P-PrP represents a molten globule type of organisation that lacks significant tertiary 
organisation (127).
To further investigate the unfolding of M and V p-PrP using chemical denaturant, 
spectra from X 190 to 230nm were recorded in the presence of varying concentrations of 
urea.  The rationale behind this was to attempt to reveal any differences between putative 
folding intermediates that may be populated by the two codon  129 polymorphs.  As the 
concentration of denaturant increases, the tertiary and secondary structure of the protein 
is destabilised.  Whilst the J3-PrP spectra for the two forms under fully natured conditions 
are undistinguishable, it may be that individual intermediates at given concentrations of 
denaturant differ for the M and V variants of PrP.  Protein was concentrated to  1 mg/ml 
and then diluted down to 0.5mg/ml with the appropriate concentration of Urea.  Samples 
were  then  incubated  at  room  temperature  to  allow  the  protein  to  reach  a  folding 
equilibrium and spectra taken with a path length of 0.01cm as previously described.  The 
resulting circular dichroism spectra are shown in figure 2.11.
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Figure 2.11 Partially denatured circular dichroism spectra for M and VI29 p-PrP.  M l29 
(blue) and VI29 (red) p-PrPs at a final concentration of 0.5mg/ml were incubated in the 
presence of the appropriate concentration of urea.  CD spectra were recorded as for figure 
2.4.  Between  0  and  0.5M  urea,  there  was  no  observable  difference  between  the  two 
polymorphs.  At a urea concentration of 0.75M,  the  spectra  for the two  forms  diverge 
with M l29 exhibiting a greater retention of p-sheet structure.  At higher concentrations of 
urea, spectra for M l29 and VI29 converge again as both adopt random coil structures.
Between OM and 0.5M urea there is no observable difference between the spectra for the 
two polymorphs, with both forms exhibiting spectra characteristic of a predominantly p~ 
sheet  conformation.  At  a  urea  concentration  of 0.75M  the  CD  spectra  for  the  forms
90diverge,  with  that  for  VI29  PrP  shifting  from  a  minimum  at  212nm  to  one  at  208, 
indicative of the secondary structure unravelling and the polypeptide adopting a random 
coil structure.  The spectra for Ml 29 PrP, however, maintains a spectra characteristic of a 
P-rich  conformation with a minimum at 212nm.  At higher concentrations of urea the 
spectra for the two forms converge again, with both adopting a random coil structure as 
the denaturant activity increases.
2.3 Protease Resistance of the codon 129 Polymorphs
One  of the  characteristics  that  distinguishes  PrPc  from  PrPSc  is  a  marked  increase  in 
resistance to digestion with proteinase K (98).  This is thought to be due to a structural 
reorganisation  within  PrP,  a  switch  from  mainly  a-helical  to  mainly  P-sheet,  which 
results in decreased availability of peptide bonds within the structure of PrP to cleavage 
by  the  protease.  When  infectious  homogenates  containing  different  prion  strains  are 
subjected  to  proteinase  K  digestion,  different  sized  protease  resistant  fragments  are 
produced which can be distinguished by western blot analysis.  Alterations in fragment 
size resulting from digestion are representative of subtle alterations in three dimensional 
conformation exposing different residues within PrP to cleavage (224).  Based upon this, 
therefore,  proteinase  K  digestion  can  be  used  as  a  crude  tool  to  probe  alterations  in 
secondary  and  tertiary  conformation  -   with  such  changes  being  visualised  by  the 
detection of different  sized  fragments  (representative  of different cleavage points  and, 
therefore,  conformations)  separated by  SDS  PAGE.  This  method has been applied to 
recombinant PrP expressed in both prokaryotic and eukaryotic cells, with PrP in the P-
91sheet  conformation  purified  from  prokaryotic  cells  and  PrP  engineered  to  contain 
pathogenic  mutations  in  eukaryotic  cells  both  displaying  enhanced  resistance  to 
proteolytic digestion compared to a-PrP (127;287).
Methods
To  investigate  whether  the  codon  129  polymorphism  has  any  effect  on  protease 
resistance,  recombinant  human  PrP  residues  91-231  containing  either  methionine  or 
valine at codon 129 were exposed to a range of proteinase K concentrations over a one 
hour time course.  Both a and P-forms of the two polymorphic variants were examined. 
To control for alterations in proteinase K activity due to low pH, a-PrP was digested at a 
pH equivalent to  P-PrP conditions,  allowing a direct comparison between the protease 
resistance  characteristics  of the  two  conformations.  Results  were  examined  both  for 
protease resistance and for the production of different sized fragments.  10pl aliquots of 
1  mg/ml protein of the appropriate codon 129 status and predominant fold (either a or p) 
were digested with proteinase K at 0.1, 1, 10 or 100 pg/ml final concentration.  Reactions 
were terminated by the addition of 2x  SDS  loading buffer containing DME and 5mM 
AEBSF.  Samples were heated to 100°C for lOmins and then centrifuged (15,000 g) for 1  
minute.  20pl  of each  supernatant was  applied to a  16% Tris-glycine gel (Novex;  Life 
Technologies,  Paisley,  UK)  according  to  the  manufacturer’s  instructions.  Gels  were 
washed with distilled water and then stained with Coomassie blue (Coomassie brilliant 
blue 0.025%, methanol 40% and acetic acid 7%) for 1  hour followed by destaining with 
40% methanol, 7% acetic acid.
92Results
In  the  a-helical  conformation,  M l29  and  VI29  PrP  treated  with  proteinase  K 
concentrations from 0 to  lOpg/ml displayed similar levels of proteinase resistance, being 
completely degraded by digestion with lOpg/ml for 1  hour (figure 2.12).
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Figure  2.12  Protease  resistance  of a  and  p-PrP  codon  129  variants.  Using  identical 
conditions  for  digestion,  soluble  p-PrP  has  increased  resistance  to  proteinase  K  when 
compared  to  a-PrP.  The  M  and  V  polymorphs  have  identical  levels  of resistance  and 
display similar patterns of cleavage products. The concentrations of PK indicated are the 
final concentrations in the digestion reactions.
The  fragments produced by  incomplete  digestion with <  lOpg/ml  PK were  similar  for 
both  polymorphs  -   indicating  that,  within  the  limits  of  this  technique,  there  is  no 
observable difference between either the absolute resistance to proteolysis, or the location 
of proteinase  K cleavage  sites  in the  two  codon  129  variants.  This  is  what would  be 
expected based upon the structural  studies of the a-conformation, considering the close
93coincidence of the a-structures of M  and V PrP,  and agrees with work carried out by 
Wong et al using codon 129 variants on a mouse background (269).
Due to the absence of an atomic resolution structure of the p-sheet rich conformer 
of PrP, the impact of the codon  129 polymorphism on the protease resistance of PrP is 
more difficult to predict.  Using proteinase K concentrations up to lOOpg/ml, both a and 
p-PrP  were  digested  at  pH  4.  As  previously  reported,  P-PrP  exhibits  an  increased 
resistance to proteinase K as compared to a-PrP, with substantial  fragments remaining 
after digestion with  lOOpg/ml (a concentration which completely digested a-PrP) (127). 
It should also be noted that a-PrP exhibited an apparent increase in protease resistance at 
this pH.  This is due to proteinase K having a lower activity at pH 4 as compared to pH 8. 
The pattern of fragments produced by digestion of P-PrP by proteinase K also differed 
from those  produced by  digestion  of a-PrP  (which  produced  similar patterns  whether 
digested  at  pH  4  or  8,  although  at  different  concentrations  of proteinase  K),  again 
agreeing with previous work (127).  Comparing the two polymorphic variants, both M 
and V PrP proteins exhibited similar levels of protease resistance at pH 4, whether in the 
a-helical  or  p-sheet  rich  conformation,  and  no  difference  could  be  observed  in  the 
fragment  patterns  produced  by  the  two  forms  after  protease  digestion.  With  special 
regard to the p-sheet conformation, this suggests that similar cleavage sites are available 
to  proteinase  K  that,  in  turn,  is  suggestive  of structural  similarities  between  the  two 
forms.  Beyond  this,  due  to  the  crudity  of proteinase  digestion  as  a  determinant  of 
structural characteristics, further conclusions are difficult to draw.  However, due to the 
absence of data using more refined techniques, this does supply evidence that there is no 
gross alteration in structure of p-PrP due to the codon 129 polymorphism.
942.4 Copper Binding Properties of the codon 129 Polymorphs
As previously described (section  1.3), the prion protein binds copper with femtomolar 
efficiency.  It is possible that the polymorphism at codon 129 has an impact on the ability 
of PrP to bind copper, a subject that was investigated by Wong et al, who used mouse 
PrP with an artificial variation introduced at codon  129 to model the binding of copper 
ions to PrP (269).  They found no alteration in copper binding, but did find evidence for 
different conformations in M and V forms of the protein that they used upon binding of 
copper.  To investigate whether there are any differences in copper binding between the 
human  codon  129  variants,  as  opposed  to  this  polymorphism  on  an  artificial  mouse 
background (see section  1.5), and to establish if this resulted in alterations in structure, 
recombinant  prion  proteins  containing  methionine  and  valine  at  codon  129  were 
subjected to  metal  binding  analysis  in  an  attempt to  uncover  any  differential  binding 
ability.
Methods
To analyse the copper binding properties of M l29 and VI29 recombinant human a-PrP 
comprising  residues 91-231, both forms were dialysed into  5mM MOPS  at pH  8  and 
diluted to a final concentration of lpM.  Copper binding was carried out as described by 
Jackson et al (183).  Briefly,  2.5ml  of protein in solution was aliquoted into  a quartz 
cuvette  and  the  intrinsic  fluorescence  of the  protein  (based  upon  the  presence  of a 
tryptophan at codon 99) was measured using a Jasco Fp-750 Spectrofluorimeter at 20°C. 
The excitation wavelength was set at 285nm, with emission recorded at 350nm.  Once a 
baseline was set, 25pM Cu2+ (Q 1SO4 in solution) was added 20pl at a time using a glass
95syringe,  followed  immediately by thorough mixing.  The decrease  in the  fluorescence 
was measured and the process  repeated until the  curve was  saturated.  This was  then 
carried out in the presence of increasing concentrations of glycine (200pM and  ImM), 
which acted as a mild chelator to mitigate the effect of the copper on the fluorescence of 
the protein and to suppress any weak binding effects, allowing an accurate estimation of 
copper binding.  Fluorescence  was  then plotted against  copper concentration  for  each 
condition and data fitted using the equation:
Fu=P.-(F^CLJ/(K*AW t+[L]))
Where  Fl  is  the  fluorescence  at  a  concentration  of  ligand,  L;  Fo  is  the  starting 
fluorescence;  Famp is the flouresence amplitude and Kd(app) is the apparent dissociation 
constant.  This allowed the determination of apparent dissociation constants for the two 
forms.  These  data  were  then  corrected  using  the  equation  below  to  take  into 
consideration the presence of glycine as a chelator, allowing the real dissociation constant 
- kd(reai) - to be calculated.
Kd(real) “ Kd(App)  X (Kd1 /[G]) x <Kd2/[G])
Results
The binding of copper to the two polymorphic variants of PrP was examined at glycine 
concentrations of 200pM and ImM (figure 2.13).
96Figure 2.13 Affinity of Cu2 +  for M and V
a-PrP.  Copper binding to 1  pM M and V
a-PrP was calculated by measuring
quenching of intrinsic fluorescence from
Trp 99 concomitant with addition of Cu2+.
Results are shown for Ml29 and VI29
in the presence of 200pM glycine (squares;
blue for M129, red for V129) and lOOOmM
glycine (circles; blue for Ml29, red for VI29)
The lines superimposed represent an
optimal fit with the equation:
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At 200pM glycine, the apparent dissociation constant was 2.0 x  10'6 for VI29 PrP and 
2.5  x  10‘6  for  VI29  PrP.  These  increased  to  48  x  10'6  and  58  x  10'6  for  M  and  V 
respectively at  ImM glycine.  Once the presence of glycine had been accounted for, the 
K <i values observed for both binding conditions were equivalent (table 2.1).
v200 m200 V1000 m1000
% Quench 58 51 49 59
k d < « p p ) 2.0 x 10* 2.5 x 10* 48x10* 58x10*
K 3 x 101 4 4 x 101 4 3 x 101 4 4 x 10'1 4
kd  pH 7.5 7.5x101 0 9.0x1 O'1 0 7.5 x101 ° 8.5 x101 °
Table 2.1 Dissociation constants for binding of Cu2+ to M l29 and VI29 a-PrP 
In neither case was there an observable difference between the two polymorphic variants, 
indicating  that  codon  129  does  not  affect  the  binding  of copper  to  the  structured  C- 







The  codon  129  polymorphism  of the  human prion protein  is  intimately  linked to  the 
disease process  in the TSEs,  with the codon  129  status  of individuals having a major 
impact on both susceptibility and molecular pathogenesis of these disorders.  Although 
this polymorphism was identified as a modifying factor in the prion diseases over fifteen 
years ago,  very little is known about the biochemical mechanism whereby it exerts its 
influence.  This is partly a reflection of our lack of knowledge about all aspects of the 
prion replication process, but the codon  129 issue has certainly proved to be one of the 
more  enigmatic  of the  molecular  characteristics  of the  scrapie  agent.  In  this  study, 
recombinant human PrP protein encoding either methionine or valine at codon  129 was 
examined using a variety of molecular techniques in an attempt to establish a biochemical 
basis for the effect of this polymorphism.
The starting point for this investigation was to examine whether the codon  129 
polymorphism has any impact on the a-helical form of recombinant human PrP, thought 
to best reflect the cellular isoform of the prion protein.  In agreement with previous work, 
both  M  and  V  forms  of recombinant  human  PrP  exhibited  similar  CD  spectra  and 
stabilities  (as  evaluated  by  equilibrium  unfolding  in  the  presence  of  Guanidine 
Hydrochloride)  (274).  Several  studies  have  now  indicated  that  it  is  unlikely  that 
pathological  differences  between  the  two  forms  of the  prion  protein  originate  in  the 
native a-helical state.
The  conversion  from a mainly  a-helical  form to  a predominantly beta  form  is 
central to the pathogenic process in the prion diseases.  The equal proclivity of M and V
98recombinant PrP to form a predominantly p-fold by refolding at low pH and in reducing 
conditions  was  examined  by  calculating  the  percentage  yield  from  the  conversion 
process.  There was no significant difference between the ability of the two polymorphs 
to undergo this conversion, indicating that (in this system at least) the ability to convert to 
the p-rich form is not involved in the pathological differences between the polymorphs. 
It is, however, difficult to generalise based upon this result as there is much debate as to 
the exact relationship between the recombinant p-rich form and infectious PrPSc in vivo.
Once in the p-rich form, CD spectra were taken of both M l29 and VI29 PrP -  
again with no significant differences observed between the spectra.  This indicates that 
the  overall  global  folds  of the  two  polymorphs  coincide  closely  once  in  the  P-sheet 
conformation, although circular dichroism is too blunt a determinant of protein structure 
to elucidate the finer details of their molecular structure.  It is therefore impossible, based 
upon these data, to exclude the possibility that there are significant differences between 
the secondary and/or tertiary structures of M and V p-rich forms of PrP that are below the 
threshold  of  CD  detection,  and  that  these  result  in  the  phenotypic  impact  of  the 
polymorphism.  Here, the stumbling block of structural determination of the P-rich form 
appears.  As previously discussed in section  1.4, attempts to define the structure of the 
scrapie agent have, thus far, proved futile.  Confirmation of whether there are structural 
differences between the M and V forms of p-PrP will have to await the development of 
atomic  resolution  structures  of  the  two  codon  129  variants.  Although  equilibrium 
unfolding failed to reveal any difference between the two polymorphs, it is intriguing that 
the CD spectra of partially denatured M and V PrP in the p-rich conformation revealed 
different structures at a concentration of 0.75M urea.  This suggests that there may be an
99underlying  difference  in  the  stability  and  the  structure  of  the  two  polymorphs,  a 
possibility that requires further investigation.
Another technique used to investigate any structural differences between the two 
polymorphs  was  resistance  to  the  action  of  the  proteolytic  enzyme  proteinase  K. 
Although, again, a very crude guide to the structure of PrP, for the purposes of this study 
(the uncovering of any biochemical characteristics that differ between the M and V forms 
of the human prion protein), resistance and proteolytic degradation patterns can be used 
as a pointer to underlying structural variation.  For PrPSc associated with sporadic and 
familial CJD, alterations in glycoform ratio following PK digestion have previously been 
described  (see  section  1.5).  Unfortunately,  due  to  the  complex  nature  of the  in  vivo 
situation, it is technically very difficult to compare absolute resistance of PrPSc between 
cases.  This is mainly due to the fact that it is very difficult to calculate the exact starting 
quantity of resistant material as a percentage of total PrP using existing techniques.  This 
percentage will vary based upon genetic  factors,  disease progression at time  of death, 
regional  PrPSc  deposition  patterns  within  the  brain  and  post-mortem  delays.  With 
recombinant protein in the  p-rich  conformation,  however,  the  initial  concentrations  of 
protein can be carefully controlled and so any differences in protease resistance can be 
revealed.  Using this approach, and studying recombinant PrP in both a-helical and p~ 
sheet rich conformations, no difference in either protease resistance or fragment pattern 
was observed between the M and V polymorphic variants.  Again, this technique is far 
too crude to exclude the possibility that there are structural differences between the two 
forms -  but it does  suggest that  any  differences  that are present are not gross,  major 
alterations  in  conformation.  It  is  of  interest  that,  in  contrast  to  these  results  with
100recombinant PrP, the codon  129 polymorphism in vivo does seem to have an impact on 
the  protease  resistant  strain  profile.  This  illustrates  the  limitations  of the  existing 
recombinant models of PrPSc, as these are as yet unable to fully or accurately replicate the 
range  of  conformations  occupied  by  different  naturally  occurring  and  experimental 
strains of infectious prions.
The prion protein binds  copper with  a  femtomolar affinity,  although  the  exact 
nature of this interaction is still a matter of debate with regard to how many copper atoms 
PrP binds, and the manner and locations in which this occurs.  Using recombinant PrP in 
the a-helical conformation, the copper binding characteristics of the M and V forms of 
the human prion protein were examined.  As noted in section 2, Wong and colleagues had 
previously investigated the ability of M and V containing mouse PrP recombinant protein 
to bind copper, although the relationship between humanised mouse prion protein and the 
in vivo situation in humans is difficult to determine (269).  Using human prion protein 
constructs  covering  residues  91-231,  no  significant  difference  in  the  copper  binding 
characteristics of M and V forms were observed, agreeing with the results published by 
Wong  et al.  Based upon examination  of 91-231  recombinant prion protein,  it  seems 
unlikely that differences in the copper binding abilities (or alterations in structure upon 
binding of Cu2+) of the M and V forms of the human prion protein plays a significant role 
in the phenotypic  impact this polymorphism has.  The possibility cannot be  excluded, 
however, that there is a difference in copper binding between these two forms, but that it 
would only be revealed by examining copper co-ordination in full length PrP in the P- 
sheet  rich  conformation.  Although  this  is  not  likely,  as  it  would  require  intimate
101cooperation between the unstructured N terminus and residue  129, further studies would 
be required, using full length (23-231) M and V protein, to resolve this issue.
1023.0 Aggregation Properties of the Codon 129 Polymorphs
One of the hallmarks of prion disease, along with other neurodegenerative disorders such 
as Alzheimer’s disease and Parkinson’s disease, is the deposition of aggregated protein in 
the  brain.  These  deposits  are  often  in  the  form  of  amyloid,  distinguished 
neuropathologically  by  its  ability  to  bind  Congo  red  (288).  The  formation  of small 
aggregates and the deposition of larger,  ordered species  in the  form of amyloid fibrils 
play an important part in the pathogenesis of the prion diseases, and in the wider field of 
protein folding disorders, although the exact nature of this role is unclear.  One possible 
mechanism for the codon 129 polymorphism to affect the phenotype of prion disease is 
by altering the aggregation properties of the prion protein and impacting on the formation 
of oligomers and larger aggregates.  Several studies looking at the formation of oligomers 
and aggregates by the codon  129 variants have been carried out (see section  1.5), with 
some evidence that the methionine form has a greater propensity to form oligomers and 
aggregates than the valine form (262;272;273).  There are, however, several areas of the 
aggregation  properties  of the  two  polymorphs  that  have  not  yet  been  investigated  in 
depth, meriting further examination.
Methods
To further investigate the aggregation properties of the M and V codon 129 variants, two 
approaches were used.  First, the properties of both the alpha and beta forms of the two 
polymorphs  were  analysed  using  analytical  ultracentrifugation  (AUC).  AUC  is  a 
technique  that  uses  analysis  of  the  sedimentation  properties  of  macromolecules  in
103solution to  examine their hydrodynamics  and self-association properties.  If one  starts 
with a protein in solution, equally distributed, and place it under a centrifugal force the 
rate at which the protein sediments (once the solvent and centrifuge conditions have been 
taken  into  consideration)  is  a  function  of its  molecular  mass  and  its  partial  specific 
volume, described in the Svedberg equation:
o_ u  _ M(1-vp)_MD(1-yp) 
afr  “  RT
Where S is the sedimentation velocity, u is the observed radial velocity of the protein, oo 
is the angular velocity of the rotor,  co2r is the centrifugal field, v is the partial specific 
volume, M is the relative molecular mass in Daltons, Na is Avogadro’s number, f is the 
frictional coefficient, D is the diffusion coefficient and R is the gas constant (289).  S 
values are given in Svedbergs, equivalent to 10'13 seconds (a none SI unit).  An analytical 
ultracentrifuge measures the radial velocity (u) of a given protein in solution by either 
ultraviolet absorption or visible absorption relying on alterations to the refractive index as 
the protein concentration changes (figure 3.1) (290).
Figure 3.1 Analytical ultracentrifugation 
setup.  Sedimentation in the sample of 
interest is measured by monitoring changes 
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104This allows the velocity of sedimentation to be calculated.  Stokes law, which describes 
the  frictional  coefficient  for  a  perfect  sphere,  can  be  combined  with  the  Svedberg 
equation to produce an equation that allows you to predict the S value assuming that the 
protein is perfectly spherical, taking into account the viscosity of water (291;292).
f0=6nnR0
M^O-vp)  ^  0.012  ^
Where  is the frictional coefficient for a perfect sphere, r\ is the viscosity of solvent and 
Ro is  the  radius  of the  sphere  in  question.  Using  this  information,  it  is  possible  to 
compare actual data to the predicted properties assuming a perfectly spherical structure 
and thus uncover any deviations due to asymmetry or elongation of the protein structure. 
With more advanced hydrodynamic modelling, accurate values for molecular mass and 
important structural information can be gleaned (293).  Data captured from sedimentation 
analysis of a protein in an analytical ultracentrifuge also yields information about the self 
association properties of that protein.  If a population of protein in solution is undergoing 
sedimentation as  an aggregate, be that dimer,  trimer or larger association,  this will be 
detected and represented by higher order peaks in the sedimentation profile of the protein 
(294).  This has been used within the field of neurodegenerative disease to examine, for
105example,  the  aggregation  properties  of wild  type  a-Synuclein  and  disease  associated 
mutants (295).  Within the remit of this  investigation AUC  is being used as a tool  for 
probing differences between two proteins: PrP containing methionine at codon  129, and 
PrP  with  valine  at  this  position.  Any  difference  in  the  Svedberg  values  for  the 
monomeric forms of the protein will be due to altered partial specific volume that is in 
turn  representative  of differing  three-dimensional  structures.  In  addition  to  this,  the 
presence of self-associated aggregates (and the ratio of these to the monomeric forms) 
will  also  be  revealed,  with  any  differences  between  the  two  polymorphs  being 
highlighted.
AUC was carried out using a Beckman Optima XL-1  analytical ultracentrifuge. 
The protein to be analysed was concentrated to  lmg/ml and then three aliquots of 400pl 
of each were loaded into sample cells, with 400pl of buffer (exactly matched to sample) 
loaded into reference cells.  The rotor was then put under vacuum and spun at 50,000 rpm 
for  16  hours.  During this  period,  990  scans  were  collected.  These  scans  were  then 
analysed using the SEDFIT analysis program (National Institutes of Health, MD, USA), 
which derives Svedberg values from the sedimentation profile.  Both the alpha and beta 
forms of the two polymorphs were analysed.
Secondly, the ability of the two variants to form ordered aggregates or amyloid 
fibrils was analysed using a protocol adapted from that used by Baskakov and colleagues 
(128).  This protocol allows real time analysis of amyloid growth by taking advantage of 
the  increase  in  fluorescence  associated  with  the  binding  of the  dye  thioflavin  T  to 
amyloid  fibrils.  Thioflavin T  discriminates between disordered aggregates  and highly 
regular amyloid formations, facilitating a specific assay for amyloid growth -  a process
106also confirmed by analysis of aggregated material using electron microscopy (128).  The 
stimulation of amyloid growth from recombinant prion protein is carried out by agitating 
the  protein  in  the  presence  of denaturants,  acting  to  unfolding  PrP  to  an  extent  that 
favours its polymerisation*.  This has been used by Baskakov and colleagues to analyse 
the  kinetics  of amyloid  formation by  recombinant prion protein  from  several  species, 
including mouse and human (129).  The kinetics of amyloid growth observed with this 
protocol are consistent with the nucleated seeding model of amyloid generation, showing 
a lag phase prior to exponential growth of fibrils.  Crucially, this lag phase is significantly 
reduced by the addition of preformed fibrils to the initial starting mixture, again agreeing 
well with the  seeding model.  The ability of preformed fibrils to reduce the  lag phase 
prior to amyloid growth has been used by Baskakov to examine the species barrier, using 
preformed mouse fibrils to seed human growth and vice versa.  He found that a species 
barrier does operate in this system, recommending it for use in analysis of any possible 
differences in amyloid formation between the M and V forms of the human prion protein, 
and  any  barrier  that  may  operate  between  the  two  polymorphs  (129).  Crucially,  as 
regards the relevance of this protocol to the in vivo situation, mouse PrP fibrils produced 
using  this  protocol  initiated  prion  disease  when  introduced  into  highly  susceptible 
transgenic mice over-expressing a homologous mouse prion protein construct at a level 
16 times greater than wild type (112).  The proteinase K resistance of fibril material, and 
ability  of  proteinase  K  treated  seeds  to  stimulate  fibril  growth,  have  also  been 
investigated  with  the  evidence  suggesting  that  this  model  recapitulates  many  of the 
structural features of PrPSc (277).  This suggests that the there is a relationship between
*  If the protein is shaken at low pH (<pH 4), PrP forms oligomeric species.  At higher pH 
(around pH 6), the formation of amyloid fibrils is favoured.
107fibrils formed using this protocol and the in vivo infectious process.  In order to examine 
the  aggregation  properties  of the  two  codon  129  variants  PrP,  fibril  formation  was 
analysed using a protocol adapted from that of Baskakov ei al (128;129).  Recombinant 
a-PrP  of both  M  and  V  codon  129  variants  were  transferred  by  dialysis  into  20mM 
Sodium Acetate pH 3.7 and denatured by the addition of 10M Urea.  The protein was 
then refolded by dialysis into 1.3M Urea, 1M GuHCl pH 6.  A sample of each was taken 
and analysed by CD as described in section 3.2.  To stimulate assembly of monomeric 
PrP  into  fibrils,  800pi  of 0.8mg/ml  protein  was  aliquoted  into  1.5ml  eppendorfs  and 
shaken  at  37°C  and  600rpm.  The  formation  of amyloid  fibrils  was  determined  by 
monitoring of thioflavin T fluorescence.  lOpl of sample was removed from the shaking 
aliquots and diluted 1  in 200 into 5mM Sodium Acetate pH 5.5.  Thioflavin T was then 
added to a final concentration of 50pM and fluorescence measured on a Jasco  Fp-750 
Spectrofluorimeter (excitation 450nm, emission 485nm) with 5nm band widths.
3.1  Analytical Ultracentrifugation
To examine the self association properties  of the two polymorphic variants,  and as  an 
additional method of structural  comparison,  the  sedimentation properties  of VI29  and 
M l29 human PrP were examined by analytical ultracentrifugation.  Protein samples were 
examined  in the  absence  of denaturants  (that is,  in their native  folded conformation). 
Methionine  and valine PrP  in a predominantly  a-helical conformation were present  as 
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Figure 3.2 AUC profile of M and V129 a-PrP.  Protein at a concentration of lmg/ml was 
centrifuged at 50,000rpm for  16hrs  in a Beckman Optima XL-1  centrifuge.  990  scans 
were collected and analysed using SEDFIT software.  Profiles for M l29 (blue) and V I29 
(red) are shown.
Protein folded into the p-rich conformation was also examined by the same method, with 















Figure 3.3 AUC profile of M and V129  p-PrP.  Protein was analysed as for figure 3.2, 
with profiles for M l29 (blue) and V I29 (red) shown.
109Both were present as monomeric species, with only one peak Svedberg value identified 
by this process, although both methionine and valine PrP exhibited a broader range of 
Svedberg values.  This is demonstrated by the greater standard deviation exhibited by the 







M p 1.53 0.116
vp 1.81 0.167
Table 3.1 Svedberg coefficients for a-PrP and P-PrP, M l29 and VI29 variants.
3.2  Amyloid Formation
Initially,  protein  containing  either  M l29  or  VI29  was  incubated  under  the  described 
conditions to investigate the kinetics of fibril formation of these two species.  Following 
an incubation period of 35 hours, M l29 containing protein rapidly formed amyloid fibrils 
as measured by fluorescence following binding of Thioflavin T.  Despite an incubation 
period of over 200 hours, VI29 PrP aliquots did not exhibit any increase in thioflavin T 
fluorescence, indicating a failure to form amyloid (figure 3.4).
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Figure  3.4 Fibrillisation of M l29  and V I29  PrP.  The  formation of amyloid  fibrils  as 
determined by Thioflavin T fluorescence is shown as a function of time. Fibrillogenesis 
of M l29 PrP (blue, • )  occurs after a lag time of 35 hours, whereas VI29 PrP at the same 
concentration  (red,  A),  and  twice  the  concentration  (green,  ▲)  shows  no  evidence  of 
fibril formation.  Data were fitted using the equation F=Fj+Ff/(l+exp(-(t-tm /x))
In order to model the heterozygous state, M l29 and VI29 in equal proportions (but with 
a  final  concentration  equal  to  that  used  in  single  species  experiments)  were  incubated 
under  the  same  conditions.  Interestingly,  this  did  not  exhibit  any  amyloid  growth, 
suggesting that there  may be  a  dominant negative  impact as  methionine protein on  its 
own at an equivalent concentration to the M l29 PrP in the  1:1 mixture did form amyloid 
deposits (figure 3.5).
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Figure 3.5  Fibrillisation of MV PrP mixture.  The amyloid forming properties of a  1:1 
MV mixture (A) are compared to the properties of M l29 at an equivalent concentration 
( • )  with a lag time of 37 hours.  Measurements were carried out as for figure 3.4.
To  investigate  the  potential  for  mature  fibrils  to  seed  amyloid  formation,  preformed 
fibrils made up of PrP containing methionine at codon 129 were spiked at a level of 1% 
w/w total protein into monomeric V and M huPrP in solution.  Spiking of M l29 fibrils 
into  M l29  monomeric  PrP  resulted  in  a  rapid  seeding  process  with  a  significantly 
reduced  lag  phase,  as  would  be  expected  based  upon  the  seeding  model  of  prion 
propagation  and  upon  previous  work  carried  out  using  this  system  (129;262). 
Introduction  of  M l29  PrP  into  VI29  monomeric  PrP  also  resulted  in  formation  of 
amyloid fibrils, although after a significantly extended lag phase (figure 3.6).
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Figure 3.6 Seeding of M l29 and V I29 fibrillisation.  1% w/w protein (either preformed 
methionine fibrils or valine 129 incubated in parallel) was spiked into M l29 or V I29 PrP 
and incubated at 37°C with shaking.  Measurements were taken as for figure 3.4.
This  indicates that VI29 protein is  capable of amyloid formation in suitable conditions 
(in  this  case,  the presence  of a preformed  amyloidogenic  seed).  It  is  unfortunate  that 
biosafety  protocols  preclude  the  analysis  of fibrils  produced  in  these  experiments  by 
electron  microscopy:  our  group  does  not  have  access  to  an  electron  microscope  in 
containment level III conditions, required for experiments involving human recombinant 
PrP.  It  is  possible  that  important  information  regarding  structural  diversity  between 
fibrils made up of methionine and valine could be uncovered using this technique.  To 
gain some insight into any structural alterations that may have occurred, M l29 and VI29 
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Figure  3.7  Circular  dichroism  spectra  of  M l29  and  VI29  PrP  before  and  after 
fibrillisation.  Samples of PrP were taken before and after fibrillisation and CD spectra 
collected  for both M and V codon  129  variants.  A) PrP refolded into  1M GuHCl and 
1.3M urea prior to incubation in fibril stimulating conditions (37°C and agitation), M129 
PrP  (blue,#)  and  V129  PrP  (red,A).  B)  PrP  after  incubation  in  fibril  stimulating 
conditions, M l29 PrP in blue ( • )  and V I29 PrP in red (A).
CD  analysis  revealed  both  forms  in  a  predominantly  a-helical  conformation  prior  to 
fibrillisation,  although with different molecular ellipticity absorption values with M l29 
exhibiting a less structured conformation.  Following incubation in conditions conducive 
to fibril formation, VI29 PrP maintained a predominantly a-helical conformation, whilst 
M l29  PrP  exhibited  dramatically  reduced  absorption  and  a  single  minimum  around 
220nm.
3.3  Discussion
Using analytical ultracentrifugation, several biophysical characteristics of the two codon 
129  forms  were  examined.  AUC  studies  reveal  information  about  the  sedimentation
114properties of macromolecules in solution.  This, in turn, can be used to ascertain details 
about both the overall shape of the protein (the three dimensional shape of the protein 
having  a  defining  role  in  its  sedimentation  through  solution)  and  its  self-association 
properties  For the purposes of this  study, AUC provides a useful tool that allows the 
direct comparison of M and V codon  129 prion protein.  For both a-helical and p-sheet 
rich forms of PrP, under the protein concentration and buffer conditions examined, the 
protein was found to be in a monomeric state.  Based upon the work of Baskakov and 
colleagues, it may well be of interest to investigate the sedimentation properties of PrP 
under mildly denaturing conditions, since it is these that are used (in combination with 
agitation)  to  stimulate the  formation of oligomers  and amyloid fibrils.  It may be that 
some  measure  of self association  can  be  stimulated  by  the  presence  of partly  folded 
intermediates.  With regard to the  Svedberg  coefficients,  describing the  sedimentation 
properties  of the  proteins,  the  a-helical  folded  M  and  V  PrP  variants  exhibited  very 
similar S values of 1.74 and  1.80 respectively, with standard deviations of 0.074 for M 
and 0.068  for V.  This  is  in agreement with  work using  a wide variety of techniques 
suggesting  that  there  is  no  major  structural  difference  between  the  a-PrP  codon  129 
polymorphs -  as, if there were a structural difference that altered the overall space filling 
shape of the protein then,  this would result in a greater difference in  Svedberg values. 
Both  of  the  p-PrP  forms  exhibited  Svedberg  values  with  a  broader  distribution, 
suggesting greater structural heterogeneity (that is, a heterogeneous population of species 
with  very  similar  structures  but  with  slight  variations  resulting  in  subtly  altered 
sedimentation  characteristics),  reflected  in  a  higher  standard  deviation  from  the  mean 
than those exhibited by the a-PrP forms -  0.116 and 0.167 p-PrP SD versus 0.074 and
1150.067  a-PrP  for  M  and  V  respectively.  The  Svedberg  coefficients  for  the  two 
polymorphs were qualitatively different (M129  1.52S, V129  1.78S).  This is evidence, 
albeit  inconclusive,  of  structural  differences  between  the  two  forms  in  the  p- 
conformation,  with  the  suggestion  that  M l29  p-PrP  occupies  a  more  spherical 
conformation than VI29 p-PrP, reflected in the lower S value for M l29.  With regard to 
both  the  sedimentation  properties  of  the  monomeric  species  and  the  possibility  of 
stimulating self association, it would be of great interest to  examine the  sedimentation 
properties of p-PrP in mildly denaturing conditions.
Finally, the amyloid fibril forming characteristics of the M and V variants of the 
prion  protein  were  investigated  using  the  technique  developed  by  Baskakov  and  co­
workers  (128).  First,  the spontaneous  formation of amyloid fibrils by methionine  and 
valine recombinant PrP was examined.  Surprisingly, it was found that only the protein 
encoding methionine at residue  129 formed fibrils, as measured by thioflavin T binding, 
with a lag phase of 35 hours.  In contrast, VI29 PrP did not form fibrils after a period in 
excess  of 250  hours.  This  is  in  disagreement  with  the  results  gained  by  Come  and 
Lansbury, who observed amyloid formation by a 16 amino acid peptide covering residues 
118 to 133 of PrP, including both valine and methionine at codon 129 (262).  It should be 
noted, however, that the 91-231  residue polypeptide in semi-denaturing conditions used 
in the current investigation provides a very different model system to the short peptide in 
non-denaturing  conditions  used  by  Come  and  Lansbury,  and  so  this  result  does  not 
contradict their work as much as it might at first appear.  This is also the case for the 
work  of Tahiri-Alaoui  and  James,  who  observed  no  difference  in  amyloid  formation 
between  the  two  forms  under  native  conditions  using  recombinant  protein  covering
116residues  91-231  (273).  They note that they  observe  differences  in amyloid formation 
under denaturing conditions similar to those used in this investigation, but do not describe 
these.
The  inability  of valine  129  PrP  to  form  amyloid  fibrils  in  this  model  system 
certainly  represents  a  tangible  biochemical  difference  between  the  two  polymorphic 
variants,  but how  does  this  relate  to  the  phenotypic  differences  observed  in the  prion 
diseases  based upon this  polymorphism?  As  with  any  in  vitro  model  of disease,  the 
extrapolation or relation of results to the  in vivo  situation must be made with caution. 
Although there is some evidence that the Baskakov system can generate infectivity in a 
transgenic mouse model,  it is not yet known what molecular species may be acting to 
stimulate  this  {id est small  oligomeric  aggregates,  mature amyloid  fibrils  or an as  yet 
unidentified species) or by what mechanism this may occur, calling into question whether 
the generation of fibrils has relevance for the infectious process.  This is in addition to the 
issue  of what  species  is  actually  causing  cell  death  in  both  the  prion  diseases  and 
amyloidopothies in general, a matter that is still very much a matter of debate (see section 
1.4).  With regard to the link between amyloid and the prion diseases, it is noteworthy 
that, for many prion disorders, amyloid pathology is either not present or not the primary 
presenting neuropathological feature -  again raising questions about the role of mature 
amyloid fibrils in prion pathogenesis (296).  It is also important to take into consideration 
the  conditions  under  which  the  fibril  formation  occurs:  in  an  entirely  cell  free
environment and under partially denaturing conditions.  These are artificial conditions, 
and are not representative of those that would occur in the cellular environment.  This 
may be critical with regard to the interaction of PrP with other cofactors important for the
117infectious  process  (for  example  protein  X,  implicated  in  the  replication  of PrPSc  by 
transgenic studies), which may be altered by the codon 129 polymorphism (297;298).  It 
should also be noted that, with respect to the formation of amyloid material from other 
polypeptides,  the  conditions  under  which  this  can  occur  vary  greatly  from protein  to 
protein -  for example the formation of amyloid from the SH3 domain occurs at low pH 
and  in  native  conditions,  in  contrast  to  the  pH  5.5  denaturing  conditions  used  in  the 
Baskakov protocol  (299).  The  inability  of VI29  PrP  to  form  fibrils  could,  therefore, 
represent  behaviour  in  none  ideal  conditions,  with  amyloid  formation  occurring  at  a 
different  pH  or  under  slightly  different  denaturing  conditions.  This  would  still  be 
indicative of a biochemical impact of the codon  129 polymorphism, but perhaps a more 
subtle alteration in structure or stability favouring the formation of amyloid in different 
conditions than such a stark difference in amyloid forming ability in this system would 
suggest.
It  is,  however,  of  interest  that  methionine  homozygotes  are  significantly 
overrepresented in transmissible and sporadic human prion disease, most obviously in the 
case of vCJD  (valine homozygotes  are also  overrepresented,  although not to the  same 
extent -  see section 1.5).  Making the assumption that mature amyloid fibrils are directly 
involved in the disease cascade (as indicated above, not necessarily warranted), the high 
numbers of methionine homozygotes afflicted by these diseases would be congruent with 
the fibril forming data.  This would not, however, explain why valine homozygotes are 
also more likely to develop disease than heterozygotes, which suggests that the situation 
is more complex than methionine 129 PrP forming amyloid and valine 129 PrP not doing 
so.
118Thus far, only the homozygote condition had been examined.  In order to further 
investigate  the  amyloid  forming  properties  of  huPrP  in  this  system,  a  1:1  mix  of 
methionine and valine was incubated under standard conditions, modelling the situation 
in heterozygotes.  In addition to this, methionine fibrils, and valine protein incubated in 
parallel to the fibrils, were spiked into methionine and valine protein samples which were 
then incubated using the  standard protocol.  This had the dual  aim of providing more 
information about the mechanism of growth in heterozygote conditions as well as acting 
as a simple model of transmissible disease.  Under these conditions, the 1:1 M/V mix did 
not  exhibit  fibril  growth,  suggesting  the  possibility  of a  dominant  negative  effect  of 
valine on the growth of methionine fibrils.  In the spiking experiments, methionine fibrils 
spiked into a methionine substrate resulted in a decrease of the lag phase prior to fibril 
formation  from  35  hours  to  15  hours,  as  one  would  expect  based  upon  the  work  of 
Baskakov and colleagues.  Valine spiked into valine had no impact, with no stimulation 
of fibril growth.  When methionine fibrils were spiked into a VI29 substrate population, 
however,  fibrils  were  generated,  albeit  with  an  extended  lag  phase  as  compared  to 
methionine  only  growth.  When  valine  was  spiked  into  a  methionine  substrate,  fibril 
growth did occur with a reduced lag phase as compared to ab initio methionine growth -  
although  not  as  rapidly  as  induced  methionine  fibril  growth  due  to  introduction  of a 
preformed methionine fibril spike.
These  data  reveal  a  complex  picture  of  amyloid  fibril  growth  on  a 
methionine/valine background in this in vitro system, perhaps only to be expected given 
the  complexities  of the  in  vivo  situation.  The  decrease  in  lag  phase  seen  with  the 
methionine fibrils spiked into a methionine substrate certainly supports the supposition
119that this echoes the work carried out by Baskakov and colleagues, and is consistent with 
the seeded nucleation model of prion - and amyloid -  replication (see section 1.2.3).  The 
spiking of valine into valine did not result in any fibril growth -  since no fibrils were 
detectable in the material acting as a spike despite incubation in conditions favourable for 
amyloid  formation  this  was  only  to  be  expected.  Intriguingly,  when  preformed 
methionine  fibrils  were  spiked  into  a  valine  substrate  population,  fibril  growth  was 
stimulated  -   although  both  less  rapidly  and  after  a  longer  lag  phase  than  either 
methionine  129 PrP alone or seeded methionine PrP.  This provides evidence that valine 
is capable of forming fibrils in this model system and under these conditions if the kinetic 
barrier to  the  formation of nuclei  capable  of stimulating  fibril  growth  is  overcome  in 
some  way  (either  through  the  addition  of  preformed  nuclei  or  possibly  by  the 
manipulation of conditions to favour nuclei formation ab initio).  This, again,  supports 
the hypothesis that the difference between the two forms is more subtle than initial results 
would indicate.  It is of interest that valine spiked into a methionine substrate appears to 
slightly decrease the lag phase prior to exponential growth, especially in the light of the 
fact that no growth was observed in a 1:1 mix of M and V.  This suggests the possibility 
that although valine  129 PrP is not capable of forming fibrils on its own, there may be 
disordered oligomers present that are capable of stimulating the  growth of methionine 
fibrils  -   again  suggestive  of  a  mechanism  dependent  upon  subtle  differences  in 
secondary/tertiary  structure  or  in  stability  for  initiation  of  fibril  growth  in  a  strain 
dependent manner (were there no strain barrier operating,  one would expect reciprocal 
growth with  identical reductions  in  lag phases).  This  is  supported by the  CD  spectra 
recorded  for the  pre-fibrillisation  experiment,  which  suggested that M l29  retains  less
120secondary structure in the conditions used in these experiments.  The increased flexibility 
in the peptide backbone  of PrP  that this  may represent might  favour the  formation of 
amyloid seeding nuclei.
The fact that no growth was observed in the MV 1:1 mix is particularly interesting 
from  the  point  of view  of the  in  vivo  heterozygote  condition.  It  provides  evidence, 
although  by  no  means  conclusive,  that  in  addition  to  a  strain  barrier  of some  kind 
operating between the two codon 129 variants (as suggested by the spiking experiments), 
that there may be an antagonistic aspect to the relationship between the variants:  with 
valine having a dominant negative impact on the growth of methionine fibrils.  Since the 
methionine PrP was present in conditions and at a concentration that had been shown to 
favour the formation of fibrils, the only possible conclusion is that the presence of valine 
PrP  is  in  someway  inhibiting  the  growth  of amyloid  consisting  of M l29.  There  are 
several  mechanisms  whereby  this  could  occur.  It  is  possible  that  the  kinetics  of 
formation for MV heterodimers/oligomers are more favourable than those for methionine 
alone or valine alone, and so recruit more of the monomers available in free solution.  If 
it  is  then  assumed  that  small  MV  aggregates  do  not  favour  the  formation  of nuclei 
capable of seeding amyloid fibril growth, or that the MV heterodimer itself is a kinetic 
dead end, a dominant negative affect would result.  It is also possible that the addition of 
a  monomeric  species  not  related  to  a  nascent  fibril  has  a  chain  terminating  impact 
(iexempli  gratia  VI29  PrP  “capping”  M l29  PrP  fibrils)  similar  to  that  of 
dideoxynucleotides  in  the  process  of DNA  replication  (300;301).  This  is  unlikely, 
however,  due  to  the  positive  growth  results  of  the  spiking  experiments  -   where  a 
methionine seed could stimulate valine fibril growth and vice versa.  This must have the
121proviso,  however,  that  there  is  not  a  critical  threshold  operating  below  which 
heterologous monomer addition terminates growth, perhaps below the nucleation point, 
and above which the maturing fibril can tolerate such addition, a possibility that requires 
investigation.  If the results of the MV growth experiments are bourn out by examination 
of the behaviour of MV  1:1  mixed populations in a range of conditions, they may have 
important ramifications  for our understanding of the heterozygote situation in vivo.  If 
there  is  some  form  of dominant  negative  impact  by  VI29  containing  protein  on  the 
aggregation properties of the M l29 form, this may go some way towards explaining the 
resistance  of heterozygotes  to  transmissible  prion  disease,  and  their  low  frequency  in 
sporadic prion disease.  Again, this requires much in the way of further investigation, but 
is certainly an intriguing possibility.
These data, taking into consideration M and V individually, spiking experiments 
and  the  MV  mix  results,  suggest  a  model  for  this  system  (utilising  recombinant  PrP 
covering the structured domain of PrP, at pH 5.5 and in partly denaturing conditions) that 
differs  from  the  model  proposed  by  Come  and  Lansbury  (section  1.5).  This  model 
excludes growth in the MV heterozygote situation, although the mechanism of this is not 
yet clear,  and assumes that the kinetic barrier for formation of MV oligomers is lower 
than that for M l29 fibrils, which is turn is lower than that for VI29 fibrils (figure 3.8).
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Figure  3.8  Nucleation model  of codon  129  polymorphism variation.  Based upon  the 
model proposed by Come and Lansbury (figure  1.15), this model takes into account the 
dominant negative affect witnessed with the MV  1:1  mixture and the inability of valine 
129 PrP to form fibrils (262).
In the current conditions, the barrier preventing formation of VI29 nuclei (and thence 
fibrils) is high enough to prevent amyloid growth unless it is circumvented, for example, 
by the addition of preformed M l29  fibril nuclei.  This is not to  say that,  in conditions 
perhaps more favourable to the development of valine 129 fibrils, the reverse situation is 
possible with valine growth favoured over methionine or that MV amyloid fibril growth 
may  occur.  There  is  obviously  much  that  remains  to  be  investigated  regarding  the 
behaviour of PrP in this system, and any model based on this work must be considered 
incomplete  at  best.  The  in  vitro  techniques  used  in  this  investigation  do,  however, 
provide  a  powerful  tool  for  the  dissection  of the  basic  mechanisms  of aggregation 
involved in the prion diseases, in particular for the molecular properties that result in the 




123regard to this, the experiments described herein have identified the molecular aggregation 
properties of the two codon 129 variants as an area that merits further investigation, and 
potentially  a  molecular  characteristic  that  may  provide  a  biochemical  basis  for  the 
phenotypic impact of this polymorphism.
1244.0 Characterisation of the Cathepsin D Proteolytic Cleavage of PrP
4.0.1 PrP and its GPI Anchor
The attachment of a glycosylphosphatidylinositol (GPI) anchor to the prion protein was 
first described in  1987  (122).  GPI anchors  are glycolipid moieties that are covalently 
linked  to  polypeptides  and  facilitate  their  attachment  to  the  plasma  membrane  (302). 
They  are  found  throughout  the  eukaryotes,  and  can be  found  attached  to  a  range  of 
proteins with differing functions (303).  The main theme uniting GPI anchored proteins in 
terms of their biology is their attachment to the plasma membrane, and their localisation 
to  cholesterol-rich  regions  in  the  membrane  (known  as  lipid  rafts)  (191).  As  post 
translational modifications, GPI anchors are added to nascent proteins upon translation in 
the  ER,  and  are  often  themselves  modified  as  they  pass  through  the  Golgi  apparatus
(304).  Although the  structures of several  GPIs have been elucidated,  there  is  marked 
heterogeneity in the exact chemical composition of GPIs attached to specific proteins and 
much remains  to be uncovered about the biochemistry  of these  lipid tails  (figure  4.1)
(305).
Figure 4.1 Glycosylphosphatidylinositol anchor 
structure.  This shows the fatty acid moeities 
that sit within die membrane to anchor the GPI 
to the cell surface, with the sugars and phosphate 
groups that link the intramembrane region to the 
protein to be anchored.
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125Since  the  cellular  role  of the  prion  protein per  se  is  somewhat  enigmatic,  it  is  not 
surprising  that  the  role  of the  GPI  in  the  function  of PrP  is  unknown.  It  has  been 
suggested, however, that the localisation of PrP to lipids rafts on the cell surface (due to 
its GPI attachment) is indicative of a role in either copper transport or signal transduction, 
although this is still very much a matter of debate (see section 1.3).
A useful tool in the study of GPI anchors and their role in the biochemistry of the 
proteins  to  which  they  are  attached  is  the  enzyme  phosphodiesterase  phosphoinositide 
phospholipase  C  (PIPLC).  This  enzyme  acts  to  cleave  the  polar  head  group  from 
inositide  residues  (306).  In  the  case  of GPI  anchored  proteins,  this  has  the  effect  of 
separating  the  membrane  imbedded  lipid  tail  from  the  protein  linked  polar  head 
group(figure 4.2).
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Figure 4.2 Phospholipase cleavage of GPI anchor.  A) A GPI anchored protein sits on the 
cell membrane attached by the hydrophobic fatty acid tail of the GPI.  B) PIPLC attaches 
to the inositol link between the fatty acid tail and the anchored protein, and breaks this 
link C) the anchored protein is released from the cell membrane, whilst the fatty acid tail 
remains inserted into the bilayer
126In most cases this results in the release of the protein from the cell membrane, although 
some  proteins  maintain  association  with  the  extracellular  face  of the  membrane  via 
hydrophobic  interactions  or transmembrane  domains.  In  the  case  of cells  in  culture, 
treatment with PIPLC results in the release of anchored proteins into the cell medium, 
leaving the GPI anchor attached to the cells.  This is the case with PrPc, and treatment 
with  PIPLC  has  been  used  to  investigate  the  cell  biology  of the  prion protein  (307). 
Interestingly, in addition to increasing the protease resistance of PrP, conversion to the 
scrapie  isoform  also  results  in  resistance  of the  GPI  anchor  to  cleavage  by  PIPLC 
(217;308).  It has also been noted that PrP containing pathogenic mutations expressed in 
cell culture acquires resistance to PIPLC cleavage of its GPI (218).
The resistance  of PrPSc  to  PIPLC  has  precluded the use  of this  enzyme  in the 
investigation of the involvement of the GPI in the biology of the scrapie agent, at least in 
a direct fashion.  Indirectly, the issue of whether or not a GPI is required for the infective 
process to occur has been looked at in two ways.  First, by the treatment of cell models of 
scrapie  infection  with  PIPLC.  In  the  case  of cells  chronically  infected  with  PrPSc, 
treatment with PIPLC abrogates infectivity (137).  It is difficult to draw conclusions as to 
the  mechanism  by  which  this  occurs,  however,  as  the  removal  of surface  PrPc,  the 
consequence  of  treatment  of  these  cells  with  PIPLC,  would  act  to  decrease  the 
concentration  of cellular  PrP  available  for  propagation  of the  scrapie  isoform.  The 
treatment of cells prior to their infection has also been investigated, with the same affect 
(137).  This could  suggest that the  loss  of surface  PrPc prevents  infection,  although a 
mechanism involving a decrease in the absolute quantity of PrPc cannot be excluded.
127Secondly,  PrP  constructs  with  a  stop  codon  at position  231  rather than  a  GPI 
attachment peptide sequence have been produced in cell culture (309).  These cells have 
then been exposed to infectious agents and it has been shown that they are capable of 
propagating PrPRES, although with decreased efficiency as compared to wild type protein. 
It  should  be  noted  that  the  infectivity  of this  protease  resistant  PrP  without  the  GPI 
anchor has not been examined, and the cell culture system in which this was carried out 
(N2a  cells  over-expressing  a  truncated  mouse/hamster  chimeric  PrP)  could  produce 
confounding conditions due to the presence of a heterologous population of PrP  -  the 
endogenous wild type mouse PrP and the chimeric  fusion interfering with each others 
propagation.  Work has also been carried out to examine whether the localisation of PrP 
to lipid rafts is essential for the conversion of PrPc to PrPSc, examined by depleting the 
cholesterol levels of cells in culture using Lovastatin (310).  Cholesterol is an essential 
component of lipid rafts, and GPI anchored proteins cannot be inserted into rafts without 
it (311 ;312).  The impact of this was to prevent infection with scrapie, although whether 
this is specifically due to loss of lipid raft domains or due to increased cell stress per se as 
a result of cholesterol depletion is difficult to assess.  In the same study, chimeric PrP 
with a transmembrane domain replacing the GPI was also produced in cells -  resulting in 
the protein locating away  from lipid rafts  in the  lipid bilayer.  This  construct did  not 
convert to the protease resistant state, suggesting that either the GPI or the association of 
PrP with lipid rafts is important in the conversion process.  Intriguingly, a recent report 
from  the  group  of  Bruce  Chesebro  at  the  Rocky  Mountain  Laboratories  described 
transgenic  mice  expressing  moPrP  23-231 stop  on  a  mouse  PrP  knockout background 
(thereby avoiding the problem of a heterogeneous population of PrP).  These mice did not
128develop disease when exposed to mouse adapted scrapie strains, but neuropathological 
examination revealed extensive extracellular deposits of protease resistant prion protein. 
This  would  suggest  that  the  location  of PrP  at  the  cell  surface  due  to  its  anchor  is 
important  in  the  toxicity  of PrPSc  but  not  necessarily  in  its  generation.  Again,  this 
experiment does not directly examine the role of the GPI in infectivity.  Rather it looks at 
the importance of cellular location (since much of the PrP is secreted from the cells) in 
the toxicity of the infective process, and the requirement of the GPI dependent location in 
susceptibility to infection (313).
A recent study by Kishida et al examined the introduction C-terminally truncated 
recombinant PrP  as  an antagonist of the  replicative process  in cell culture  (314).  By 
exposing chronically infected N2a cells to recombinant human PrP containing a Q218K 
mutation,  the  cells  were  cured  of  infection.  The  authors  suggested  that  this  was 
indicative  of PrP  lacking  a GPI  anchor  inhibiting  the  process  of replication,  although 
again it is difficult to extricate the absence of a GPI from the impact of the mutation at 
codon  218  and  the  absence  of  glycosylation.  It  should  also  be  noted  that  many 
compounds have been shown to be efficacious in curing cells in culture of “infection” 
without replicating such affects in infected animals, calling into question the relevance of 
this to the in vivo situation (138).
Of greater relevance to the disease situation is a familial GSS mutation reported 
by  Kitamoto  and  colleagues  in  1993.  They  described  a  GSS  patient  with  an  amber 
Y145Stop mutation in the Pmp gene, which results in a C-terminally truncated form of 
the prion protein (315).  The patient in question had a large number of kuru-like plaques 
and, unusually, deposition of PrP as amyloid in the cerebral vascular system (316).  This
129was coupled with accumulation of the microtubule associated protein t as paired helical 
filaments,  indistinguishable  from those  found in Alzheimer’s  disease.  Analysis of the 
deposited PrP revealed that only C-terminally truncated protein had been laid down,  a 
finding that has been replicated in some amyloid plaque bearing cases of GSS without 
truncating mutations (317).  This suggests the possibility that C-terminal truncation may 
play a role in deposition of PrP as an amyloid species.  Unfortunately, this mutation has 
only been described in one patient and has not been proven to  segregate with disease, 
making categorical statements about its disease causing nature impossible.  It should also 
be noted that attempts to transmit experimentally this case of GSS proved unsuccessful, 
calling  into  question  whether  this  case  represents  genuine  prion  disease  (where  the 
presence  of infective  material  can  be  established)  or  a  rare  case  of PrP  amyloidosis 
(318;319).
As PrPSc is resistant to the action of PIPLC, this enzyme cannot be used to investigate 
the role of the GPI in the biology of the scrapie agent.  An alternate approach to the use 
of PIPLC is to use a proteolytic activity that can remove a small C-terminal fragment of 
PrP, and thereby the GPI anchor, whilst leaving the core of PrP27"30 intact.  Following a 
screen of proteases for the generation of novel cleavage patterns of type 4 human PrPSc 
such an activity was identified.  During this screen, treatment of type 4 vCJD homogenate 
with the enzyme cathepsin D was discovered to result in an anomalous apparent increase 
in  relative  molecular  mass.  This  is  counter  to  what  one  would  expect  following 
treatment of a protein with a protease, as this  should result in a decrease in molecular 
mass following cleavage of the protein and loss of amino acids.  This apparent increase in 
molecular mass is analogous to that seen when PrPc is treated with PIPLC to remove the
130GPI  anchor  (218).  The  band  shift  upward  that  occurs  with  the  loss  of the  GPI  is 
essentially an artefact of SDS  polyacrilamide  gel  electrophoresis  (303).  As the GPI  is 
highly hydrophobic, it binds SDS with high affinity and its acyl chains attract more SDS 
molecules  per  unit  mass  than  the  polypeptide  backbone  of the  protein  (which  binds 
approximately 1 molecule of SDS for every 2 amino acid residues) (320).  This results in 
the  GPI  having  a  high  negative  charge  following  boiling  in  SDS  as  preparation  for 
running on an acrilamide denaturing gel, yielding a faster rate of migration through the 
gel towards the cathode than would be expected for a protein of a given size.  When the 
GPI is removed, this decreases the overall negative charge of the denatured protein more 
than  the  proportional  loss  of mass,  resulting  in  an  apparent  retardation  of the  protein 
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Figure  4.3  Polypeptide gel  retardation  due  to loss  of GPI  anchor.  Protein with  a GPI 
attached  (left  hand  panel)  binds  a  disproportionately  large  amount  of  SDS  when 
denatured prior to  SDS  gel electrophoresis due to the extremely hydrophobic nature of 
the GPI.  With the GPI removed (right hand panel), the protein has a lower net negative 
charge.  This results in decreased migration under electrophoretic field as compared to a 
protein with an intact GPI (central panel).
131In order to examine the  impact of GPI  removal on the  molecular characteristics of the 
scrapie agent, this study has two parts.  First, an investigation of the cleavage event itself 
to characterise the nature of the interaction between cathepsin D and the scrapie agent. 
Secondly, to use the C-terminal truncation of PrPSc by cathepsin D to examine the impact, 
if any, that removal of the GPI anchor has on the infectivity of the scrapie agent.
4.0.2 Cathepsin D
Cathepsin D  is  an aspartic  endoprotease  located  in the  lysosomal  degradation pathway 
(321;322).  As  would be  expected  for  a  protein  involved  in  such  a pervasive  cellular 
pathway,  cathepsin  D  is  expressed  ubiquitously  and  indeed  constitutes  up  to  10%  of 
lysosomal liver proteins (323;324).  The NMR solution structure of cathepsin D has been 
elucidated, and this has contributed to the enzyme being one of the more heavily studied 
lysosomal proteases (325-327).  Despite the existence of a 2.5A resolution structure, and 
detailed  study  using  both  synthetic  and  natural  substrates,  as  well  as  mutagenesis 
experiments,  the  specificity  of cathepsin  D  remains  only  vaguely  defined  (figure  4.4) 
(328;329).
Figure 4.4 Atomic resolution structure of cathepsin D.  Taken from reference (327).
132Such  specificity  as  exists  is  limited  to  a  preference  for  cleavage  between  two 
hydrophobic  residues  (330-332).  The  protein  itself is  produced  as  circa  400  residue 
precursor (412 in the case of human cathepsin D,  from a gene located on chromosome 
11)  termed  procathepsin  D  (333).  Following  translation,  the  protein  can  undergo 
cleavage to form heavy and light chains which then associate to form an active protease, 
although  the  uncleaved  form also  has  proteolytic  activity  (334).  In terms  of the  cell 
biology of cathepsin D, it is found in an active form in the lysosomes and endosomes, 
where it plays an active role in the degradation of proteins targeted to these organelles 
(326).
Cathepsin  D  has  been  implicated  in  several  diseases.  The  enzyme  is  over­
expressed in breast tumours and is sometimes used as a biochemical marker for breast 
cancer,  although  whether  it  is  involved  in the  aetiology  of the  disease  is  a matter  of 
debate (335).  Of greater relevance to this investigation, cathepsin D has been linked to 
several neurodegenerative diseases, most notably Alzheimer’s disease.  At a biochemical 
level,  evidence  from  both  in  vitro  and  in  vivo  studies  has  shown  cathepsin  D  to  be 
involved  in  the  normal  degradation  of  the  amyloidogenic  protein  central  to  the 
pathogenesis of Alzheimer’s disease, the amyloid p peptide (336;337).  Other,  scantier, 
evidence based mainly on in vitro degradation studies suggests that cathepsin D may also 
act  on  a-Synuclein,  involved  in  Parkinson’s  disease,  and  the  microtubule  associated 
protein t,  involved in AD and frontal temporal dementia (338;339).  In relation to the 
disease state, further investigations have linked the protease to clearance of amyloid p in 
the  Alzheimer’s  brain,  and  the  several  studies  have  shown  that  cathepsin  D  is  up- 
regulated in brain tissue from Alzheimer’s patients (340-342).  It is, however, unclear as
133to  whether  this  is  specific  for  cathepsin  D  or  a  more  general  up-regulation  of the 
lysosomal degradation pathway (343).  Providing an interesting genetic parallel for the 
biochemical interactions of cathepsin D and amyloid (3  is evidence that a polymorphism 
in the human form of cathepsin D, a C => T transition (resulting in a switch from alanine 
to  valine)  in codon 224,  is  a  risk factor for late  onset Alzheimer’s  disease  (344;345). 
Researchers  have  found  that  the  valine  form  of  this  allele  was  significantly  over­
represented in patients affected by Alzheimer’s disease, with carriers of this allele having 
a  3.1  fold  increased  risk  of  developing  disease  as  compared  to  non-carriers.  The 
association is, however, controversial, as a subsequent attempt at verification in another 
population has returned a negative result (346).
There is also evidence that cathepsin D has some links to the disease process in 
the prion disorders.  A study by Diedrich et al looking at neuropathology in scrapie and 
Alzheimer’s disease  showed that changes  associated with disease were also associated 
with  increased  levels  of  cathepsin  D  (347).  Cathepsin  D  has  been  identified  in 
microarray  screens  looking  for up-regulated proteins  in  scrapie  infected mouse  brains 
(348).  Whether there  is  a link between upregulated cathepsin D  and the  fact that the 
endosomes  and  lysosomes  have been  linked  with  the  replication  of PrP  has  not been 
examined.  A caveat to these studies is that, as in Alzheimer’s disease, it remains unclear 
as  to whether this  is  representative  of a cathepsin D  specific  affect or whether this  is 
representative of a more general up-regulation of lysosomal degradation in the diseased 
brain as would be expected to be concomitant with the deposition of abnormally folded 
protein.
134Methods
Whole mouse brains from normal and RML-infected CD-I mice were homogenised as a 
10% w/v preparation in Dulbecco’s phosphate-buffered saline (PBS) without calcium and 
magnesium ions using a Dounce homogeniser. Homogenates were split into aliquots and 
stored at -80°C.  Mouse recombinant protein comprising residues 91-231  was produced 
as described in section 3.1.
Protease Treatment
Cathepsin D digests were carried out using bovine spleen cathepsin D (Merck), freshly 
made up  in  lx PBS.  Standard digest conditions were as  follows:  10% w/v infectious 
brain homogenates were thawed and centrifuged at  lOOg for  1   minute to remove gross 
cellular debris.  lOpl aliquots of 10% w/v homogenate  supernatant were then digested 
with  100 units of cathepsin D for 4 hours at 37°C with shaking at 450rpm.  Following 
this,  samples  were  digested  with  Proteinase  K  (Sigma)  at  a  final  concentration  of 
50pg/ml for  1   hour at 37°C (232;349).  Digests were terminated by the addition of 2x 
SDS sample buffer buffer [125 mM Tris.HCl (pH 6.8), 20% v/v glycerol, 4% w/v sodium 
dodecyl sulphate, 4% v/v 2-mercaptoethanol, 0.02% (w/v) bromophenol blue] containing 
8 mM 4-(2-aminoethyl)-benzene sulfonyl fluoride (AEBSF; Pefabloc SC, Roche, Lewes, 
UK).  In  the  case  of  cathepsin  D  digests  carried  out  in  the  presence  of 
ethylenediaminetetracetic acid (EDTA), 20mM EDTA (Sigma) was added to the reaction 
mixture and RML control samples.
135Western Blot Analysis
Following the addition of 20pl of 2 x SDS-loading buffer, samples were heated to 100°C 
for lOmins and then subjected to centrifugation in a microfuge (15,000 g) for 1   minute. 
20pl  of  each  supernatant  was  applied  to  a  16%  Tris-glycine  gel  (Novex;  Life 
Technologies,  Paisley,  UK)  according  to  the  manufacturer’s  instructions.  Gels  were 
electrophoresed at 200 volts for 80 minutes and electroblotted onto PVDF membrane at 
35  volts  for  90  minutes  (Immobilon-P;  Millipore,  Watford,  UK).  The  resulting 
membrane with bound protein was then blocked in PBS containing 0.05% (v/v) Tween- 
20 (PBST) and 5% (w/v) non-fat milk powder for 60 min. After washing in PBST, the 
membranes  were  incubated  with anti-PrP  monoclonal  antibody  ICSM35  (D-Gen  Ltd, 
London) diluted to 0.2pg/ml in PBST for at least 60 min before washing in PBST (30 
min) and incubation with an alkaline phosphatase-conjugated goat anti-mouse antibody 
(Sigma, Dorset, UK) diluted  1:10,000 in PBST for 60 min. Following washing in PBST 
(30 min), the membranes were developed using AttoPhos reagent (Promega Corp., USA) 
and visualized on a Molecular Dynamics Storm 840 (Amersham, UK).
Cell Culture
The murine neuroblastoma cell  line, N2a, was used throughout.  Cells were cultured in 
OPTI-MEM  with  10%  fetal  calf serum  (OFCS)  and  lOOU/ml  of both  penicillin  and 
streptomycin (Invitrogen Corp.).  PIPLC treatment of cells was carried out by removal of
136growth media from confluent cells in a 10cm dish and addition of PBS containing either 
200mUnits PIPLC (Sigma) or lOOUnits cathepsin D.  Cells were incubated for 3hrs and 
the  culture  supernatant  harvested.  300pl  of  culture  supernatant  was  mixed  with  4 
volumes of ice-cold methanol and centrifuged for 30 minutes at 25,000g and 4°C.  The 
precipitated protein was then re-suspended in 20 jal of PBS and analysed by western blot 
as described above.
Phase Separation
Phase separation was carried out based upon the protocol of Parkin et al (350).  Prior to 
phase separation, 25pl RML samples were incubated with either 25pi of 20U/pl cathepsin 
D or with an equivalent volume of PBS  as a control for 2hrs at 37°C with shaking at 
450rpm.  Both samples were then digested with proteinase K at a final concentration of 
50pg/ml for  lhr at 37°C.  Digests were terminated by the addition of AEBSF to a final 
concentration of 5mM.  The samples were then mixed with  150pl of lOmM TrisCl pH 
7.4,  150mM NaCl, 2% Triton X-114 and incubated at 4°C for  lOmins, followed by a 3 
min incubation at 30°C.  Both aliquots were then layered onto a 300pl 6% w/v sucrose 
cushion and spun for 3mins at 3000g.  Aqueous and detergent phases were separated and 
volumes made equivalent using lOmM TrisCl pH 7.4,  150mM NaCl.  20pl of each phase 
was then taken and western blotted using standard protocols.
137Solubility Analysis
20pl of 10% w/v brain homogenate from RML infected mice were treated for 2hrs with 
20pl of 20U/pl cathepsin D or an equivalent volume of PBS as a control.  Both were then 
digested with proteinase K under standard conditions, with the digest terminated by the 
addition of AEBSF to a final concentration of 5 mM.  Following this, 2% sarkosyl was 
added to the samples.  These were then layered onto a  10%=>60% w/v discontinuous 
sucrose  gradient  and  centrifuged  at  100,000g  for  lhr  at  4°C  in  an  Optima XL  100K 
ultracentrifuge  (Beckman)  using  a  swing  bucket  rotor (SW  60Ti).  Gradient  fractions 
were then collected, with the interface between each discontinuous step in the middle of 
each fraction.  250pl of each fraction was then subjected to methanol precipitation:  4 
volumes of ice cold methanol was added to each sample and mixed thoroughly prior to 
centrifugation at 15,000g, 4°C.  The methanol was then aspirated and the pellets air dried 
for 30mins.  Following this, the protein pellets were re-suspended in 20pl of PBS  and 
western blotted using standard protocols.
4.1  Species Specificity
The  initial  observation  of gel  retardation  following  cathepsin  D  treatment  was  made 
during  a  screen  of proteases  looking  for  differential  impact  on  type  4  human  PrPSc, 
associated exclusively with vCJD.  To investigate the strain and species specificity of this 
phenomenon further,  infectious brain homogenates  from two other human strain types, 
type 2 and type 3 (associated with sporadic and hereditary forms of the disease), and from
138a selection of animal  models  of prion disease  (the  mouse  adapted scrapie strain RML, 
mouse  adapted BSE  strains  MRC1  and  MRC2,  and  the hamster adapted  scrapie  strain 
263K)  were  taken  and  treated  with  cathepsin  D  under  standardised  conditions.  The 
human strains type 2, 3  and 4, RML and MRC  strains  1   and 2 all exhibited marked gel 
retardation upon treatment with cathepsin D (figure 4.5).
RML  263k  Type 2  Type 3  Type 4
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Figure  4.5  Gel  retardation  of  PrPSc  due  to  C-terminal  truncation  by  cathepsin  D. 
Cathepsin D digestion of mouse RML, hamster 263K, human types 2, 3 and 4 PrPSc and 
mouse MRC strains 1   and 2 visualised by western blot.  Samples were digested with 20U 
cathepsin D per pi of 10% w/v brain homogenate and exhibit retarded migration in SDS 
PAGE as compared to untreated controls, indicative of C-terminal truncation and loss of 
GPI
139Hamster strain 263K, although not exhibiting the same degree of retardation, did show a 
small but significant band shift upward upon digestion with cathepsin D.  To assess this, 
samples  from multiple independent digests were western blotted and the resulting band 
images  quantified  for  migration  retardation  using  Imagequant  software  (Amersham 
biotech).  The migration for digested versus undigested material was compared using an 
unpaired two-tailed t-test, p < 0.005 (figure 4.6).
Figure 4.6 Box plot showing cathepsin D digest 
of hamster 263k PrP^.  Plot shows combined 
data from 10 individual digests plus controls.
Gel retardation of hamster 263k PrPSc due to 
cathepsin D digestion was small but statistically 
significant as compared to undigested controls.
Cat D  +
4.2  Time and Concentration Dependence of the Cleavage
If the  gel  retardation  of PrPSc  after  treatment  with  cathepsin  D  is  indeed  due  to  an 
enzymatic cleavage event, one would expect the phenomena to exhibit both concentration 
and time dependence. These were examined primarily using RML mouse adapted scrapie 
as a model system, which provides a well studied strain type amenable to both laboratory 
manipulation and studies of infectivity.  Initially, digests were carried out using different 
concentrations  of cathepsin D  over a  set time  course  (2  hours)  and under  standardised 
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Figure  4.7  Concentration  dependence  of  gel  retardation  following  digestion  with 
cathepsin D.  A) RML mouse PrPSc digested with increasing concentrations of cathepsin 
D.  Gel retardation is only exhibited when digestion occurs with 50U or greater enzyme 
activity.  B)  263k  hamster  PrPSc  treated  likewise.  The  gel  retardation  again  exhibits 
concentration dependence, strongly suggesting that this is an enzymatic phenomenon.
Following  this,  and  using  a  concentration  of  cathepsin  D  that  did  not  result  in  gel 
retardation  after  two  hours  of digestion,  the  time  dependence  of PrPSc  cleavage  was 
examined.  Samples were removed at the start of the digest and at two-hour time points 
during its progression.  Gel retardation occurred only after a period of 4 hours using this 
concentration, with no band shift in evidence at the two-hour time point, demonstrating 
the time dependence of this phenomenon (figure 4.8).
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Figure 4.8 Time dependence of gel 
retardation following digestion with 




incubated with 10U of cathepsin D for
the indicated period.  Gel retardation 
was observed only after 4 hours of 
digestion, supporting an enzymatic,
1 6 - proteolytic origin for this phenomenon.
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The gel retardation of PrPSc following treatment with cathepsin D showed dependence on 
both  length  of digest  and  concentration  of cathepsin  D.  This  strongly  supports  the 
argument  that  this  is  an  enzymatic  phenomenon,  and  one  mediated by  the  proteolytic 
action of cathepsin D upon the scrapie isoform of PrP.
4.3  Investigation of Glvcoform Ratio Alteration
An observation made in the case of several cathepsin D digested samples of PrPSc  was 
that there appeared to be alterations in the glycoform ratio presented by western blotted 
prion protein before and after cathepsin D digestion.  The glycoform ratio exists between 
the  three  possible  glycosylation  states  of the  prion  protein  -   di-glycosylated,  mono­
glycosylated  or  with  no  glycosylation.  This  is  reflected  by  the  presence  of  three 
immunoreactive bands  for PrP  (for both the  cellular and the  scrapie isoform),  with the 
highest molecular mass band having two glycosylated sites, the middle band one and the 
lowest band none (figure 4.9).
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Figure 4.9 Prion protein glycoforms.  Western blot (left hand panel), schematic (central 
panel) and glycoform status (right hand panel) for Type 2 human PrPSc.  This illustrates 
the  three  different possible  glycosylation  states  that PrPSc  can occupy -  diglycosylated 
with the  largest relative molecular mass, monoglycosylated running as the middle band 
and unglycosylated with the lowest relative molecular mass.
For  reasons  not  well  understood,  the  predominance  of the  glycoforms  varies  widely 
between  the  different  strain  types  found  in  natural  and  experimental  prion  disease, 
resulting  in  significantly  different ratios between the  three  glycoforms.  In the  case  of 
some, but not all, cathepsin D digests of PrPSc, a decrease in the unglycosylated species 
of PrP  was  witnessed  (see  figure  4.5  -   strains  MRC  1  and  2  as  an  example).  To 
investigate this, multiple independent digests were carried out in parallel under identical 
conditions.  These  were  then  western  blotted  and  imaged  on  a  Storm  840  scanner 
(Molecular Dynamics corp), facilitating analysis of band intensity using the Imagemaster 
ID software program (Amersham biotech).  This allowed relative densities of bands from 
individual blots to be calculated and glycoform ratios established.  The data from these 
multiple  digests  were  then pooled and  statistically compared using a T  test.  Analyses 
were carried out of human types 2  and 3,  and mouse  RML.  These lend themselves to 
such  strain  analysis  due  to  their  relatively  even  distribution  of glycoforms  (257;351).
143Although some variation was observed, no statistically significant alteration in glycoform 












Figure 4.10 Glycoform analysis of RML PrPSc following digestion with cathepsin D and 
proteinase K.  The percentage of the total PrP represented by each glycoform is  shown 
for RML (blue)  and for RML digested with cathepsin D  (purple).  Data was compiled 
from  10  independent  digests  with  controls,  with  standard  deviation  indicated  by  error 
bars.  No significant difference in the glycoform ratio was observed following cathepsin 
D digestion.
It  is possible  that the  removal  of the  GPI  anchor has  a disproportionate  impact on the 
ability  of unglycosylated  PrP  to  transfer  from  gel  to  membrane  in  a  western  blotting 
system;  an  impact  mitigated  by  the  presence  of  sugar  chains  on  the  di-  and  mono­
glycosylated species.  If this were the case, the differences between individual blots and 




1444.4 Metal Ion Independence of Cleavage
An  alternative  explanation  for  this  alteration  in  electrophoretic  properties  following 
digestion  with  cathepsin  D  is  that  there  is  a  change  in  conformation  of  the  PrPSc 
dependent upon the inadvertent introduction or loss of metal ions during the experimental 
process.  Studies by Wadsworth and colleagues showed that removal of metal ions from 
PrPSc using the metal chelator EDTA resulted in strain specific alterations in proteolytic 
fingerprint following proteinase K digestion (352).  This is due to changes in the tertiary 
structure  of the  scrapie  agent  strains  following  removal  of metal  ions,  alterations  that 
result  in  different  regions  of the  amino  acid backbone  being  exposed  to  proteinase  K 
digestion.  To  eliminate  the  possibility  that  alterations  in  gel  mobility  following 
digestion  with  cathepsin  D  were  due  to  metal  dependent  conformational  changes, 
cathepsin D digests were carried out in the presence and absence of the metal chelating 
agent EDTA and the affect of increasing concentrations of Cu2+ upon the strain profile of 
RML were investigated (figure 4.11).
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Figure 4.11  Metal ion independence of gel retardation following cathepsin D digestion. 
A)  Cathepsin  D  digestion  of mouse  RML  carried  out  in  the  presence  of the  metal 
chelating agent EDTA.  No impact on gel retardation was observed.  B) Impact of Cu2+ 
ions on RML strain profile.  No alteration was observed.
145The presence of EDTA did not affect the apparent increase in relative molecular mass of 
PrP  in SDS  gel electrophoresis following cathepsin D digestion, not did the addition of 
copper to RML result in any strain specific alteration - indicating that the phenomenon is 
not dependent on the metal ion status of PrPSc.
4.5  Cathepsin D Catalysed Release of PrP from Cell Membranes
If  treatment  with  cathepsin  D  removes  the  GPI  anchor,  it  would  be  expected  that 
treatment of intact cells in culture with the enzyme would result in release of membrane 
anchored PrP into the cell media.  To examine this, wild type N2a cells were treated with 
either cathepsin D  or PIPLC,  with the  incubation media  subsequently analysed for the 
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Figure  4.12  Release  of  PrP  from  cultured  cells  following  exposure  to  cathepsin  D. 
Release  of PrP  from  the  cell  membrane  of wild  type  N2a  cells  by  PIPLC  (A)  and 
cathepsin D (B).  Cells were treated with the indicated concentration of enzyme for three 
hours, with the supernatant collected and analysed by western blotting.  The presence of
r~t
PrP  in the supernatant, recognised by ICSM 35, signifies release of the protein from the 
cell membrane upon either GPI cleavage (PIPLC) or C-terminal truncation (cathepsin D)
146Under  these  conditions,  treatment  with  both  cathepsin  D  and  PIPLC  resulted  in  the 
release of PrPc, as measured by an increase in the PrPc collected from the media.  This, 
again, supports the c-terminal truncation of PrP by cathepsin D, with the removal of the 
GPI anchor concomitant with release from the cell membrane.
4.6  Solubility of Cathespin D Treated PrPSc
The scrapie isoform of PrP is, by definition, highly insoluble.  It is characterised by its 
ability  to  aggregate  and,  indeed,  many  of  the  problems  in  defining  the  molecular 
properties of PrPSc can be traced back to its poor solubility.  To investigate whether C- 
terminal  truncation  of PrPSc  has  any  impact upon  its  solubility,  RML  infected  mouse 
brain homogenates were treated with cathepsin D, digested with proteinase K, exposed to 
low  levels  of  detergents  (in  order  to  increase  solubility)  and  then  subjected  to 
centrifugation through a discontinuous sucrose gradient.  Fractions were then collected 
from  this  gradient,  specifically  around  the  discontinuous  interfaces,  and  the  protein 
methanol precipitated.  The resulting precipitates were subjected to western blotting using 
standard  operating  procedure  and  the  distribution  of PrPSc  in  the  gradient  compared 
between cathepsin D treated and untreated material (figure 4.13).
147Figure 4.13 Protocol for solubility 
analysis.  RML samples were treated 
with proteases and then subjected to 
centrifugation at 100,000g for lhr 
through a sucrose gradient.  Fractions 
were then collected, methanol 
precipitated and then analysed by 
western blot using standard procedures. 
Cathepsin D digested RML and an 
undigested control were compared.
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Analysis of mouse RML PrPSc and cathepsin D treated mouse RML revealed alterations 
in the solubility of the scrapie isoform following C-terminal truncation with cathepsin D. 
C-terminally  truncated  RML  exhibited  a  loss  of solubility  in  lower  concentrations  of 
sucrose, with more of the PrP migrating to form a pellet at the bottom of the gradient 
(figure 4.14).
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Figure 4.14 Solubility analysis of PrPSc and C-terminally truncated PrPSc.  Samples were 
subjected protease digestion and separation on a sucrose gradient as described in figure 
4.13.  Upper panel  shows  mouse  RML  PrPSc  digested with  proteinase  K  as  a  control, 
lower panel shows mouse RML digested with cathepsin D and proteinase K.
4.7  Cathepsin D digest of recombinant PrP
As  an  alternate  approach  to  investigating  the  digestion  of  PrP  with  cathepsin  D, 
recombinant  moPrP  residues  91-231  was  exposed  to  the  enzyme.  Using  a  fixed 
concentration of cathepsin D,  a decrease in the relative molecular mass of recombinant 
mouse PrP 91-231  (as measured using  SDS  PAGE) was observed after 8  hours (figure 
4.15).  Since bacterially produced moPrP does not have post translational modifications 
(i.e. glycosylation or GPI anchor) the loss of the C-terminus of PrP would not result in
149kDa Figure 4.15 Cathepsin D digest of 
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gel retardation in SDS PAGE due to this.  Again, the time dependence of this interaction 
and  the  decrease  in  relative  molecular  mass  supports  the  hypothesis  that  proteolytic 
digestion of PrP by cathepsin D results in loss of the GPI anchor.
4.8  Ascertainment of GPI Loss
Several  techniques  were used to  attempt to  ascertain  the  loss  of the  GPI  from  PrP,  in 
addition to gel retardation as a biophysical marker of this  loss.  In the first instance, an 
antibody specific residue left after for the PIPLC cleavage of the GPI anchor, the cross 
reacting determinate, was used.  PrPSc was treated with cathepsin D and then proteinase K 
digested.  Following this, the digested PrP was partially denatured by the addition of SDS 
and  heating  to  100°C  for  10  mins.  The  detergent  was  then  diluted  out  and  PIPLC 
digestion carried  out.  The resulting  homogenate was  then western blotted  and probed
_  p
with the cross reacting determinant antibody.  With PrP  digested directly with PIPLC or 
PrPSc  digested  with  cathepsin  D  and/or  PIPLC  following  denaturation,  no  positive 
immunoreactivity was revealed.
The second technique used to examine the presence of absence of the GPI was phase 
separation.  Phase  separation refers to  the  transfer of proteins  from the aqueous to the
150detergent phase of a solution containing non-ionic detergents such as triton X-l 14 based 
upon their lipophilic and hydrophilic properties (353).  Triton X-l 14 undergoes a cloud 
point as it passes from below 20°C to above this temperature (354).  The detergent comes 
out  of  solution  at  low  concentration  and  can  be  centrifuged  into  a  pellet.  Highly 
lipophilic  proteins  will  associate  with  the  pellet,  with  hydrophilic  proteins  staying  in 
solution (figure 4.16).
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Figure  4.16  Phase  separation  protocol.  Mouse  RML  PrPSc  subjected  to  C-terminal 
truncation  with  cathepsin  D  and  then  digested  with  proteinase  K  underwent  phase 
separation using Triton X-114.  Untreated RML was used as a control and both samples 
analysed by western blot for partition of PrP into the aqueous and detergent phases.
This technique has been used to successfully evaluate the presence of the GPI anchor on
PrP  , but has not been applied to  scrapie  isoform.  With PrPc,  GPI anchored protein
151partitions exclusively to the lipid phase.  After PIPLC treatment, all PrP localizes to the 
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Figure  4.17  Phase  separation  analysis  of C-terminally  truncated  PrPSc.  RML  and  C- 
terminally truncated RML were subjected to phase separation as described in figure 4.16. 
Control  (cathepsin  D  minus)  and  C-terminally  truncated  PrPSc  are  shown  in  aqueous 
phase (Aq) and detergent phase (Det).
After  treatment  with  cathepsin  D,  there  was  an  alteration  in  the  distribution  of PrP 
between the two phases, but not enough to provide conclusive evidence of GPI loss.  It is 
likely  that  the  hydrophobic  nature  of aggregated  PrPSc  interferes  with  the  use  of this 
technique as a means  to evaluate the presence of the GPI,  altering the  solubility of the 
protein in the lipid and aqueous phases.
4.9  Discussion
In  this  study,  cathepsin  D  has  been  used  to  remove  a  short  carboxyl  terminal  peptide 
fragment from infectious PrPSc, removing at the same time the GPI anchor attached to the
+PK
152C-terminus of PrP.  In doing so, several major technical difficulties prevented the precise 
characterisation of the nature and location of the cleavage event.  The scrapie-associated 
isoform of PrP resists purification due to its propensity to aggregate.  This has severely 
hampered efforts to define many of the molecular characteristics of PrPSc per se in the 
past, and is the case for C-terminally truncated PrPSc following treatment with cathepsin 
D.  The  impact  of this  is  that,  with  current  protocols,  it  is  not  possible  to  directly 
sequence  the  cleavage  products  of  PrPSc  following  digestion,  whether  that  is  with 
proteinase  K or with cathepsin D.  This,  allied with the hydrophobicity of the  scrapie 
agent, precludes the identification of exactly which residues in the C-terminus cathepsin 
D  cleaves  between.  Unfortunately,  this  is  coupled to  the  fact that  cathepsin D  has  a 
poorly defined cleavage consensus sequence (characterised only as a preference to cleave 
between two hydrophobic residues -  see  section 5.2),  increasing the difficulty of even 
putatively locating the cleavage site.
The conclusion that treatment of PrPSc with cathepsin D results in cleavage at the 
C-terminal is, therefore, based on several indirect lines of evidence.  First and foremost is 
the gel retardation observed upon treatment of several strains of scrapie,  from multiple 
species, with cathepsin D.  This is analogous to the retardation observed upon treatment 
of PrPc with PIPLC, which also results in the removal of the GPI anchor (described in 
section  5.1).  Importantly,  cathepsin  D  mediated  retardation  displays  both  time  and 
concentration  dependence,  strongly  supporting  the  hypothesis  that  this  is  indeed  an 
enzymatic  event,  rather  than  a  none-specific  interaction  with  PrPSc.  An  alternative 
explanation for this phenomenon, alteration of PrPSc metal occupancy due to the addition 
of cathepsin D resulting in modification of the three dimensional structure of the protein
153and an altered proteinase K digestion pattern, was excluded by investigation of this in the 
RML model  system.  Gel retardation was  not affected by removal  of metal  ions with 
EDTA, and the fragmentation pattern of RML was not altered by the addition of excess 
Cu2+ ions.
Further support for the C-terminal truncation of PrP along with removal of the 
GPI anchor due to cathepsin D treatment comes from the cell release studies carried out 
using N2a mouse neuroblastoma cells, where increased levels of PrP were detected in the 
media following treatment of cells with either PIPLC or with cathepsin D (as compared 
to untreated cells).  The simplest explanation for this is that cathepsin D removes the GPI 
anchor from PrP, thereby releasing the protein into the cell media.  This is also backed up 
by studies of recombinant mouse PrP, which exhibits a loss in molecular mass following 
treatment with cathepsin D (also in a time dependent manner).  As stated in section 6.7, 
this is as one would expect if cathepsin D is cleaving PrP, since recombinant PrP has no 
post translational modifications and so would not exhibit gel retardation as there is no 
GPI anchor to be removed.
Several other techniques were used in an attempt to confirm that the GPI anchor 
was  being  removed  from  PrPSc,  however  these  were  severely  hampered  by  the 
aforementioned problems raised by the nature of the scrapie agent:  its hydrophobicity 
and tendency to aggregate.  This prevented the generation of clear results using either the 
cross reacting determinant antibody to recognise the presence or absence of the remnant 
of the GPI anchor, or the use of phase separation to identify PrP species with or without a 
GPI anchor.
1545.0 Investigation of the Impact of GPI Removal on the infectivitv of PrPS c
The C-terminal truncation of PrPSc by cathepsin D, removing the GPI anchor, provides an 
alternative to PIPLC treatment as a method to investigate the impact of GPI loss on the 
biology  of the  scrapie  agent.  As  PIPLC  cannot  be  used  to  remove  the  GPI  from 
infectious PrPSc, this opens up the possibility of examining whether the GPI anchor is 
required for the  infectivity of PrPSc.  To  analyse  the  impact of C-terminal  truncation, 
including the removal of its GPI anchor, on the ability of PrPSc to propagate and initiate 
infection, three separate models of prion replication was used.  Mouse models of prion 
replication are well characterised, and have the advantage that in vitro, ex vivo and in vivo 
systems  exist allowing  a broad approach  to  analysis  of scrapie  replication.  A  mouse 
based analysis also allows continuity of strain type across all forms of analysis (in this 
case  the  Rocky  Mountain  Line  strain  of  mouse-adapted  scrapie),  which  eliminates 
variability originating from strain specific characteristics from the experimental process. 
In terms of the mechanism of prion replication, carrying out analysis under cell free, cell 
culture and whole animal conditions may be useful  in revealing a possible differential 
impact of C-terminal truncation on infectivity.  For example, it is plausible to hypothesise 
that C-terminal truncation would have no impact on infectivity in cell free conditions, but 
would decrease infectivity when assayed using cells in culture due to a decreased ability 
to reach the site of conversion following removal of the GPI.  It is important to note, 
however,  that  in  vivo  analysis  of scrapie  infectivity remains the ultimate test of PrPSc 




Analysis of in vitro amplification of PrPSc was carried out using a modification of the 
protocol developed by Lucassen et al (156).  10% w/v homogenates were produced in 
PBS from RML infected CD-I, wild type CD-I  and FVB/Prnf^1 0  ablate mouse brains. 
RML homogenates were produced in the presence of 1% v/v Triton X-l00 (Sigma), with 
the  wild  type  and  ablate  homogenates  containing  lx  Complete  protease  inhibitors 
(Roche).  20pl of RML homogenate was digested with 200Units of cathepsin D  for 2 
hours and then, in parallel with undigested RML control, diluted 1  in 25 into lx PBS with 
1% v/v Triton X-l00.  These were then diluted 1:1  with CD-I  wild type or ablate brain 
homogenate  and incubated for  16 hours at 37°C with shaking at 450 rpm.  Following 
incubation,  homogenates  were  digested  with  proteinase  K  at  a  final  concentration  of 
50jag/ml  for  1   hour at  37°C.  The  digest  was  terminated  by  the  addition  of 2x  SDS 
loading  buffer  containing  AEBSF  at  a  final  concentration  of 5mM  and  analysed  by 
western blotting.  Each condition was repeated in triplicate.
Scrapie Cell Assay
Assay for prion infectivity was carried out as described by Klohn et al (140).  Briefly, 
N2a murine neuroblastoma cells were cultured in OPTI-MEM with  10% v/v fetal calf
156serum (OFCS) and  lOOUnits/ml of both penicillin and streptomycin (Invitrogen Corp.). 
PK1  cells, a subcloned N2a line highly susceptible to infection with the RML strain of 
mouse  adapted  scrapie,  were  used  to  assay  the  infectivity  of cathepsin D  treated,  C- 
terminally truncated RML.  Cells were plated out at a density of 20,000 cells per well in 
96  well  plates  (cells  were  resuspended  from  stock  flasks  and  counted  using  a 
haemocytometer prior to plating) in 200pl of OFCS.  Plates were incubated at 37°C for 
16hrs.  RML  homogenates  thawed  from  frozen  samples  were  prepared  for  assay  by 
treatment with cathepsin D (20pl of cathepsin D was added to 20pl of 10% w/v RML 
homogenate) or an equivalent volume of PBS as a control.  These were incubated for 2hrs 
at 37°C  with  shaking at 450rpm.  In parallel with this,  PBS  alone,  cathepsin D  at an 
equivalent  concentration  to  treated  samples,  cathepsin  D  treated  mouse  CD1  brain 
homogenate and RML thawed directly from stocks  immediately prior to dilution were 
prepared as  controls.  All samples were diluted to a range of concentrations (from 10'4 to 
10' ).  To  achieve  this,  they  were  first  diluted  into  10%  w/v  mouse  CD1  brain 
homogenate  and then into  OFCS  at  a concentration  appropriate  to  ensure  that  a  final 
concentration of brain homogenate (infectious and wild type) of 10"4.  300pl of diluted 
sample was added to each well, with 8 wells used for each dilution of each condition in 
triplicate.  Controls  were  included  on  each  plate  to  allow  plate  to  plate  variation 
following development to be taken into consideration.
The  initial  diluted  inocula  were  aspirated  after  3  days  and  the  confluent  cells 
resuspended by pipetting up and down 40 times in 300pl of OFCS.  30pl of resuspended 
cells were transferred into sterile 96 well plates and diluted 1:10 into fresh OFCS.  This 
was carried out three times, with the cells being grown to confluence after the final split.
157The  cells  were  then  transferred  to  ELISPOT  plates  (Enzyme  Linked  Immunospot 
multiscreen immobilon P 96 well format filtration plates, Millopore), activated prior to 
addition of cells by washing with 50pl of 70% ethanol.  To ensure an equal number of 
cells  per  well,  confluent  monolayers  were  resuspended  in  200pl  of  OFCS  and 
representative  samples  from  each  experimental  condition  were  counted  using  a 
haemocytometer.  25,000 cells per well were than added to the prepared ELISPOT plate. 
Vacuum was applied to the plates, pulling the cells onto the membrane, and the plates 
were then dried in a 50°C oven for  lhr.  50pl of 0.5pg/ml proteinase K in lysis buffer 
(50mM TrisCl pH 8.0,  150mM NaCl, 0.5% Deoxycholate, 0.5% Triton X-l00) was then 
added per well,  incubated at  37°C  for  90mins  and removed by vacuum.  Wells  were 
washed twice with  160pl of PBS, and 160pl of ImM PMSF was added to each well for 
lOmins then aspirated.  To denature cellular proteins attached to the membrane,  160pl of 
Guanidine Isothiocyanate (3M GSCN,  lOmM TrisCl, pH  8.0) was added to  each well, 
incubated for lOmins at room temperature and discarded into 2M NaOH.  The wells were 
then washed 4 times with 160pl of PBS.
Plates were then immunoprobed:  160pl of superblock (Pierce) was added to the 
cells for lhr, removed by vacuum, followed by the addition of 50pl of anti-moPrP ICSM 
18 antibody (D-Gen ltd., London) at a  1:5000 dilution in TBST with  1% milk powder. 
These were incubated for 1  hr at room temperature, the antibody discarded and the plate 
washed seven times with  160p TBST (10 mM TrisCl pH 8.0,  150 mM NaCl, 0.1% v/v 
Tween  20).  50pl  of secondary  antibody  (anti-IgGl  alkaline  phosphatase  conjugated, 
Sigma) was added to the wells at a dilution of 1:4500, again in TBST with 1% w/v milk 
powder,  and incubated for  lhr at room temperature.  This was then discarded and the
158wells washed seven times with 160pl of TBST.  The underdrains of the plates were then 
removed and the plates  dried under  airflow.  To  develop the plates,  50jnl  of Alkaline 
Phosphotase reactive development reagent was added to each well and incubated at room 
temperature for 16mins.  The supernatant was discarded and the plates washed twice with 
160pl of de-ionised H2O  before being dried under airflow.  To quantify the PrPSc positive 
cells in each well, Zeiss KS ELISPOT system was used.  Plates were read using a Stemi 
2000c  stereo microscope with a Hitachi  HV-C20A color camera.  Positive  spots  were 
detected using well scan software (Imaging Associates, Bicester UK), trained to detect 
appropriate colonies.
In vivo Bio-assay of Cathepsin D Treated PrPSc
Cathepsin D treated RML was subjected to conventional bio-assay using Tg20 transgenic 
mice  (355).  10%  w/v  RML  was  treated  with  20U/pl  cathepsin D  or mixed  with  an 
equivalent volume of PBS and incubated for 2hrs at 37°C. The treated and control RML 
were then diluted with PBS to a final concentration of 0.1% w/v in parallel with cathepsin 
D  alone  and  PBS  as  control  conditions.  RML,  cathepsin  D  treated  RML,  PBS  and 
cathepsin D only controls were then inoculated (30pl) intra-cerebrally into anaesthetised 
Tg20 transgenic mice over expressing the murine Prn-p gene (20 mice each for RML and 
cathepsin D treated RML experimental conditions, 10 mice each for PBS and cathepsin D 
alone control conditions).  Animal husbandry adhered to institutional and Home Office 
guidelines and animals were  examined daily for signs of clinical prion disease.  Brain 
samples were taken from all groups  following death,  analysed by western blot for the
159presence of PrPSc and histologically for neuropathological evidence of prion disease.  For 
western blots, 20pl of brain homogenate was taken from each experimental condition and 
digested with proteinase K for 1   hour at 37°C at a final concentration of 50pg/ml.  SDS 
PAGE  and transfer to  PVDF  were  carried  out  as  described  in  section  6.0,  with brain 
homogenate  not  treated  with  proteinase  K  run  in  parallel  with  each  digested  sample. 
Immunoprobing was carried out using ICSM 35 primary antibody (D-Gen Ltd., London) 
and  anti-IgGl  alkaline  phosphatase  conjugated  secondary  antibody  (Sigma)  and  blots 
scanned using a Molecular Dynamics  Storm 840 imaging machine.  Neuropathological 
examination was also carried out to ascertain the presence of scrapie pathology.  Brain 
tissue was fixed in 10% buffered formal saline and prion infectivity abolished by boiling 
in 98% formic acid for one hour.  The samples were then washed for 24 hours in  10% 
formal saline prior to embedding in paraffin wax.  Sections were cut from the fixed brains 
to a thickness of 4pm and treated with formic acid for 5 minutes.  These sections were 
then  boiled  in  EDTA-TRIS-citrate  buffer  (pH  7.8)  for  20  minutes  before 
immunohistochemical staining was carried out.  The anti-PrP monoclonal antibody ICSM 
35  (D-Gen  Ltd.,  London)  was  used  for  this,  applied  using  a  Ventana  automated 
immunohistochemical staining machine with a basic diaminobenzidine detection system 
according to the manufacturers instructions (Ventana medical systems, Tucson Arizona).
5.1  In vitro amplification of PrPS c
As noted in section  1.2.3,  several  in vitro models of scrapie replication exist.  For the 
purposes of this investigation, a protocol adapted from that described by Lucassen et al
160was adopted.  This relies on incubation of infectious homogenate with either wild type or 
knock out brain homogenate in the presence of mild detergents and protease inhibitors 
and has been widely used to investigate the biochemical requirements and environment of 
the prion conversion process  (155;157;356).  The detergents act to break up PrPSc  into
p   n
multiple seeds, which can then recruit PrP  for conversion.  When PrP  is  spiked into 
wild  type  homogenate  in  this  way,  amplification  of protease  resistant  PrP  signal  is 
observed.  This  is  compared to PrPSc  incubated with homogenate  from PrP0/0 mice not 
containing PrP  , where amplification of signal is not observed (figure 5.1).
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Figure 5.1 In vitro amplification protocol.  PrPSc is diluted into wild type and ablate brain 
homogenate  in  the  presence  of protease  inhibitors  and  1%  v/v  Triton  X-l00.  After 
incubation  for  16hrs,  PrPSc  diluted  into  wild  type  homogenate  exhibits  an  increase  in 
protease resistant signal as compared to PrPSc diluted into ablate homogenate as analysed 
by western blot.  Adapted from the protocol of Lucassen et al (156)
161Although the exact nature of the amplification is not yet clear, for example as to whether 
or not the resulting increase correlates with an increase  in infectivity*,  the technique is 
more robust than the PMCA technique described by Saborio et al and does not require 
the use of radiolabelled PrP,  as the cell  free conversion process originated by Caughey 
and colleagues does, therefore making it both cheaper and safer to replicate (147; 153).
To investigate the in vitro replication of C-terminally truncated PrPSc, RML was 
either  treated  with  cathepsin  D  for  two  hours  or  diluted  with  PBS  as  a  control  and 
incubated  in  parallel.  These  were  then  subjected  to  the  amplification  protocol  as 
described.  Each condition was repeated in triplicate,  and signal intensity data for each 
replicate  generated  by  scanning  western  blots  with  a  Storm  840  imager  (Molecular 
Dynamics).  Band  analysis  was  carried  out using  Imagemaster  ID  Elite  (Amersham). 
Following incubation, both cathepsin D  treated and cathepsin D untreated PrPSc  spiked 
into wild type homogenate exhibited an increase in signal of 100% over signal recorded 
with PrPSc spiked into knockout homogenate (figure 5.2).
Figure 5.2 In vitro amplification of C-terminally 
truncated PrP8 *.  Both treated and untreated RML 
infected brain homogenate diluted into wild type 
CD1 brain homogenate exhibited amplification of 
protease resistant signal (compared to RML diluted 
into PrPao  brain homogenate) as  quantified by 
band intensity following western blot analysis.
Data shown is the mean of three separate reactions 
with standard deviation indicated by error bars.
No significant difference was observed between 
treated and untreated samples.
*  Although recent work by Suppatapone and colleagues suggests that there is a least a 
transient increase in the infectivity of amplified samples (357).
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162There  was  no  significant  difference  in  amplification  of  signal  between  treated  and 
untreated samples  (p >  0.35,  paired T-test),  indicating  that C-terminal truncation with 
cathepsin D does not affect in vitro amplification in this system.
5.2  Scranie Cell Assay of PrPSc
Several  cell  lines that are capable  of propagating PrPSc have been characterised.  The 
most widely used, and most intensely studied, is the murine neuroblastoma cell line N2a. 
N2a cells are susceptible to infection with the RML strain of mouse adapted scrapie, and 
can be used to  assay for infectivity.  By  subcloning N2a cells,  it is possible to  select 
clonal lines with heightened susceptibility to RML.  Such a line, the PK1  subclone, was 
used in the scrapie cell assay developed by Peter Kloehn and Charles Weissmann at the 
MRC Prion unit (140).  By using a range of dilutions, this system allows highly sensitive 
detection  and titration  of the  number  of infectious  units  in  RML  homogenate,  and  is 
capable of revealing as little as a two fold alteration in infectious titre.  This makes it 
ideal  for  examining  the  infectivity  of RML  homogenates  digested  with  cathepsin  D, 
where the impact of C-terminal truncation is not known and could be anything from no 
affect,  through  a  modest decrease  in  infectivity  to  complete  ablation  of the  ability  to 
infect cells.
Using the  scrapie cell assay,  cathepsin D treated RML was  compared to  RML 
incubated in parallel with the digest, and with RML thawed directly prior to exposure to 
cells.  It should be noted that incubation at 37°C for two hours results in a decrease in 
infectivity,  hence  the  introduction  of  two  RML  controls  (F.  Properzi,  unpublished
163observations).  In addition to these two controls, cells were also exposed to cathepsin D at 
an  equivalent  concentration  to  that  used  in  the  digest,  CD1  wild  type  homogenate 
exposed to cathepsin D, CD 1   wild type homogenate alone and PBS.  These were used to 
control for any cytotoxic affect that cathepsin D may have, either intrinsically (cathepsin 
D alone) or through toxic intermediates generated through the digestion of mouse brain 
homogenate.  In both cases, no cytotoxic impact was revealed as measured by cell counts 
of treated wells compared to other controls.  PBS and CD1  wild type controls were used 
to provide uninfected controls, thereby yielding a background level as a control for the 
rest of the experimental conditions.  This is illustrated in figure 5.3.
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Figure  5.3.  Positive and negative  scrapie cell assay  samples.  96  well plate individual 
wells showing cells exposed to wild type CD1  brain  homogenate (A) and mouse RML 
PrPSc  brain  homogenate  (B).  The  cells  exposed  to  scrapie  infected brain  homogenate 
propagate PrPSc, detected by immunoprobing with anti-PrP antibodies following exposure 
of cells  to  proteinase  K.  Control  cells  exposed  to  CD1  brain  homogenate  show  no 
evidence of protease resistant PrP.
164With  the  experimental  conditions  themselves,  cathepsin  D  treated  RML  did  show  a 
decrease  in infectivity  as  compared to  RML  diluted  on  to  cells  directly  after thawing. 
However, when compared to RML incubated in parallel with the digest for two hours at 
35°C, there was no significant difference between the two (figure 5.4).
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Figure  5.4  Scrapie  cell  assay  analysis  of  C-terminally  truncated  PrPSc.  RML  was 
incubated for 4 hours at 37°C and RML digested with cathepsin D for 4 hours at 37°C.  A 
range  of dilutions  of RML  brain  homogenates  from  10-4  to  10'7   were  used  to  allow 
estimation of any  impact of cathepsin  D  digestion on the  infectivity  of RML,  with no 
significant difference between digested and undigested samples.  Data shown is the mean 
number of cells that contain detectable PrPR ES per 25,000 viable cells from 3 independent 
experiments with standard deviations as indicated.
Using the scrapie cell assay model of RML prion infection and propagation, there was no 
significant difference between wild type and C-terminally truncated, GPI minus cathepsin 
D treated RML.  As was mentioned above, the scrapie cell assay is capable of detecting
165alterations in titre of approximately 2  fold, making it a highly sensitive technique even 
compared to titrated animal assay.
5.3  In vivo Analysis of PrPSc Infectivity
There  are  many  in  vivo  models  of prion  replication,  ranging  from the  experimentally 
infected primates that established the transmissible nature of kuru and CJD through to the 
Tg 9949 mouse transgenic model utilised by Legname et al for the artificial stimulation 
of prion protein neurodegeneration (90;112;358).  Consistent with the in vitro and ex vivo 
investigation of C-terminally truncated PrPSc, in vivo analysis of infectivity was carried 
out using RML mouse adapted scrapie and a mouse model of prion disease.  Due to the 
long  incubation  times  associated  with  the  wild  type  mice  (in  excess  of  150  days),  a 
transgenic  model  was  chosen:  the  Tg20  mouse  line  over-expressing MoPrP  at a  level 
approximately  eight times  greater than  wild type  (355).  These  mice  develop  scrapie 
sickness  between 60  and  120  days  post  intra cerebral  inoculation with  RML  infected 
mouse brain homogenate, allowing far more rapid appraisal of infectivity.
To  examine  the  infectivity  of  C-terminally  truncated  PrPSc  lacking  the  GPI 
anchor,  10% w/v RML infected brain homogenate was treated with cathepsin D using a 
standardised protocol.  In parallel, RML was diluted to an equivalent concentration to the 
experimental group for use as a positive control and cathepsin D was diluted likewise to 
control for the possibility of toxicity and/or neurodegeneration (however unlikely) due to 
the  presence  of the  enzyme.  PBS  was  included  as  a  negative  control.  All  of these 
samples  were  then  examined  for  infectivity  by  intra  cerebral  inoculation  into  Tg20
166transgenic mice.  These mice were  examined on a daily basis  for any evidence  of the 
symptoms  of  scrapie,  with  the  incubation  period  between  inoculation  and  onset  of 
symptoms noted.  Following death or culling, brain samples were taken and examined for 
the  presence  of PrPSc,  to  confirm  the  diagnosis  of prion  disease  and  to  examine  any 
possible molecular alterations upon transmission due to C-terminal truncation.  Samples 
were  also  taken  for  examination  by  immunohistochemistry,  again  to  confirm  the 
diagnosis  of  prion  disease  by  revealing  the  presence  or  absence  of  pathology 
characteristic of infection.
Following  inoculation,  one  hundred  percent  of both  RML  and  C-terminally 






RML 17/17 67.5 (±2.2)
Cathepsin D 
treated RML 17/17 67.4 (±2.5)
Cathepsin D 0/10 >200
PBS 0/10 >200
Table 5.1 In vivo bioassay of C-terminally truncated PrPSc.  TG20 transgenic mice were 
inoculated  intra  cerebrally with  0.1%  w/v  RML  brain  homogenate  and monitored  for 
clinical signs of prion disease. Groups of mice inoculated with either cathepsin D treated 
RML or native RML exhibited similar incubation times shown in days post-inoculation. 
The presence of protease resistant material in the brains of both experimental groups was 
confirmed by western blotting. Control groups (PBS and cathepsin D alone) showed no 
evidence of prion disease.
167After death, brain samples from each affected mouse were examined by western blot for 
the presence of PrPSc.  All animals diagnosed with scrapie also had protease resistant PrP 
within  their  brains,  with  a  protease  resistant  fragment  profile  and  glycoform  ratio 
characteristic of the RML strain of mouse adapted scrapie (figure 5.5).
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Figure  5.5  Protease resistant prion protein from  in  vivo bioassay.  Brain samples  were 
taken from PBS inoculated animals, RML inoculated animals and C-terminally truncated 
RML  inoculated  animals.  10%  w/v  homogenates  were  prepared  and  analysed  by 
proteinase  K  digestion  and  western  blot  as  described.  RML  and  cathepsin  D  treated 
RML  inoculated  mouse  brain  homogenates  contain  protease  resistant  prion  protein, 
whereas PBS inoculated brain homogenate does not.
Neuropathological  examination  of experimental  and  control  animals  were  also  carried 
out.  No evidence of scrapie pathology was revealed in the control cases, with pathology 
typical  of RML  strain  prion  disease  being  found  in  both  the  RML  and  C-terminally 
truncated RML inoculated animals (figure 5.6).
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Figure  5.6  Histological  analysis  of  in  vivo  bioassay  brain  sections.  Samples  were 
prepared  by  fixation  in  formalin  and  boiling  in  formic  acid.  Immunhistochemistry 
reveals widespread gliosis (using GFAP  as  a marker)  in RML and cathepsin D treated 
RML  brain  slices.  Analysis  using  anti-PrP  antibody  ICSM  35  reveals  deposition  of 
protease  resistant  PrP  in the  brains  of animals  inoculated  with  RML  and  cathepsin  D 
treated RML, correlating with the western blot analysis of homogenates and symptomatic 
diagnosis of scrapie.  Control samples show no evidence of PrPSc accumulation.
To  summarise  the  in  vivo  infectivity  analysis  of  C-terminally  truncated  RML,  no 
significant difference in mortality, incubation period,  strain type or neuropathology was 
revealed following inoculation of Tg20 mice with RML and with C-terminally truncated 
RML lacking the GPI anchor.  Subject to certain caveats (see discussion) this  suggests 
that removing the GPI anchor from PrPSc does not reduce infectivity.
1695.4 Discussion
In order to yield as much information as possible about the impact of the removal of the 
GPI anchor upon the replication and  infectivity  of PrPSc,  three different  systems  were 
used: an in vitro amplification system, the ex vivo scrapie cell assay model of infection 
and in vivo analysis using the Tg20 transgenic mouse model.  No significant effect on 
either replication or infectivity was observed with any of these techniques.
The relationship of the first two systems to the in vivo situation remains a subject 
of debate.  In  the  case  of in  vitro  amplification  of PrPSc,  several  systems  have  been 
reported to generate an amplification of signal but no categorical proof of a concomitant 
increase in infectivity has been produced and so these systems may reflect an increase in 
protease resistant PrP rather than a genuine amplification of infectivity.  Despite these 
drawbacks,  such systems offer a window on a specific aspect of prion replication -  in 
isolation  from  issues  of  cell  entry  and  tissue  tropism.  From  this  point  of  view, 
unimpaired  in  vitro  replication  of  PrPSc  lacking  the  GPI  anchor  is  informative.  It 
suggests that at the basic level of prion replication, be it a template assisted enzymatic 
process  or a  seeded polymerisation  event,  the  GPI  anchor  is  not required.  This  is  in 
agreement with in vitro work utilising recombinant prion protein lacking a GPI anchor by 
several groups, showing that recombinant protein can adopt a (3-sheet conformation and 
undergo amyloid polymerisation under suitable conditions (127;277).
N2a  models  of  scrapie  cellular  infection,  whilst  exhibiting  demonstrable 
propagation of infectivity, are limited by the fact that they are sensitive to infection by 
only a small range of prion strains, notably RML, and are easily cured of the infection as
170compared to experimental in vivo prion disease (138).  As neuroblastoma cells, N2a are 
also continually replicating, in contrast to the situation in the brain where prion infections 
propagate within a static neuronal population (359).  It is also important to note that the 
mechanisms whereby N2a cells are capable of propagating scrapie, where so many other 
cell lines cannot, have not been identified (360).  The central features of the model,  in 
terms of the replication of PrPSc, remain unknown.  N2a cells recapitulate, therefore, only 
certain aspects of the cellular pathology of the prion disorders and are not, of themselves, 
a complete model of the disease process.  The high sensitivity of the scrapie cell assay 
does,  however,  lend  itself to  evaluation  of infectivity.  The  lack  of any  significant 
difference in infectivity as measured by this assay suggests that, if there is an impact on 
infectivity  due  to  the  removal  of the  GPI  anchor,  it  results  in  less  than  a  two  fold 
reduction {id est, below the detection levels of the assay).  This is an important finding as 
the dynamic range of western blot detection of PrP does not exclude the possibility that 
less than one percent of PrPSc molecules retain their GPI anchor.  A contamination with 
one percent uncleaved material might be sufficient to produce similar patterns of prion 
infection in a conventional bio-assay, but would be detected by the scrapie cell assay.  As 
a cellular model, the scrapie cell assay also simulates prion replication at a higher order 
of complexity to in vitro systems, and suggests that (in addition to not impacting on the 
replication of PrPSc) loss of the GPI anchor does not result in a decrease in the ability of 
RML to infect cells.
In vivo models of prion disease remain the most complete system within which to 
study the TSEs, mirroring many of the features of the naturally occurring disorders.  They 
provide a model of prion propagation, of the infection process and, as indicated by the
171terminal nature of the disease generated,  of the toxicity and cell death associated with 
prion replication.  The fact that no significant difference between cathepsin D treated and 
untreated  RML  was  observed using  the  Tg20  transgenic  mouse  line  indicates  that  C- 
terminal  truncation  does  not  interfere  (within  the  limits  of  this  model)  with  these 
processes.  A major problem with in vivo analysis of infectivity such as that used here is 
that only large alterations in infectivity would be detected, highlighting the importance of 
using in vivo analysis in parallel with other techniques such as the scrapie cell assay.
Taken individually, each of the three systems used to investigate the infective and 
replicative properties of C-terminally truncated PrPSc suggest that the removal of the GPI 
does not result in a reduced ability to replicate, infect cells or cause disease.  Although 
each system carries with it different drawbacks, taken cumulatively this body of work 
argues  strongly that removal  of the  GPI  by  C-terminal  truncation  does  not  affect  the 
infectious properties of the scrapie agent.  This is particularly well demonstrated by the 
scrapie  cell  assay which  is  capable  of detecting just  a two-fold  change  in titre.  This 
finding  has  several  implications.  First,  it  demonstrates  that  the  GPI  does  not  play  a 
central  role  in the process  of infection and replication of PrPSc,  and  is  not  a required 
molecular characteristic of the scrapie agent.  It follows that membrane insertion of the 
disease associated form of PrP via the GPI anchor is not part of the process of infection, 
suggesting that the initial infection either occurs at the cell surface via a direct interaction 
with  exogenous  PrPSc or following  internalisation of the  scrapie agent.  This  does not 
necessarily contradict work carried out in vivo and in cell culture using PrP constructs 
lacking the GPI attachment sequence, resulting in a loss of the symptomatic prion disease 
although not a loss of protease resistant prion protein (309;313).  As noted in section 5.1,
172these studies significantly alter the location of PrP as well as its molecular characteristics. 
Secondly,  since  endogenous  proteolytic  release  of PrPc  has  been  reported,  this  may 
provide  a  mechanism  whereby  infectious  PrPSc  could  spread  from  cell  to  cell  (350). 
Infectious PrP could be released from the cell in a c-terminally truncated form following 
endogenous proteolytic  digest.  This  study  demonstrates that,  were  this to occur,  then 
such PrP could go on to infect further cells.  Thirdly, the absence of decreased infectivity 
following removal of the GPI from PrPSc means that this is not a factor preventing the 
production of de novo prion infectivity using recombinant protein.  This is in agreement 
with the recent work by Legname et al which showed that PrP generated in E. coli cells 
by  recombinant  expression  (lacking  both  glycosylation  and  a  GPI)  is  capable  of 
stimulating  prion  associated  neurodegenerative  disease  in  a  transgenic  mouse  model 
(112).
1736.0 Conclusions
It  is  only  by  defining  the  molecular  characteristics  of  the  scrapie  agent  that  an 
understanding can be gained as to the mechanism of replication and of cell death in the 
prion diseases.  The  clarification  of how  these  occur will,  in turn,  shed  light both on 
methods  of intervening  and  halting  the  progression  of devastating  disorders  such  as 
scrapie and CJD and upon a fascinating novel area of basic biology -  that of protein only 
replication.  It is unfortunate that the very nature of the scrapie agent has made the task of 
investigating and defining these characteristics an arduous one.  The research contained 
within this thesis has concentrated on two of the molecular characteristics of the scrapie 
agent:  the  impact  of the  codon  129  polymorphism  on  the  biochemistry  of the  prion 
protein,  and  thence  the  scrapie  agent;  and  the  role  of the  Gycosylphophatidylinositol 
anchor on the infectious capabilities of PrPSc.
As  discussed  in  the  introduction,  the  codon  129  polymorphism  of the  prion 
protein has a surprisingly large impact on several aspects of the pathogenesis of the prion 
diseases, affecting susceptibility, disease progression, phenotype and pathology.  To date, 
a biochemical basis  for this  impact has not been identified.  In this thesis,  a range  of 
biochemical properties were investigated for both the methionine and valine prion protein 
codon 129 variants using recombinant PrP in the a-helical and p-sheet rich conformations 
to model the behaviour of PrPc and PrPSc respectively.  The structure of the a-helical rich 
form  of  PrP  was  investigated  using  circular  dichroism,  proteolytic  degradation  and 
analytical ultracentrifugation, with no significant difference between the two polymorphs 
being observed.  The ability of both forms of a-PrP to bind copper was also investigated,
174again with no significant difference observed.  These data are in agreement with previous 
research  into  the  biochemical  characteristics  of the  codon  129  variants  of a-PrP  and 
suggest that,  if there is  an alteration  in the properties of the prion protein based upon 
variation at codon 129, then this difference must be expressed in the (3-sheet rich form or 
an  intermediate  in  the  formation  of the  p-rich  isoform  (269;271;275).  Due  to  the 
difficulties in elucidating a detailed atomic level structure for p-PrP using high resolution 
techniques  such  as  NMR  or  X-ray  crystallography,  several  indirect  or  low  resolution 
techniques  were  used  to  investigate  the  structural  characteristics  of  the  codon  129 
variants folded into a predominantly p-sheet conformation.  No significant difference was 
observed in the ability of the two polymorphs to convert from the a-helical to the p-sheet 
state in vitro and, once in the P-rich conformation, there was no observable difference in 
the  CD  spectra  or  proteolytic  resistance  of the  two  polymorphs.  Using  urea  as  a 
denaturant, the stabilities of the P-rich M and V polymorphs were examined.  Although 
no  obvious  difference  between  the  two  polymorphs  was  observed  with  equilibrium 
unfolding (using molecular ellipticity at A220nm as  a marker for secondary  structure), 
when spectra covering A200 to 220nm were collected for the two forms a difference was 
uncovered between the two forms in the presence of 0.75M urea.  At this concentration of 
denaturant,  M l29  PrP  exhibited  a  greater retention  of p-sheet  structure.  The  lack  of 
resolution provided by CD makes it difficult to define the exact difference in structure 
between the two polymorphs in these conditions, and further study of this phenomenon 
using higher resolution techniques is required.  This apparent difference in structure in 
the presence of mild denaturants is especially interesting when taken in tandem with the
175result from fibrillisation experiments carried out in similar conditions with the two codon 
129 variants (see below).
Analysis  of  the  sedimentation  behaviour  of  M  and  V  (3-PrP  revealed  that 
methionine  p-Prp has a lower Svedberg coefficient than valine  p-PrP.  Taken together 
with  CD  analysis of the two  variants,  this  suggests  that although the two polymorphs 
share  a  common  p-sheet  structure,  M l29  occupies  a more  compact three-dimensional 
conformation  than VI29.  It  is  possible  that  this  more  compact  structure  favours  the 
ordered self-association of M l29 over VI29 -  an intriguing possibility when considered 
in the light of fibril forming experiments with the two variants.  It should be noted that, in 
the conditions examined using AUC in these experiments, no significant self-association 
of either form into dimers, trimers or higher order oligomers was observed.  However, 
given the  long  lag phase  for fibril  formation it is possible that ordered polymerisation 
initiates from a very small population of self associated molecules.
Using the model of PrP fibrillisation developed by Baskakov and co-workers, the 
formation  of  amyloid  by  the  two  codon  129  polymorphs  was  examined.  In  mild 
denaturing conditions (1M GuHCl,  1.3M urea), M l29 PrP formed fibrils after a lag phase 
of 35hrs,  whilst VI29  PrP  did not  form  fibrils  after a  lag phase  in excess  of 200hrs. 
Results from seeding experiments, where valine PrP amyloid growth could be stimulated 
by the  addition  of preformed methionine  fibril  seeds,  suggest that VI29  is  capable of 
forming fibrils in energetically favourable conditions (provided here by seeding).  It is of 
interest that a  1:1  mix of M and V PrP did not form fibrils -  indicating that VI29 PrP 
may  have  a  dominant  negative  effect  on  the  fibrillisation  of  M l29  PrP.  AUC 
experiments and CD analysis of partially denatured p-PrP may suggest a reason for the
176differing fibril forming properties of the two polymorphs.  Data from these investigations 
suggest M l29 p-PrP has a more compact structure than VI29 p-PrP, and is also slightly 
more resistant to denaturation.  It is possible that the combination of these factors is the 
reason  why  PrP  containing  methionine  at  codon  129  forms  amyloid  in  these  specific 
conditions whilst PrP with valine at the same residue does not.  How this biochemical 
difference relates to the disease state is difficult to assess.  As discussed in chapter 3, the 
link between amyloid and disease in neurological disorders of protein misfolding where 
amyloid deposits are described is unclear.  There is still a great deal of argument as to 
whether amyloid is on the disease pathway itself, if it is merely a marker for the end stage 
of disease or perhaps even a protective mechanism to minimise toxicity (174).  With the 
prion diseases in particular, the lack of amyloid pathology in the majority of cases blurs 
the link between the amyloid forming properties of PrP and disease.  A counter to this is 
the  evidence  from  in  vivo  bioassay  that  suggests  that  fibril  mixtures  formed  from 
recombinant mouse  PrP  can  stimulate  disease  in  a  transgenic  mouse  model  (112).  It 
should  be  noted that  it  is  not yet clear what  species  within  the  fibril  mixture  acts  to 
stimulate disease and, therefore, the amyloid generated in the Baskakov system may yet 
represent  an  extraneous  by-product  of a  disease  process  that  occurs  via  small  toxic 
oligomers.  Regardless of this  issue,  evidence is accruing that suggests that it is  some 
aspect of the aggregation or fibrillisation properties of the two polymorphs that results in 
the phenotypic impact of this polymorphism -  both from the work contained in this thesis 
and through the  efforts  of other researchers  (272).  It is  important to  remember when 
considering this  that  any  alteration  in  oligomerisation  or  fibrillisation dependent  upon 
codon  129 status is but a marker for an alteration in a more fundamental aspect of the
177biochemistry of 0-PrP.  This  emphasises once again the importance of high resolution 
structures of the two codon 129 variants in the p-rich conformation.
The  codon  129  polymorphism  of PrP  is  one  of the  most  fascinating  of the 
molecular characteristics of the scrapie agent.  Recent genetic evidence suggests that the 
continued presence of this polymorphism (or similar polymorphisms such as the E219K 
variant) in human populations may be a protective mechanism resulting from multiple 
historic  or  prehistoric  exposures  to  epidemic  prion  disease.  As  a  natural  defence 
mechanism against these diseases, an increased comprehension of the molecular basis for 
the protective effect of this polymorphism may lead to both a greater understanding of the 
infectious behaviour and replication of the scrapie agent and the development of effective 
interventional strategies as therapy for diseases such as CJD.
The  second  molecular  characteristic  to  be  investigated  in  this  thesis  was  the 
Glycosylphosphatidylinositol anchor attached to the C-terminus of mature PrP.  Although 
the role of the GPI in the biology of the cellular prion protein has been well documented, 
the technical difficulties associated with investigating PrPSc (especially the resistance of 
PrPSc to treatment with phospholipase C) have hampered any examination of the role of 
the GPI in the biology of the scrapie agent.  The research in this thesis presents treatment 
of PrPSc with the aspartic endoprotease cathepsin D as an alternative to PIPLC treatment 
for removal of the GPI anchor.  This activity was identified by retardation of PrPSc in 
SDS  gel  electrophoresis  following  treatment  with  cathepsin  D,  analogous  to  the 
retardation observed when PIPLC  is used to  remove  the GPI  anchor  from  PrPc.  The 
initial part of this work concentrated on the characterisation of the interaction between 
PrPSc and cathepsin D,  showing that the gel retardation was  dependent on the time of
178incubation with and the concentration of cathepsin D.  This strongly supported the idea 
that  this  was  an  enzymatic  phenomenon,  and  that  treatment  with  cathepsin  D  was 
resulting  in the  loss  of C-terminal  peptides  and  the  GPI  anchor.  Further evidence  to 
support  this  was  provided  by  the  release  of PrPc  from  cells  in  culture  following 
treatment with cathepsin D and the decrease in molecular mass exhibited by recombinant 
PrP  upon  treatment  with  cathepsin  D  -   no  gel  retardation  would  be  expected  since 
recombinant PrP lacks a GPI anchor.  Unfortunately, direct sequencing of the cleavage 
products was not possible due to the hydrophobic, aggregation prone nature of PrPSc.
Following investigation of the cleavage of PrPSc by cathepsin D,  the  impact of 
GPI loss on the infectivity of PrPSc was examined.  To achieve this, cathepsin D treated 
PrPSc was compared to untreated PrPSc in three different models of prion replication and 
infectivity.  There was no alteration in the ability of PrPSc to replicate in an in vitro model 
of prion propagation after C-terminal truncation by treatment with cathepsin D, a result 
echoed by ex vivo examination using a cell assay of infectivity.  The third model used to 
investigate infectivity following C-terminal truncation was a transgenic mouse model of 
prion disease utilising Tg20 mice  overexpressing mouse  PrP.  Again,  no difference  in 
infectivity was observed between PrPSc and C-terminal truncated PrPSc lacking the GPI 
anchor.  Although each of these models have drawbacks, as discussed in chapter 5, taken 
in toto these data strongly support the argument that removing the GPI from PrPSc does 
not decrease its infectivity.
The  absence  of any  impact  on  the  infectivity  of PrPSc  due  to  loss  of the  GPI 
anchor has several implications.  First, these data make it highly unlikely that the GPI 
plays a direct role in the replication of the scrapie agent.  From a mechanistic point of
179view,  it is also less likely that the GPI plays a role in the process of cell infection,  for 
example  by  aiding  the  insertion  of the  scrapie  agent  into  the  cell  membrane.  It  is 
important to stress that the results presented in this thesis with regard to loss of the GPI 
are  focussed  on  C-terminal  truncation  of the  infectious  agent  and  these  data  do  not 
exclude the possibility that loss of the GPI  from the cellular form of PrP  has a major 
impact on the pathogenesis of prion disease.  Indeed, there is some evidence that this may 
be the case (313).  The lack of any decrease in the infectivity of PrPS c due to GPI loss 
does, however, suggest that any alteration in pathogenesis would be due to changes in the 
spatial location of PrPc within the cell concomitant with GPI loss rather than an intrinsic 
change in the mechanism of prion replication.
The  essential  conclusion  of these  investigations  into  the  removal  of the  GPI 
anchor from  PrPSc  is  a negative one -  that removal  of the  GPI  has  no  impact on the 
infectivity  of the  scrapie agent.  The importance of this  finding  is that it takes a step, 
however small, towards narrowing the definition of prion infectivity.  By excluding the 
GPI as a requirement for the infectious process, the minimum molecular infectious unit 
(with PrP at its heart) is closer to comprehensive characterisation.  Approaching this from 
the reverse standpoint, the work of Legname and colleagues supports these findings by 
suggesting that recombinant PrP, lacking both GPI and glycosylation, can stimulate prion 
disease  in  a  transgenic  mouse  model  (112).  By  extending  our  knowledge  of  the 
minimum prerequisites for the infectious process to occur, a greater understanding of the 
mechanisms  of prion  replication  can  be  gleaned  -   with  ramifications  for  therapeutic 
development.
1807.0 Future Work
There  are  several  avenues  of investigation  that  the  work  contained  within  this  thesis 
highlights  for  further  examination.  In  terms  of the  codon  129  polymorphism,  major 
questions remain as to the basis of the phenotypic variance witnessed between the two 
allelic forms.  It has become increasingly apparent that the origin of the codon 129 affect 
is likely to reside in the structure and properties of the p-form, a statement supported by 
the work in this thesis.  The most important gap in our knowledge regarding this is, of 
course, an atomic resolution structure of the p-form.  As noted (section 1.4), this has long 
been the  focus of much of the biochemical  investigations  into prion biology.  For the 
codon  129 polymorphism, a true understanding of the mechanism whereby it exerts its 
affect  is  unlikely  to  be  arrived  until  atomic  resolution  structures  of  the  p-rich 
conformation of both M l29 and V I29 forms of the prion protein are elucidated.  With 
regard to  this,  it  is  of interest that  some  evidence  for differential  unfolding  pathways 
followed by the M and V forms of recombinant prion protein in the presence of urea have 
been revealed  (see  section  2.2.2).  It may be  that more  detailed examination  of these 
partially  unfolded  states  using  higher  resolution  techniques  will  yield  important 
information as to any molecular level conformational differences in the p-rich form due 
to the codon 129 polymorphism.
In  addition  to  structural  determination,  there  are  several  aspects  of  the 
biochemistry  of M  and  V  PrP  investigated  in  this  body  of work  that  merit  further 
investigation.  In terms of the binding of Cu2+ to the prion protein, only interactions with 
91-231  a-PrP were  investigated.  Whilst the  amino  acids covered by this recombinant
181protein represent the structured domains of PrP,  it is impossible to exclude (except by 
experimentation) that there may be differential copper binding to full length M  and V 
forms.  It  is  also  important  to  exclude  differential  copper  binding  to  the  p-rich 
conformation  as  a  possible  molecular  characteristic  that  varies  between  the  two 
polymorphs -  although there are technical difficulties associated with carrying  out the 
copper binding in the low pH conditions that favour the p-rich isoform.  It would also be 
of interest to revisit the super oxide dismutase properties of the M and V forms of the 
human  prion  protein,  examined  by  Wong  and  colleagues  using  mouse  PrP  with  an 
anthropomorphous codon 129 polymorphism (269).  As has been discussed (section 1.5), 
a mouse PrP peptide sequence background does not present the best model in which to 
investigate  human  polymorphisms  or  mutations,  and  would  not  necessarily  reveal 
alterations  that  may  be  present  in  the  human  in  vivo  system.  This  suggests  the 
investigation  of  SOD-1  activity  using  human  PrP  may  be  worthwhile.  Any  such 
investigation should be qualified, however, by increasing evidence that PrP may lack a 
physiologically relevant SOD-1 activity (207).
Whilst  the  fibrillisation  experiments  described  herein  provide  provocative 
evidence  of a  biochemical  difference  between  the  two  polymorphs,  there  are  many 
aspects of the aggregation properties of human M l29 and VI29 PrP that merit further 
investigation.  Only a very small selection of possible fibrillisation conditions, in terms of 
pH, temperature, denaturant concentration and substrate concentration, were examined in 
this  investigation  for  the  M  and  V  codon  129  variants.  To  fully  understand  the 
interaction  of  the  two  codon  129  polymorphs  in  the  model  system  developed  by 
Baskakov et al, a wider range of conditions needs to be investigated.  As discussed in
182section 3.3, it is possible that there are conditions that would favour the fibrillisation of 
valine 129 PrP over methionine  129 PrP (that is, the reverse of what was observed with 
the conditions used in the current experiments).  There are also several other investigative 
techniques that could be applied to this system in order to shed light on the nature of the 
biochemical  difference  that  is  leading  to  this  divergence  in  aggregation  properties. 
Electron microscopy has been applied to several types of amyloid deposits, including PrP 
amyloid, yielding much important structural data (268;361;362).  Due to the potentially 
infectious nature of the fibrils generated using the Baskakov protocol from recombinant 
human prion protein, it has not been possible under local biosafety rules to examine the 
fibrils formed from methionine or valine seeded by methionine by electron microscopy. 
This technique does, however, have the potential to reveal much information about any 
structural  variation  in  fibrils  due  to  the  codon  129  polymorphism.  Were  the  correct 
facilities  to  become  available,  electron  microscopy  should  be  applied  to  the  amyloid 
generated in this study.  Another technique that has the potential to reveal  information 
about the fibril forming characteristics of M l29 and VI29 PrP is total internal reflection 
fluorescence  microscopy  (TIRFM).  This  technique  allows  direct observation  of fibril 
growth by exploiting the fluorescent properties of thioflavin T bound to amyloid deposits. 
TIRFM has been successfully used to visualise amyloid generation by p2-microglobulin, 
revealing information about the kinetics and directionality of amyloid growth (363).
The codon  129 polymorphism has  received a considerable amount of scientific 
scrutiny  due  to  its  role  in  the  pathogenesis  of the  prion  diseases,  and  especially  its 
importance  in susceptibility to vCJD.  In contrast,  the  E219K polymorphism  found  in 
Asian  populations  has  received  very  little  attention  in  regards  to  its  role  in  the
183epidemiology of prion diseases,  or in terms of any  structural or biochemical impact it 
may  have  on  the  biology  of PrP  (39).  Since  it  has  been  suggested  that  the  E219K 
polymorphism  plays  essentially  the  same  protective  role  fulfilled  by  the  codon  129 
polymorphism  in  other  populations,  further  studies  of the  structural  and  biophysical 
characteristics of the codon 219 polymorphism may prove illuminating to the biology of 
codon 129 and its interaction with the disease process, as well as the pathogenesis of the 
prion diseases per se (64).
There  are  several  questions  surrounding  the  C-terminal  truncation  of PrPSc  by 
cathepsin D that remain to be answered.  The central issue that remains to be resolved is 
exactly where in the primary C-terminal sequence of PrP cathepsin D is cleaving.  As 
noted in chapter 4, there are several technical difficulties that must be overcome before 
this can be achieved.  Techniques for the purification of PrPSc are improving, but are not 
yet  at  the  point  where  reliable  peptide  mapping,  and  therefore  identification  of the 
cleavage  point,  is  attainable  (232).  An  alternative  approach  to  this  would  be  the 
sequencing  of  recombinant  PrP  digested  with  cathepsin  D,  which  might  reveal 
information about which residues in the C-terminus of PrP are susceptible to cleavage by 
the  enzyme.  A  major  criticism  of  this  approach,  however,  is  that  digestion  of 
recombinant PrP, whether this be a-rich or p-rich, does not necessarily recapitulate the 
situation with PrPSc in vivo and so,  at best, could only be used as indirect evidence of 
cleavage.
An interesting possible application of cathepsin D would be to use the enzyme to 
treat scrapie infected cell lines in an attempt to release PrPSc from the cell surface.  In the 
course of the current research, it was shown that treatment of non-scrapie infected cells
184with cathepsin D resulted in the release of PrPc  from the plasma membrane -  but the 
impact on infected cells was not investigated.  This approach may settle the question as to 
whether or not the  scrapie  agent  is  intracellular  or membrane  associated  in  cell  lines 
propagating PrPSc, still a matter of some debate.
A final future area of investigation that is suggested by this body of work is to 
examine  both  a  possible  physiological  interaction  between  either  PrPc  or  PrPSc  and 
cathepsin D, and whether cathepsin D is involved in susceptibility to the prion diseases. 
In  the  first  case,  work  carried  out  by  Parkin  et  al  suggests  that  endogenous  PrP 
undergoes proteolytic release from cells (350).  Although this study has not uncovered 
any direct evidence of an in vivo interaction between cathepsin D and PrP, it is intriguing 
to speculate as to whether this enzyme plays a role in proteolytic shedding or degradation 
of either the cellular or scrapie associated form of PrP -  a possibility that warrants further 
investigation.  As regards cathepsin D and susceptibility to the prion diseases, it would be 
of interest to investigate whether polymorphisms in the cathepsin D gene are risk factors 
for prion disease -  as may be the case with the A224V polymorphism in cathepsin D and 
Alzheimer’s disease (344).  It would also be informative to investigate using western and 
northern blots any up or down regulation of cathepsin D associated with prion disease -  
again with the aim of identifying any link between the disease state and this proteolytic 
enzyme.
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The human prion protein has a 
common polymorphism at residue 129 
which  can  be  valine  or  methionine. 
This  polymorphism  has  a  strong 
influence  on  susceptibility  to  prion 
diseases  and  on  prion  strain 
properties.  Previous work has shown 
that this amino acid variation  has no 
effect on the a-helical PrPc structure 
and  does  not  influence  its  stability. 
Here we show that the polymorphism 
also does not change the efficiency of 
conversion to the p-PrP conformation 
and  has  no  effect  on  stability  or 
protease  resistance.  However,  in  a 
partially  denatured  conformation  the 
polymorphic variation has a profound 
influence on the ability of the protein 
to form amyloid fibrils.
The  prion  diseases  or 
transmissible  spongiform
encephalopathies (TSEs) are a group of 
closely  related  neurodegenerative 
disorders  characterised  by  spongiform 
degeneration of the brain.  They include 
scrapie of sheep, BSE in cattle, chronic 
wasting  disease  affecting  deer  and  elk 
and the human disorders CJD, GSS, FFI 
and vCJD  (1).  A  unique  and  defining 
feature of diseases in humans is that they 
can be inherited, arise sporadically or be 
acquired  through  infection  (1). 
According  to  the  protein-only
hypothesis,  the  central  event  in  the 
pathogenesis of prion diseases is the 
conversion of the normal,  cellular form 
of  the  prion  protein  (PrPc)  into  an 
aberrantly  folded,  disease  associated 
form known as PrPS c (2;3).
Inherited forms  of prion  disease 
are  caused  by  mutations  in  the  PRNP 
gene located on human chromosome 20 
(4).  Many pathogenic mutations in PrP 
have  now  been  described,  along  with 
two  polymorphisms:  methionine  or
valine  at  codon  129  (Ml29V)  and 
glutamine  or  lysine  at  codon  219 
(E219K) (5;6).  These polymorphisms, 
although not pathogenic, have a complex 
interaction  with  the  disease  process. 
Heterozygosity at either of these codons 
is associated with resistance to sporadic 
CJD  (7;8).  In  addition  to  this, 
differences in codon  129 status result in 
phenotypic  variation  within  pedigrees 
also  carrying  a  pathogenic  mutation  in 
PrP  (9-12),  and  homozygosity  at  this 
codon is a significant risk factor for the 
acquisition  of  transmissible  forms  of 
CJD, such as Kuru, vCJD and iatrogenic 
CJD (13-17).  Whilst there is a great deal 
of  genetic  and  clinical  evidence 
supporting  the  role  of  the  codon  129 
polymorphism  in  prion  disease,  no 
obvious biochemical basis for this affect 
has so far been uncovered.
208Based upon the nucleated seeding model 
of prion  propagation  (18),  it  has  been 
suggested that the phenotypic impact of 
the  codon  129  polymorphism  may  be 
due  to  incompatibilities  between  the 
nucleated  growth  of  the  two  variants 
(19).  The  fact  that  all  cases  of vCJD 
thus  far  recorded  are  methionine 
homozygotes,  that  bovine  PrP  contains 
methionine at the homologous codon and 
that sequence complementarity has been 
shown  to  be  important  for  the 
propagation of scrapie in in vitro and in 
vivo  models  (20-24)  provides  some 
evidence  to  support  this.  The 
methionine-valine variation is, however, 
relatively  conservative  with  respect  to 
the  volume  and  hydrophobicity  of the 
side  chains  (25),  and  NMR  studies 
comparing  the  three  dimensional 
structures of the two forms in the PrPc 
conformation  failed  to  find  any 
difference in structure or global stability 
(26).
From these observations it seems 
likely  that  the  influence  of residue-129 
on prion disease results from its effect on 
the  physical  properties  of  the  PrPS c 
isoform.  While  there  is  no  reliable, 
high-resolution  information  on  the 
structure  of  this  disease-associated 
conformer,  the  purified  infectious 
material is aggregated, insoluble and has 
a  predominantly  p-sheet  secondary 
structure.  We  have  previously  shown 
that  acidification  and  disulphide 
reduction  of the  PrPc  species  switches 
the  conformation  to  one  that  is 
dominated by P-sheet and is capable of 
forming ordered fibrils.  Given that it is a 
p-sheet form of the prion protein that is 
involved  in  the  formation  of  prion 
aggregates in vivo, we wanted to look at 
the behaviour of this p-PrP species to see 
whether the  switch between  valine  and 
methionine  at  codon  129  had  any 
influence  on  its  physical  properties. 
Here we present an analysis of the prion 
protein codon 129 polymorphism and its 
affect  on  several  aspects  of  the
behaviour  of  recombinant  human  PrP 
comprising  residues  91-231.  Using  a 
variety  of  techniques,  the  stability, 
structural  plasticity,  aggregation 
properties,  protease  resistance  and 
amyloid formation of the methionine and 
valine  forms  of human  PrP  have  been 
investigated.
EXPERIMENTAL PROCEDURES
Strict biosafety protocols were followed 
and  all  work  with  recombinant  human 
prion  protein  was  carried  out  in  a 
microbiological  containment  level  3 
facility.
Protein Production
Recombinant prion protein residues  91- 
231  containing  either  methionine  or 
valine  at  codon  129  was  produced  as 
described  elsewhere  (27).  The 
conversion  of recombinant  a-PrP  to  p- 
PrP  was  carried  out  at  pH  4.0  and  in 
reducing conditions using the protocol of 
Jackson  et  al  (28).  Total  protein  was 
calculated  by  UV  absorption  using  a 
calculated molar extinction coefficient of 
19632  M 1   cm'1   at  280nm  in  order  to 
determine  refolding  yield.  The 
conversion reactions were independently 
repeated  5  times  and  the  mean  yields 
with standard deviations calculated.
Circular  Dichroism  and  Unfolding 
Analysis
Spectra were recorded with a Jasco J715 
spectropolarimeter  and  measured  at  a 
protein concentration of 1  mg/ml with a 
0.01cm  pathlength.  Equilibrium 
unfolding  analysis  of  protein  stability 
was  carried  out  with  a  protein 
concentration  of 0.1 mg/ml  and  a  1cm 
pathlength  (measurements  were  taken 
over  a  lOnm  bandwith  centred  around 
X220nm).  Protein  denaturation  was 
carried  out  by  addition  of  aliquots  of 
either  10M  Urea  or  6M  Guanidine 
Hydrochloride  (GuHCl).  The  ellipticity 
signal (0) was converted to proportion of
209molecules  in  the  native  state  o,n 
according  to  the  relationship  a,N=  (0- 
Ou )/(0 n -0 u),  where  0u  and  0 n  are  the 
ellipticity  signals  for  the  unfolded  and 
native  states  respectively.  Data  were 
fitted to the function:
aN  = (K< N /U ).exp(m.D))/(l+K< N /U ).exp(m.D))
where m represents the sensitivity of the 
unfolding transition to denaturant and D 
is the denaturant activity (29).
Protease Resistance
10(4.1  aliquots  of 1  mg/ml  protein  of the 
appropriate  codon  129  status  and 
predominant  fold  (either  a  or  (3)  were 
digested with proteinase K at 0.1,  1,  10 
or  100  pg/ml  final  concentration. 
Reactions  were  terminated  by  the 
addition  of  2x  SDS-loading  buffer 
buffer [125 mM Tris-HCl (pH 6.8), 20% 
v/v  glycerol,  4%  w/v  sodium  dodecyl 
sulphate,  4%  v/v  2-mercaptoethanol,
0.02%  (w/v)  bromophenol  blue]
containing  8  mM  4-(2-aminoethyl)- 
benzene  sulfonyl  fluoride  (AEBSF; 
Pefabloc  SC,  Roche,  Lewes,  UK). 
Samples  were  heated  to  100°C  for 
lOmins  and  then  subjected  to 
centrifugation in a microfuge (15,000 g) 
for  1   minute.  20jnl  of each  supernatant 
was  applied  to  a  16%  Tris-glycine  gel 
(Novex; Life Technologies, Paisley, UK) 
according  to  the  manufacturer’s 
instructions.  Gels  were  washed  with 
distilled  water  and  then  stained  with 
Coomassie  blue  (Coomassie  brilliant 
blue  0.025%  w/v,  methanol  40%  v/v, 
acetic acid 7% v/v in ddH20) for 1  hour 
followed  by  destaining  with  40%  v/v 
methanol, 7% v/v acetic acid in ddH20.
Fibril Formation
Fibril  formation  was  analysed  using  a 
protocol adapted from that of Baskakov 
et  al  (30;31).  Briefly,  recombinant  a- 
PrP  of both  M  and  V  129  status  was 
transferred  into  20mM  Sodium  Acetate 
pH 3.7 and denatured by the addition of
10M  Urea.  The  protein  was  then 
dialysed into 1.3M Urea, 1M GuHCl pH
6.  To stimulate assembly of monomeric 
PrP  into  fibrils,  800pl  of  0.8mg/ml 
protein  was  aliquoted  into  a  1.5 ml 
microfuge tube and shaken at 37°C and 
600rpm.  An identical reaction was  also 
performed with twice  the  concentration 
VI29  PrP  (1.6mg/ml).  Monitoring  of 
fibril  formation  was  carried  out  by 
determination  of  Thioflavin  T 
fluorescence.  10(4.1  of  sample  was 
removed from the  shaking aliquots and 
diluted  1   in  20  into  5mM  Sodium 
Acetate pH 5.5.  Thioflavin T was then 
added to a final concentration of 50pM 
and  fluorescence  measured  on  a  Jasco 
FP-750  spectrofluorimeter  (excitation 
450nm, emission 485nm) with 5nm band 
widths. All experiments were performed 
at 20°C.
RESULTS
a-PrP Structure and Stability 
To examine the impact of the codon 129 
polymorphism  on  a-PrP,  recombinant 
PrP  residues  91-231  with  either 
methionine  or  valine  at  position  129 
were  examined  by  using  circular 
dichroism  (CD)  for  differences  in 
structure or stability.  Spectra in the far 
UV range (A , 190-250nm) were recorded 
(Figure  1A), with both Ml29 and VI29 
exhibiting  spectra  characteristic  of  a 
predominantly  a-helical  fold  with  no 
significant  difference  between  the 
spectra,  agreeing  with  data  from  NMR 
studies  of the  two  variants.  To  assess 
whether  the  polymorphism  has  any 
impact on the stability of a-PrP, both M 
and  V  forms  were  subjected  to 
equilibrium  unfolding  using  GuHCl  as 
described in the previous section.  Both 
M  and  V  containing  proteins  exhibited 
profiles characteristic of a single domain 
undergoing  a  co-operative  unfolding 
event  (Figure  IB).  The  free  energy  of 
folding  in  water  calculated  for  both 
polymorphs  were  6.62  kcal  mol'1
210(Ml29)  and  6.52  kcal  mol'1   (V129) 
demonstrating  that  the  polymorphism 
has no  significant impact on the  global 
stability of the a-PrP fold.
fi-PrP  Conversion,  Structure  and 
Stability
The  lack  of  significant  differences 
between the NMR  solution  structure  of 
the two polymorphic  variants  in  the  a- 
conformation suggests that, if there is a 
structural  difference  between  the  two 
forms,  it  lies  either  in  partly  folded 
intermediates or in the p-sheet state.  To 
investigate  this,  both  polymorphs  were 
converted  to  p-PrP  and  the  yield  for 
conversion  calculated.  No  significant 
difference was found between the two as 
regards  their propensity to  form  the  p- 
sheet  conformer  (Figure  2).  Circular 
dichroism spectra recorded in the far UV 
range  for  both  P-PrP  Ml29  and  P-PrP 
VI29  were  qualitatively  compared. 
Again,  no  significant  difference  was 
revealed,  with  both  forms  exhibiting 
spectra  indicative  of predominantly  p- 
sheet  structure  with  a  minimum  at  X 
217nm  (Figure  3A).  Following  this, 
equilibrium unfolding was carried out on 
to  analyse  the  stability  of  the  p- 
conformers  (Figure  3B).  Both  showed 
none  co-operative  unfolding  profiles, 
consistent with the view that p-PrP has 
characteristics similar to that of a molten 
globule  folding  intermediate  (32)  with 
no  significant  difference  between  their 
respective  stabilities  (Ml29  2.36  kcal 
mol'1  and VI29 2.73 kcal mol'1 ).
Protease Resistance
Both M and V variants of a-PrP digested 
for  1   hour  at  pH  8  with  a  variety  of 
concentrations of proteinase K exhibited 
similar levels of protease resistance and 
fragmentation patterns.  Both forms were 
completely  digested  by  treatment  with 
lOpg/ml proteinase K for 1   hour.  p-PrP 
was  digested  at  pH  4,  with  a-PrP 
digested  at  the  same  pH  to  act  as  a 
control  for the pH  dependent reduction
in proteinase K activity.  M and V p-PrP 
were  more  resistant  to  proteinase  K 
treatment  than  their  a-PrPcounterparts, 
but no difference in fragment pattern or 
resistance  to  digestion  between  the  M 
and  V  polymorphs  could  be  discerned 
(Figure 4).
Fibril Formation
Using  the  conditions  described,  human 
recombinant  PrP91'231,  containing 
methionine  at  codon  129  formed 
amyloid  material  after  a  lag  phase  of 
approximately  35  hours.  In  contrast, 
recombinant  PrP  containing  valine  at 
codon 129 did not form amyloid material 
after a period exceeding 200 hours with 
twice  the  protein  concentration  (Figure
5).
DISCUSSION
This  study  of  the  physical 
behaviour  of  the  methionine  and  the 
valine forms of human prion protein was 
stimulated by the dramatic effect of the 
codon  129  variations  both  on 
susceptibility to and phenotype of human 
prion disease.  It has long been observed 
that  individuals  with  an  MV  genotype 
are  highly protected against developing 
sporadic  and  acquired  prion  diseases. 
This  effect  can  be  explained  by  the 
principle  of molecular complementarity 
combined  with  a  gene-dosage  effect. 
That  is,  if  there  is  a  spontaneous 
conversion  of PrPc  to  PrPS c  and  only 
identical  molecules  can  be  recruited  in 
the  propagation  process  owing  to 
structural  complementarity,  then  a 
homozygote will have a double dose of 
available substrate hence the probability 
of  initiation  and  and  the  rate  of 
propagation will be enhanced. Moreover, 
recent work has demonstrated that BSE 
and  vCJD  prion infection  in  transgenic 
mice  can  result  in  the  propagation  of 
distinct molecular and neuropathological 
phenotypes  dependent  on  host  PrP
211residue  129  status.  These  data  were 
interpreted as revealing a critical role for 
codon  129  in  governing  the 
thermodynamic balance between human 
PrPSc  conformations  that  determine 
strain  type  and  gave  rise  to  a 
conformational selection model of prion 
transmission barriers in which there is no 
overlapping preferred  conformation  for 
the  valine  and  methionine  forms  of 
human  PrP  that can  be  generated  as  a 
result  of  exposure  to  the  BSE  prion 
strain.
Such  effects  on  the  propagation 
of  the  scrapie  agent  mean  that  the 
methionine-valine  change  must  affect 
the  structure  and  stability  of either the 
□ -helical PrPc species or the PrPS c state 
of  the  protein  or  indeed  both. 
Alternatively,  the  polymorphic  state 
could influence the efficiency or kinetics 
of the PrPG -to-PrPS c conversion or alter 
the  interactions  that  stabilize  the  latter 
form.  The  ready  availability  of 
recombinant human PrP enables detailed 
experimental study of the physical effect 
of  this  amino  acid  variation  on  the 
physical properties of the PrP molecule 
in  a  variety  of  conformations  and 
assembly  states  and  some  behavioural 
differences have been claimed.
For  instance,  binding  studies 
performed on mouse PrP  engineered to 
contain  methionine  and  valine  at  the 
equivalent  position  in  the  murine 
sequence (murine PrP does not contain a 
homologous  polymorphism)  revealed 
that  when  both  were  refolded  in  the 
presence  of  copper  there  was  a 
difference  in  their  secondary  structure 
content  as  determined  by  circular 
dichroism (33).  This must, however, be 
qualified  by  the  fact  that  there  is  12% 
variation between the primary sequence 
of human  and  mouse  PrP  (34),  raising 
questions as to how representative of the 
in vivo human situation this is.
Other  studies  have  examined  the 
possibility that differences in the ability 
of  M  and  V  codon  129  PrP  to  form 
ordered amyloid aggregates underlie the 
phenotypic  variation  seen  in  these 
diseases.  Using a 30 amino acid peptide 
fragment  of human  PrP  (residues  1  Ob- 
136),  Petchanikow  co-workers  showed 
that the  methionine  form had  a greater 
ability to form a P-sheet conformation in 
a  variety  of biochemical  environments 
(35).  More recently, Tahiri-Alaoui and 
colleagues  showed that  human PrP  90- 
231  containing  methionine  at  position 
129 has a greater propensity to form 1 3 - 
rich  oligomers  than  the  equivalent 
valine-containing  protein  (3 6). In 
addition,  previous  work  from  our 
laboratory  has  shown  that  the 
methionine-valine  variation  has  no 
measurable  effect  on  the  global 
structure,  dynamics,  or  stability  of the 
normal  cellular  conformer  (the  PrPc 
conformation) and we concluded that the 
powerful effect of residue  129 on prion 
strain selection is  likely to be mediated 
by its effect on the conformation of PrPS c 
or  its  precursors  or  on  the  kinetics  of 
their formation.
This finding has prompted us to 
examine the effect of the polymorphism 
on an alternative a-sheet-dominated fold 
of the human PrP protein chain, known 
as  (3-PrP,  comprising  residues  91-231. 
At low ionic strength, the P-PrP species 
is a soluble monomer composed almost 
entirely of p-sheet as determined by CD 
spectroscopy  and,  more  recently,  infra­
red  absorption.  NMR  measurements 
show this species to be molten globule­
like with respect to the dynamics of the 
side chains.  At higher ionic strength or 
on  prolonged  incubation  in  acid 
conditions this conformer assembles into 
fibrils with partial resistance to digestion 
with  proteinase  K,  characteristic 
dseterminants of PrPSc.
212The results we present here show 
that  there  is  no  difference  in  the 
propensity of the M or the  V  forms  to 
convert  from  the  a-helical  PrPc 
conformation to p-PrP at low pH and in 
reducing  conditions.  Further,  an 
examination of CD spectra and protease 
resistance  of  p-PrP  in  the  methionine 
and  valine  forms  failed  to  reveal  any 
difference  in  global  conformation  or 
accessibility  to  enzymatic  cleavage. 
Also  the  two  polymorphic  forms  of 0- 
PrP  had  the  same  conformational 
stability when subjected to denaturation 
using chaotropic agents.
However, the polymorphic forms 
showed  a  striking  difference  in  their
propensity to form ordered fibrils.  Using 
the protocol developed by Baskakov and 
co-workers,  the methionine-129 version 
of  partially  denatured  a-PrP  readily 
formed fibrils with a lag time of 35-40 
hours  as  measured  by  thioflavin  T 
fluorescence;  a  finding  which  was  in 
agreement with previous work (37).  In 
stark contrast, the valine-129 version did 
not form amyloid even after more than 
200-hours of incubation.  This finding is 
consistent with previous  work detailing 
the  greater  propensity  of  PrP  with 
methionine  at  codon  129  to  form 
aggregates (38;39).
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FIGURE LEGENDS
Figure  1  CD  analysis  of recombinant human q-PrP^^ . (A) Overlaid far UV 
spectra of Ml29 (blue) and VI29 PrP (red), each compiled from an average of 50 
scans.  (B)  Equilibrium  denaturation  curves  of  129M  (blue)  and  129MV  (red),  as 
measured by amide CD absorption at 222nm. The lines superimposed upon the data 
are fits to the function:
aN  = (K(N /u).exp(m.D))/(l+K{N/u).exp(m.D))
Figure 2 Conversion efficiency of a-PrP to B-PrP. The  yield of folded soluble, 
monomeric protein in a beta-sheet conformation is shown for for Ml29 (blue) and 
V129 (red) polymorphs of human PrP91'231. Black bars indicate the standard deviation 
from an average of 5 independent experiments.
Figure  3  CD  spectra  of  recombinant  human  folded  in  a  B-PrP
confrontation-  (A)  Overlaid far UV spectra of Ml29  (blue) and VI29  (red)  PrP, 
compiled from an average of 50 scans. (B) Equilibrium denaturation curves of human 
p-PrP  129M  (blue)  and  129MV  (red),  as  measured  by  amide  CD  absorption  at 
222nm. The lines superimposed upon the data are fits to the function:
aN  = (K<N/u).exp(m.D))/( 1  +K{N /U ).exp(m.D))
Figure 4 Protease resistance of a and B  conformational isoforms of the M and V 
human  polymorphs.  Using  identical  conditions  for digestion,  soluble  |3-PrP  has 
increased  resistance  to  proteinase  K  when  compared  to  a-PrP.  The  M  and  V 
polymorphs have identical levels of resistance and display similar patterns of cleavage 
products.  The  concentrations  of PK  indicated  are  the  final  concentrations  in  the 
digestion reactions.
Figure 5 Amyloid fibril formation bv the M and V forms of recombinant human 
PrP. The formation of amyloid fibrils as determined by Thiofalvin T fluorescence is
215shown as a function of time. Fibrillogenesis of Ml29 PrP (blue) occurs after a lag 
time of 35 hours, whereas VI29 PrP at the same concentration (red), and twice the 
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According  to  the  protein-only 
hypothesis  of  prion  propagation,  prions 
are  composed  principally  of  PrP  ,  an 
abnormal  conformational  isoform  of the 
prion  protein,  which  like  its  normal 
cellular  precursor  (PrPc)  has  a 
glycosylphosphatidyl inositol (GPI) at the 
carboxyl  terminus.  To  date,  elucidating 
the role of this anchor on the infectivity of 
prion preparations has not been possible 
due  to  the  resistance  of  PrPSc  to  the 
activity  of  phosphoinositol  specific 
phopholipase  C  (PIPLC),  an  enzyme 
which  removes  the  GPI  moiety  from 
PrPc.  Removal of the GPI  anchor from 
PrPSc  requires  denaturation  prior  to 
treatment with PIPLC, a process that also 
abolishes infectivity.  To  circumvent this 
problem  we  have  removed  the  GPI 
anchor from PrPSc in RML prion-infected 
murine  brain  homogenate  using  the 
aspartic endoprotease Cathepsin D.  This 
enzyme eliminates a short sequence at the 
carboxyl terminal end of PrP to which the 
GPI anchor is attached.  We find that this 
modification has no effect upon (1) an in 
vitro amplification model of PrPSc, (2) the 
prion  titre  as  determined  by  a  highly 
sensitive N2a-cell based bioassay, or (3) in 
a mouse bioassay.  These data show that 
the  GPI  anchor  has  little  or  no  role  in 
either  the  propagation  of  PrP8*  or  on 
prion infectivity.
The  prion  diseases  of humans  and 
animals are a group of closely related, fatal 
neurodegenerative  disorders  that  include 
scrapie  in  sheep,  bovine  spongiform 
encephalopathy  (BSE)  in  cattle  and 
Creutzfeldt  Jakob  disease  (CJD),  kuru,
Gerstmann-Straussler-Scheinker  syndrome 
(GSS) and fatal familial insomnia (FFI) in 
humans (1).  Prion diseases in humans have 
three,  distinct  aetiologies,  being  inherited, 
acquired by exposure to infectious material 
or  arising  sporadically.  They  are 
characterised  by  accumulation  of  a 
misfolded  endogenous  protein  (the  prion 
protein  (PrP)  (2))  and  the  protein-only 
hypothesis (3;4) states that the central event 
in the pathogenesis of these diseases is the 
conversion of the normal host prion protein, 
PrPc,  into  an  aberrantly  folded  infectious 
form  denoted  PrP8 *   (5).  Although  much 
research has been directed at unravelling the 
mechanism whereby this conversion occurs, 
very  little  is  known  about  the  molecular 
basis of PrP8 *  formation.
Human  PrP  is  a  253  amino  acid 
protein produced from a single exon located 
on  chromosome  20  (6).  Following
translation, PrP is modified by the formation 
of  an  internal  disulphide  bond  between 
residues  179  and 214  (7),  glycosylation at 
asparagines residues 181 and 197, which has 
now  been  characterised  (8)  and,  following 
the removal of 22 carboxyl terminal amino 
acids, the addition of a glycosylposphatidyl 
inositol  (GPI)  anchor  to  the  C-terminal 
serine residue (9).  Cellular PrP is attached 
to the plasma membrane via this GPI-anchor 
and  localized,  along  with  other  GPI- 
anchored proteins,  to  cholesterol rich  lipid 
rafts within the membrane (10).  The GPI 
anchor attached to PrPc can be cleaved by 
treatment  of  the  protein  with 
phosphoinositide  specific  phospholipase  C 
(PIPLC),  resulting  in  the  release  of  the 
protein from the cell surface of intact cells 
(11).  This  also  results  in  an  apparent
222increase  in  the  molecular  mass  of PrP,  as 
analyzed  by  SDS-PAGE,  due  to  the 
extremely  hydrophobic  nature  of the  lost 
anchor (12; 13).  It has been shown in cell- 
culture models that location of PrPc at the 
cell membrane is crucial for both infection 
of cells  with  PrPS c  and  for  the  continued 
propagation  of  the  scrapie  isoform. 
Treatment of cell cultures with PIPLC prior 
to addition of infectious homogenates has a 
protective  effect  and  treatment  following 
establishment  of infection  cures  the  cells
(14).  Analysis of the impact of GPI loss on 
the infectivity of PrP8 0  has, to date, not been 
possible due to the resistance of the scrapie 
isoform to the enzymatic activity of PIPLC, 
thought to be due to steric exclusion of the 
enzyme by the altered conformation of PrP
(15).  It has also been shown that mutations 
found  in  inherited  prion  disease,  when 
introduced  into  PrP  expressed  in  cultured 
cell lines, increase the resistance to cleavage 
with  PIPLC  (12).  Removal  of  the  GPI 
anchor  from  PrP8 0   requires  denaturation 
prior to treatment with PIPLC, a process that 
also  abolishes  infectivity;  it has  thus  been 
impossible  to  ascertain  whether  the  GPI 
anchor is  an essential  component  of prion 
infectivity.  Answering  this  question  has 
several  consequences  regarding  our 
understanding  of prion  diseases.  From  a 
mechanistic  point  of view,  the  impact  of 
GPI removal on the ability of PrP8c to infect 
cells may shed light both on the site of the 
conversion event and on the route that the 
scrapie  isoform takes  into  the  cell.  Also, 
should the absence of a GPI anchor decrease 
the infectivity of PrP80, this has implications 
for attempts to generate infectious prions in 
vitro  from  recombinant material,  since  the 
majority  of  recombinant  prion  protein  is 
generated from bacterial sources and lacks a 
GPI anchor.
In  this  study,  we  describe  the 
removal  of the  GPI  anchor  from  PrP8c  in 
RML-infected  murine  brain  homogenate 
using  the  aspartic  endoprotease  Cathepsin
D.  This enzyme eliminates a short sequence 
at the carboxyl terminal end of PrP to which 
the GPI anchor is attached.  We have used 
this  phenomenon  as  a  tool  to  probe  the 
impact of removal of the GPI anchor upon 
an in vitro amplification model of PrPSc(16), 
and  have  assayed  prion  infectivity  using 
both  a  highly  sensitive  N2a-cell  based
bioassay, the scrapie cell assay (17) and a 
mouse bioassay (18).  We find that, in these 
systems, removal of the GPI anchor has no 
impact on either amplification of protease- 
resistant PrP or prion infectivity.
EXPERIMENTAL PROCEDURES
Source of  homogenates 
Whole mouse brains from normal and RML- 
infected CD-I mice were homogenised as a 
10%  w/v  preparation  in  Dulbecco’s 
phosphate-buffered  saline  (PBS)  without 
calcium  and  magnesium  ions  using  a 
Dounce  homogeniser.  Homogenates  were 
then split into aliquots and stored at -80°C. 
Protease Treatment
Cathepsin D digests were carried out using 
Cathepsin  D  purified  from  bovine  spleen 
(Merck),  freshly  made  up  in  lx  PBS. 
Standard digest conditions were as follows: 
10%  infectious  brain  homogenates  were 
thawed  and  centrifuged  at  lOOg  for  1  
minute.  lOpl aliquots of 10% homogenate 
supernatant  were  then  digested  with  100 
units  of Cathepsin  D  for 4  hours  at  37°C 
with  shaking  at  450  rpm.  Following  this, 
samples  were  digested  with  Proteinase  K 
(Sigma) at a final concentration of 50pg/ml 
for 1  hour at 37°C.  Digests were terminated 
by  the  addition  of 2x  SDS  sample  buffer 
buffer [125 mM Tris.HCl (pH 6.8), 20% v/v 
glycerol, 4% w/v sodium dodecyl sulphate, 
4%  v/v  2-mercaptoethanol,  0.02%  (w/v) 
bromophenol blue]  containing  8  mM  4-(2- 
aminoethyl)-benzene  sulfonyl  fluoride 
(AEBSF; Pefabloc SC, Roche, Lewes, UK). 
In the  case of Cathepsin D digests  carried 
out  in  the  presence  of 
ethylenediaminetetraacetic  acid  (EDTA), 
20mM  EDTA  (Sigma)  was  added  to  the 
reaction mixture and RML control samples. 
Western Blot Analyses
Following the addition of 20|il of 2 x SDS- 
loading  buffer,  samples  were  heated  to 
100°C  for  lOmins  and  then  subjected  to 
centrifugation in a microfuge (15,000 g) for 
1   minute.  20pl  of  each  supernatant  was 
applied to a  16% Tris-glycine gel (Novex; 
Life  Technologies, Paisley,  UK)  according 
to the manufacturer’s instructions. Gels were 
electroblotted  onto  PVDF  membrane 
(Immobilon-P; Millipore, Watford, UK) and 
subsequently  blocked  in  PBS  containing
2230.05%  (v/v)  Tween-20  (PBST)  and  5% 
(w/v) non-fat milk powder for 60 min. After 
washing  in  PBST,  the  membranes  were 
incubated  with  anti-PrP  monoclonal 
antibody ICSM35 (D-Gen Ltd, UK) diluted 
to  0.2(ig/ml  in  PBST  for  at  least  60 min 
before  washing  in  PBST  (30  min)  and 
incubation  with  an  alkaline  phosphatase- 
conjugated  goat  anti-mouse  antibody 
(Sigma,  Dorset,  UK)  diluted  1:10,000  in 
PBST  for  60  min.  Following  washing  in 
PBST  (30  min),  the  membranes  were 
developed using AttoPhos reagent (Promega 
Corp., USA) and visualized on a Molecular 
Dynamics Storm 840 (Amersham, UK).
Cell Culture
The  murine  neuroblastoma  cell  line,  N2a, 
was used throughout. Cells were cultured in 
OPTI-MEM  with  10%  fetal  calf  serum 
(OFCS) and lOOU/ml of both penicillin and 
streptomycin  (Invitrogen  Corp.).  PIPLC 
treatment  of  cells  was  carried  out  by 
removal  of  growth  media  from  confluent 
cells  in  a  10cm dish  and  addition  of PBS 
containing either 200mUnits PIPLC (Sigma) 
or  lOOUnits  Cathepsin  D.  Cells  were 
incubated  for  3hrs  and  the  culture 
supernatant  harvested.  300pl  of  culture 
supernatant  was  mixed with 4  volumes  of 
ice-cold  methanol  and  centrifuged  for  30 
minutes  at  25,000g  and  4°C.  The 
precipitated protein was  then re-suspended 
in 20  pi  of PBS  and analysed by western 
blot as described above.
In vitro Amplification
Analysis  of in  vitro  amplification of PrPS c 
was carried out using a modification of the 
protocol from Lucassen et al (16).  10% w/v 
brain  homogenates  were  produced  in  PBS 
from RML infected CD-I, wild type CD-I 
and PrP knock-out (FVB/N Prnpm) mouse 
brains.  RML homogenates were produced 
in the presence of 1%  Triton X-100 (Sigma), 
with the wild type and PrP null homogenates 
containing  lx Complete protease inhibitors 
(Roche).  20pl  of RML  homogenate  was 
digested with 200Units of Cathepsin D for 2 
hours and then, in parallel with undigested 
RML control, diluted  1   in 25  into  lx PBS 
with  1%   Triton  X-100.  These  were  then 
diluted 1:1 with CD-I wild type or PrP null 
brain  homogenate  and  incubated  for  16 
hours  at  37°C  with  shaking  at  450  rpm. 
Following  incubation,  homogenates  were
digested with PK at a final concentration of 
50fig/ml for 1  hour at 37°C and analysed by 
western  blotting.  Each  condition  was 
repeated in triplicate.
Scrapie Cell Assay
High sensitivity cell culture assays for prion 
infectivity were carried out as described by 
Klohn  et  al  (17).  Briefly,  PK1  cells,  a 
highly  scrapie  susceptible  N2a  sub  clone, 
were  exposed  for  three  days  in  96  well 
plates to serial dilutions (10"4, 10'5, 10-6  and 
10"7) of infectious RML homogenate either 
treated with Cathepsin D or untreated as a 
control.  The cells were then grown to 80% 
confluence  and  split  twice  before  finally 
being grown to confluence and re-suspended 
in  OFCS.  25,000  cells  per  well  were 
transferred  to  an  enzyme-linked 
immunospot  plate  (ELISPOT,  Millipore). 
The  cells  were  then  treated  for  one  hour 
with 0.5pg/ml Proteinase K in lysis buffer 
(50mM  Tris.HCl,  150mM  NaCl,  0.5% 
Deoxycholate, 0.5% Triton X-100. pH 8.0), 
washed and denatured by treatment with 3M 
guanidine  isothiocyanate  (Sigma).  Wells 
were  then  washed  and  blocked  prior  to 
probing  with  ICSM18  (D-Gen  Ltd.,  UK), 
washing  with  TBST  and  probing  with 
alkaline  phophatase  conjugated  anti-IgGl. 
Scrapie  positive  cells  were  identified  after 
treatment  with  alkaline  phosphatase 
conjugate substrate (Bio-rad) using the Zeiss 
KS  ELISPOT system (Carl Zeiss,  Welwyn 
Garden City UK).
Mouse  Bio-assay  of Cathepsin  D  Treated 
PrFc
Cathepsin D treated RML was bio-assayed 
using  Tg20  transgenic  mice,  which  over­
express the murine Pm-p gene (18).  10% 
RML was treated with 20u/pl Cathepsin D 
for  2hrs  at  37°C  or  mixed  with  PBS  and 
then  diluted  with  PBS  to  0.1%  final 
concentration.  RML,  Cathepsin  D  treated 
RML,  PBS  and Cathepsin  D-only  controls 
were  then  inoculated  intra-cerebrally  into 
anaesthetised Tg20 mice (18).  Animal care 
adhered to institutional guidelines and mice 
were  examined  daily  for  clinical  signs  of 
prion  disease.  Brain  samples  were  taken 
from all groups following death, analysed by 
western blot for the presence of PrP8 0  and 
for  neuropathological  evidence  of  prion 
disease.
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Cathepsin D digest of  PrP^ strains 
Treatment of 10% brain homogenate  from 
RML  infected  mice  with  Cathepsin  D 
resulted in the proteinase K resistant PrP in 
these homogenates running at an apparently 
higher molecular mass than those in control 
homogenates  as  analysed  by  SDS  PAGE 
(Figure  1A).  While  proteolytic  digestion 
should  decrease  relative  molecular  mass 
(RMM)  due  to  the  loss  of  polypeptide 
material, it has been shown previously that 
apparent  increases  in  RMM  occur  upon 
removal  of  GPI  anchors  by  the  enzyme 
PIPLC.  This  effect  is  caused  by  the 
disproportionate  amount  of  SDS  that 
associates with the acyl chains of the GPI 
anchor  on  treatment  compared  with  the 
polypeptide  component  (12; 13).  Hence, 
removal of the anchor results in a significant 
loss of SDS-associated charge and a slower 
migration  in the electric field.  Given this 
observation,  the only plausible explanation 
for  result  derived  from  cathepsin  D 
treatment  is  that  the  enzyme  cleaves  the 
chain  close  to  the  carboxy-terminus,  so 
removing only a small mass of polypeptide 
along with the anchor.
To  discover  if  this  was  a  prion 
strain-specific  phenomenon,  PrPS c  in  brain 
homogenates  isolated  from hamster (strain 
263K) and human (molecular strain types 1, 
2  and  4  (19;20))  were  subjected  to 
proteolysis  by  cathepsin  D.  All  exhibited 
the  same  apparent  increase  in  molecular 
mass  (Figure  1A).  Using  murine  RML 
prions as a model system, the concentration 
and  time-dependence  of  this  affect  was 
examined  (Figure  IB  and  1C),  with  the 
apparent  RMM  increase  showing 
dependence  upon  both  digestion  time  and 
concentration of Cathepsin D.
Cathepsin D mediated release of PrP from 
intact cell membranes
If treatment with Cathepsin D removes the 
GPI  anchor,  it  would  be  expected  that 
treatment of intact cells in culture with the 
enzyme would result in release of membrane 
anchored  PrPc  into  the  cell  media.  To 
examine  this,  wild  type  N2a  cells  were 
treated with either Cathepsin D  or PIPLC, 
with the incubation media analysed for the 
presence  of  released  PrPc.  Under  these 
conditions,  treatment with either Cathepsin
D or PIPLC resulted in the release of PrPc, 
as  measured  by  an  increase  in  the  PrPc 
collected from the media (Figure 2).
Change  in strain profile  is  independent of 
metal ion binding
An alternative explanation for this alteration 
in  electrophoretic  properties  following 
digestion with cathepsin D is that there is a
change  in  conformation  of  the  PrPS c
dependent upon the inadvertent introduction 
of  metal  ions  during  the  experimental 
process (21).  To eliminate this possibility, 
cathepsin D digests were carried out in the 
presence or absence of the metal chelating 
agent  EDTA  and  the  affect  of increasing 
concentrations  of  Cu2+   upon  the  strain 
profile  of RML  were  investigated  (Figure 
3A).  The presence of EDTA did not affect 
the  retardation  of  PrP  in  SDS  gel
electrophoresis  following  Cathepsin  D
digestion, not did the addition of copper to 
RML  result  in  any  prion  strain-specific 
alteration in electrophoretic mobility (Figure 
3B).
Loss of GPI anchor has no effect on in vitro 
amplification of  PrP^
To  investigate  the  impact that GPI  anchor 
loss has on the ability of PrPS c to replicate, 
cathepsin D treated RML was examined for 
its ability to seed amplification in an in vitro 
PrP8 0   replication  model.  Using  the 
technique of Lucassen et al (16), cathepsin 
D-digested  RML  exhibited  no  significant 
difference  in  its  ability  to  produce  an 
amplified  signal  as  compared  to  untreated 
RML (Figure 4).
Loss of GPI anchor has no effect on prion 
infectivity measured by Scrapie Cell Assay 
To  determine  whether  the  loss  of its  GPI 
anchor alters prion infectivity, cathepsin D- 
treated  RML  prions  were  assayed  for 
infectivity using a cell-culture assay  based 
upon a highly susceptible line of N2a cells, 
the  scrapie  cell  assay.  Using  a  range  of 
dilutions,  cathepsin  D-treated  RML  prion- 
infected brain homogenate was compared to 
untreated  RML  homgenate,  along  with 
cathepsin  D-only  controls  and  CD-I 
homogenate digested with cathepsin D (no 
cellular toxicity was observed with control 
treatments, data not shown).  As RML alone 
exhibits a slight decrease in infectious titre 
upon  incubation  at  37°C,  Cathepsin  D 
treated  homogenates  were  compared  with 
either RML added to the assay immediately
225following  thawing  or incubated  in parallel 
with the cathepsin D digest.  There was no 
significant reduction in prion titre following 
RML digest of Cathepsin D (Figure 5).
Loss of GPI anchor has no effect on prion 
infectivity measured using mouse bioassay 
Cathepsin  D-treated  RML  was  then 
compared with untreated RML by bioassay 
in  Tg20  transgenic  mice,  which  over- 
express  mouse  PrPc  (18).  Mice  were 
inoculated  with  untreated  RML,  cathepsin 
D-treated  RML,  PBS  control,  or  with 
cathepsin  D  alone.  Mice  inoculated  with 
cathepsin D-treated RML and with untreated 
RML  developed  clinical  scrapie  after  9 
weeks,  with  no  significant  difference 
between the incubation periods (Figure 6A) 
Homogenates  from  both  groups  were 
examined  for  protease-resistant  PrP,  and 
were  positive  in  both  cases  (Figure  6B). 
Mice  were  also  examined  for 
neuropathological  hallmarks  of  scrapie 
infection and both groups showed classical 
signs of prion disease.
DISCUSSION
Despite  decades  of  research,  the 
precise  molecular  mechanism  of  both 
pathological  injury  and  the  nature  of the 
infectious  agent  in  the  prion  disorders 
remains elusive.  One of the areas of prion 
disease  biology  that  is  not  clearly 
understood  is  the  role  of  the  post- 
translational  modifications  of  PrP.  The 
presence  of  altered  glycoform  ratios  in 
different  prion  strains  suggests  that 
glycosylation  may  play  a  role  in  the 
propagation of strain properties (19;22), and 
studies  using  PIPLC  to  remove  the  GPI 
anchor from  PrP  in  infected cells  indicate 
that perhaps this also plays a role in cell-to- 
cell propagation of infection (23).
In this study, Cathepsin D has been 
used  to  remove  a  short  carboxyl  terminal 
sequence  from  infectivity-associated  PrPS c. 
In  doing  so,  three  major  technical 
difficulties  prevented  the  precise 
characterisation of the nature and location of 
the cleavage event.  Firstly, PrPS c is difficult 
to purify without denaturation, secondly, its 
hydrophobicity  prevents  direct  sequencing 
of  the  cleavage  products  (20),  thirdly, 
Cathepsin D has a poorly defined cleavage 
consensus sequence (characterised only as a
preference  to  cleave  between  two 
hydrophobic  residues)  (24;25).  However, 
the evidence of retarded migration of PrP in 
SDS  gel electrophoresis and the release of 
PrP  from  the  cell  membrane  following 
digestion  with  Cathepsin  D  indicate  that 
Cathepsin  D  removes  a  segment  of the  C 
terminus  of  the  protein  and,  with  those 
amino acids, the GPI anchor.  This provided 
an alternate approach to the use of PIPLC 
treatment,  and  therefore  denaturing 
conditions, as a means of evaluating the role 
of the GPI in the infective process.
It  should  be  noted  that  the 
concentrations of Cathepsin D used to digest 
PrP8 0   were  greatly  in  excess  of 
physiologically  relevant  levels.  It  is 
intriguing,  however,  that  Cathepsin  D  has 
been implicated in the proteolytic processing 
of amyloid P, alpha synuclein and Tau (26- 
28).  Cathepsin D is also upregulated both in 
mouse models of scrapie (29;30) and in the 
brains  of  Alzheimer’s  disease  patients 
(although  this  may  reflect  a  general 
upregulation  of  lysosomal  degradation  in 
these  disorders  rather  than  a  substrate- 
specific effect) (31).  A polymorphism in the 
human  Cathepsin  D  gene  has  also  been 
identified  as  a  risk  factor  for  late  onset 
Alzheimer’s  disease,  providing  a  potential 
link  with  other  neurodegenerative  protein 
folding diseases (32).
The  impact  of the  removal  of the 
GPI  from  infective  PrPS c  was  studied  in 
three systems: a model in vitro amplification 
system, the ex vivo scrapie cell prion assay 
and  mouse  bioassay.  No  significant  effect 
was observed with any of these techniques. 
The relationship of the first system to the in 
vivo  situation remains a subject of debate. 
Several  systems  for  the  in  vitro 
amplification of PrPS c, have been reported to 
generate  an  amplification  of signal but  no 
categorical proof of a concomitant increase 
in infectivity has been produced and so these 
systems may reflect an increase in protease 
resistant  PrP  rather  than  amplification  of 
infectivity (33-36). However, data from the 
in  vivo  assay  of cathepsin  D-treated  RML 
agrees  with  that  from  both  the  in  vitro 
amplification and from the highly sensitive 
cell-culture analysis.
The  evidence presented from these 
three systems demonstrates that the removal 
of the  GPI  from PrPS c does not affect  the
226infective  properties  of  the  scrapie  agent. 
This is particularly well demonstrated by the 
scrapie  cell  assay  which  is  capable  of 
detecting just a two-fold change in infective 
titre.  This  finding  has  two  major 
implications.  Firstly,  since  endogenous 
proteolytic release of PrPc has been reported 
(37),  this  may  provide  a  mechanism 
whereby infectious PrPS c could spread from 
cell to cell and throughout the body of an 
infected host.  Secondly, the fact that prion
infectivity  does  not  require  a  GPI  anchor 
means that this is not a factor preventing the 
production of de novo prion infectivity using 
recombinant protein from bacterial sources. 
This  is  in  agreement  with  the  recent 
demonstration by Legname et al.  (38)  that 
PrP  generated  in  E.  coli  cells  by 
recombinant  expression  is  capable  of 
inducing  prion  disease  in  transgenic  mice 
with  high  levels  of  overexpression  of  a 
truncated PrP.
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FIGURE LEGENDS
Figure 1  Cathepsin D digestion of mouse RML, hamster 263K and human types 1, 2, 3 and 4 PrPS c 
visualised by western blot (A).  Samples were digested with 20U cathepsin D per pi of 10% w/v brain 
homogenate and exhibit retarded migration in SDS PAGE as compared to untreated controls, 
indicative of C-terminal truncation and loss of GPI.  Concentration (B) and time (C) dependence of 
gel retardation following digestion with cathepsin D are also shown, exemplifying the enzymatic 
nature of the cleavage.
Figure 2 Release of PrP from the cell membrane of wild type N2a cells by PIPLC (A) and cathepsin D 
(B).  Cells were treated with the indicated concentration of enzyme for three hours, with the 
supernatant collected and analysed by western blotting.  The presence of PrPc in the supernatant, 
recognised by ICSM 35, signifies release of the protein from the cell membrane upon either GPI 
cleavage (PIPLC) or C-terminal truncation (cathepsin D)
Figure 3 Impact of EDTA on cathepsin D digestion of RML (A) and of increasing Cu2+on RML strain 
profile (B).  The presence of the metal chelator EDTA has no effect on cathepsin D digest of RML, 
nor does the presence of Cu2 +  alter the apparent RMM of RML, indicating that the gel retardation 
following cathepsin D treatment is not metal ion dependent.
Figure 4 In vitro amplification of cathepsin D treated and normal RML.  Treated or untreated RML 
infected brain homogenate diluted into wild type CD-I brain homogenate both exhibited amplification 
of protease resistant signal (compared to RML diluted into PrP0/0 brain homogenate) as quantified by 
band intensity following western blot analysis. Data shown is the mean of 3 separate reactions with
228standard deviations indicated. No significant difference was observed between treated and untreated 
samples
Figure 5 Scrapie cell assay analysis of RML infectivity. RML was incubated for 4 hours at 37°C and 
RML digested with cathepsin D for 4 hours at 37°C.  A range of dilutions of RML brain homogenates 
from 10'4 to 10'7  were used to allow estimation of any impact of cathepsin D digestion on the 
infectivity of RML, with no significant difference between digested and undigested samples.  Data 
shown is the mean number of cells that contain detectable PrPR E S  per 25,000 viable cells from 3 
independent experiments with standard deviations as indicated.
Figure 6 In vivo analysis of the infectivity of cathepsin D treated RML (A) and the presence of 
protease resistant material in the brains of mice inoculated with both RML and cathepsin D treated 
RML (B).  TG20 transgenic mice were inoculated intra cerebrally with 0.1% w/v RML brain 
homogenate and monitored for clinical signs of prion disease. Groups of mice inoculated with either 
cathepsin D treated RML or native RML exhibited similar incubation times shown in days post­
inoculation.  The presence of protease resistant material in the brains of both experimental groups was 
confirmed by western blotting. Control groups (PBS and cathpepsin D alone) showed no evidence of 
prion disease.
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